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Abstract
After a failure of "One-Size-Fits-All" approach on traditional treatment of diseases, the age
of multi-faceted personalized medicine came into being for tailoring therapy to get the best
response in the highest safety margin. Personalized drug dosage is one of the promises of
personalized medicine and is of great importance for critical medical treatments such as anes-
thesia. General anesthesia induces a reversible state of unconsciousness in the patient due to
the synergetic action of a cocktail of drugs. A general anesthesia cocktail is made up of a hyp-
notic, such as propofol, an analgesic, such as opioid-based or paracetamol, and a myorelaxant
drug, such as midazolam. The delivery rate of these individual drugs in the cocktail has to be
continuously monitored and balanced to achieve and maintain the desired level of sedation in
the patient to avoid severe psycho-physical complications of over-/under-doses. To this end,
the common practice nowadays is to use Target Control Infusion (TCI) pumps, which regulate
the delivery of anesthetic compounds according to their mathematical pharmaco-kinetic
models that estimate the right dose for the injection on the basis of patients’ health data.
However, implementation of these models have been done considering a population that
does not cover all individuals, hence, falling in the category of "One-Size-Fits-All" approach
and fail to reproduce the inter-patient variability in metabolism. Therefore, one of the main
challenges in general anesthesia practices is the monitoring of the Depth Of Anesthesia (DOA)
in patients to be able to tune the drug dosage according to individual’s responses.
One of the most widely used methods for DOA monitoring in Europe is the BiSpectral Index
(BIS), a statistical predictor that is evaluated from ElectroEncephaloGram (EEG) signal. How-
ever, there exist several limitations regarding this technique such as being indirect measure
of DOA and prone to be affected by artifacts and production of different signals in case of
different anesthetics.
To overcome these limitations, there is a need for a Therapeutic Drug Monitoring (TDM)
system capable of continuously measuring the actual concentration of each infused drug in
the blood of patient during DOA for a safer, reliable and personalized anesthesia delivery. In
this thesis, we present the design, the implementation and the validation of a complete TDM
system for long-time and continuous monitoring of anesthetics’ concentrations.
The complete TDM system consists of: (i) a custom-built Raspberry-Pi (RPi)-based electronic
board to drive, (ii) the electrochemical sensors for propofol, paracetamol and midazolam
detection, that are encapsulated into (iii) a fluidic device to drive the sample on the sensing
sites, and (iv) an Android-based Internet of Things (IoT) network architecture to keep the
anesthesiologist always connected with the sedated patient. Thanks to the IoT network,
ix
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the developed system is capable of fast data visualization tools, as well as an alarm system
activated in case serious physical conditions are detected in patient and remote monitoring
through cloud-sharing.
This thesis describes in details the system and highlights the following results:
• Fouling-free propofol long-time monitoring by the use of Pencil Graphite Electrode (PGE)
with a specific graphite/clay/wax composition.
• Successful assembly of electronics and sensors in a novel multi-panel system capable of
monitoring several drugs in complex bio-fluids, such as undiluted human serum.
• Demonstration of simultaneous monitoring of several drugs concentrations trends over
time.
• Powerful and innovative integration of an IoT network for providing a constant monitor-
ing through Android app and for enabling telemedicine support.
Keywords: anesthesia, electrochemical sensors, multi-sensing, long-term monitoring, anes-
thetic cocktail, propofol, custom-built electronics, fluidics, Internet of Things, Cloud support.
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Résumé
Vu la carence de l’approche "One-Size-Fits-All" (une quantité égale pour tous) qui caractérise
les traitements administrés par la médecine traditionnelle, la médecine personnalisé a été in-
troduite dans le but d’administrer des thérapies individuelles dans le but d’obtenir le bénéfice
maximum garantissant la plus haute marge de sécurité. Le dosage personnalisé du médica-
ment est une des promesses essentielles de la médecine personnalisée et a une importance
fondamentale au niveau des traitements médicaux aigus, comme par exemple l’anesthésie. En
effet, l’anesthésie générale amène le patient dans un état réversible d’inconscience en exploi-
tant l’action de synergie d’un cocktail pharmaceutique. En général, le cocktail anesthésique
est composé de : un hypnotique comme le propofol, un analgésique soit à base d’opiacée ou
de paracétamol ainsi qu’un myorelaxant comme le midazolam. La quantité administrée de
ces médicaments doit être continuellement monitorée et réglée pour rejoindre et maintenir le
niveau désiré d’anesthésiant afin d’éviter de graves complications psycho-physiques causées
par un sur ou sous dosage. C’est la raison pour laquelle, de nos jours, la pompe à perfusion
contrôlée est largement utilisée. Cette dernière dose l’administration des anesthésiants sur la
base de modèles mathématiques pharmacocinétiques qui estiment (calcul) la dose correcte à
administrer au patient, sur la base de données physiques. Cependant, l’implémentation de ces
modèles est basée sur l’étude d’une population non exhaustive, retombant dans la catégorie
"One-Size-Fits-All". En effet, ces modèles mathématiques ne sont pas en mesure de reproduire
la diversité du métabolisme entre différents patients. Cependant, le défit principal dans les
pratiques d’anesthésie générale est le monitorage du niveau d’anesthésie du patient dans le
but de doser les anesthésiants sur la base de la réponse individuelle du sujet. En Europe, une
des méthodes les plus utilisée dans le monitorage de l’anesthésie est l’indice BiSpectral (BIS),
un paramètre statistique évalué par le signal de l’électroencéphalogramme. Cependant cette
technique a des limites, le BIS étant évalué de manier indirecte et pouvant être sujet à des
erreurs de mesures et variabilité due à différents médicaments. Pour dépasser ces limites, il
est nécessaire d’utiliser un système capable de mesurer la concentration effective de chaque
médicament en continu, injecté dans le sang du patient durant l’anesthésie, ce qui garantit un
dosage plus sûre, fiable et personnalisé. Dans cette thèse, nous présenterons la projection,
l’implémentation et la validation d’un système complet concernant le monitorage continu
de la concentration de différents anesthésiants dans la durée. Le système de monitorage est
constitué de (i) un circuit imprimé piloté par Raspberry-Pi (RPi) qui contrôle (ii) les senseurs
électrochimiques pour la détection de propofol, paracétamol et midazolam ; ces derniers sont
encapsulés dans (iii) un dispositif fluidique dans le but de guider l’échantillon sur les sites
xi
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de détection, et (iv) un réseau IoT basé sur Android pour maintenir l’anesthésiste en contact
permanent avec le patient anesthésié. Ce réseau offre des instruments pour une visualisation
rapide des données, un système d’alarme activé dans le cas où une souffrance du patient
serait détectée ainsi qu’un monitorage à distance au travers de Cloud. Cette thèse décrit dans
le détail le système complet et met en évidence les résultats suivants :
• Monitorage à long terme du propofol sans mettre en évidence des signes de détérioration
de l’électrode. Les mesures ont été effectuées en utilisant des électrodes avec une
composition spécifique de graphite, d’argile et de cire.
• Assemblage optimisé de l’électronique et des senseurs dans un système capable de
monitorer de manière continue et simultanée divers médicaments dans les fluides
biologiques complexes, comme le sérum humain.
• Démonstration de l’efficacité du système dans le monitorage simultané des nivaux de
concentration de différents anesthésiants dans la durée.
• Intégration innovatrice d’un réseau IoT pour fournir un monitorage constant au travers
d’applications Android et activer le support à la télémédecine.
Mots-clés: anesthésie, capteurs électrochimiques, multi-détection, surveillance à long terme,
cocktail anesthésique, propofol, électronique sur mesure, fluidique, Internet des Objets, support
Cloud.
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Sommario
Data l’inadeguatezza dell’approccio "One-Size-Fits-All" (una quantità uguale per tutti) che
caratterizza i trattamenti somministrati dalla medicina tradizionale, la poliedrica medicina
personalizzata è stata introdotta allo scopo di somministrare terapie individuali in grado
di ottenerne il massimo beneficio nel più alto margine di sicurezza. Il dosaggio personaliz-
zato del farmaco è una delle promesse fondamentali della medicina personalizzata ed è di
importanza cruciale soprattutto in trattamenti medici critici, come ad esempio l’anestesia.
Infatti, l’anestesia generale induce uno stato reversibile di incoscienza nel paziente sfruttando
l’azione sinergica di un cocktail di farmaci. Normalmente, il cocktail anestetico è composto da:
un ipnotico, come il propofol, un analgesico, solitamente a base oppiacea od il paracetamolo
e un farmaco miorilassante, come il midazolam. Il tasso di somministrazione di ciascuno di
questi farmaci deve essere continuamente monitorato e regolato per raggiungere e mantenere
il livello desiderato di sedazione nel paziente per evitare gravi complicazioni psico-fisiche
causate da sovra/sotto-dosaggi. A tal fine, la pratica più diffusa oggigiorno è quella di utilizzare
pompe ad infusione controllata (TCI, dall’inglese Target Control Infusion), che regolano la
somministrazione degli anestetici secondo modelli matematici di farmacocinetica che stima-
no la giusta dose da iniettare sulla base dei dati fisici del paziente. Tuttavia, l’implementazione
di questi modelli si è basata sullo studio di una popolazione non esaustiva, rientrando quindi
nella categoria di "One-Size-Fits-All". Infatti, questi modelli matematici non sono in grado di
riprodurre la variabilità del metabolismo tra diversi pazienti. Pertanto, una delle principali
sfide nelle pratiche di anestesia generale è il monitoraggio del livello di anestesia del singolo
paziente cosi da dosare gli anestetici in base alla risposta individuale del soggetto.
In Europa, uno dei metodi più utilizzati per il monitoraggio dell’anestesia è basato sull’in-
dice BiSpettrale (BIS), un predittore statistico che viene valutato dal segnale dell’Elettro-
EncefaloGramma (EEG). Tuttavia, questa tecnica riscontra diverse limitazioni essendo il BIS
misurato in maniera indiretta e perciò soggetto ad artefatti e variabilità in risposta a diversi
farmaci. Per superare questi limiti, è necessario un sistema in grado di misurare continua-
mente la concentrazione effettiva di ciascun farmaco infuso nel sangue del paziente durante
l’anestesia, cosi da garantire una somministrazione più sicura, affidabile e personalizzata.
In questa tesi, presenteremo la progettazione, l’implementazione e la validazione di un sistema
completo per il monitoraggio continuo della concentrazione di diversi anestetici nel tempo.
Il sistema di monitoraggio è costituito da: (i) una scheda elettronica guidata da Raspberry-Pi
(RPi) che controlla, (ii) i sensori elettrochimici per il rilevamento di propofol, paracetamolo e
midazolam; tali sensori sono incapsulati in (iii) un dispositivo fluidico per guidare il campione
xiii
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sui siti di rilevazione, ed (iv) un’architettura di rete IoT basata su Android per mantenere
l’anestesista sempre collegato al paziente sedato. Questa rete IoT offre strumenti per una
visualizzazione rapida dei dati misurati, un sistema di allarme attivato nel caso in cui si rilevino
sofferenze nel monitoraggio del paziente e un monitoraggio anche da remoto tramite supporto
cloud.
Questa tesi descrive nel dettaglio il sistema completo ed evidenzia i seguenti risultati:
• Monitoraggio a lungo termine del propofol senza evidenziare segni di deterioramento
dell’elettrodo. Le misure sono state effettuate mediante l’uso di elettrodi con una
specifica composizione di grafite, argilla e cera.
• Assemblaggio ottimizzato dell’elettronica e dei sensori in un sistema in grado di moni-
torare in maniera continue e simultanea diversi farmaci in bio-fluidi complessi, come il
siero umano.
• Dimostrazione dell’efficia del sistema nel monitoraggio simultaneo dei livelli di concen-
trazione di diversi anestetici nel tempo.
• Innovativa integrazione di una rete IoT per fornire un monitoraggio costante tramite
applicazioni Android e per abilitare il supporto alla telemedicina.
Parole chiave: anestesia, sensori elettrochimici, monitoraggio di diversi farmaci, monitoraggio
a lungo termine, cocktail anestetico, propofol, elettronica dedicata, fluidica, Internet delle Cose,
supporto Cloud.
xiv
Contents
Acknowledgements v
Abstract (English/Français/Italian) ix
List of figures xvii
List of tables xxii
1 Introduction 1
1.1 General Anesthesia (GA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.1 Cocktail of drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.1.2 PharmacoKinetics (PK) and PharmacoDinamics (PD) . . . . . . . . . . . . 5
1.1.3 Three-compartment model . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.2 Current state-of-the-art of Total Intra-Venous Anesthesia (TIVA) . . . . . . . . . 9
1.2.1 Target Controlled Infusion (TCI) pump: principles and limitations . . . . 9
1.2.2 Bispectral Index (BIS) monitoring: use and limitations . . . . . . . . . . . 10
1.2.3 Anesthesia side effects and risks . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3 Research contributions and thesis outline . . . . . . . . . . . . . . . . . . . . . . 12
2 Background 17
2.1 Drug monitoring with electrochemical sensors . . . . . . . . . . . . . . . . . . . 17
2.1.1 Electrochemical sensing techniques: an overview . . . . . . . . . . . . . . 17
2.1.2 ChronoAmperometry (CA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.3 Sensor calibration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.1.4 Enhancement of electrode performance . . . . . . . . . . . . . . . . . . . 26
2.2 Electronics for electrochemical sensing . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.1 Potentiostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.2 Equivalent circuit for an electrochemical cell . . . . . . . . . . . . . . . . 32
2.3 IoT in medical applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3.1 Cloud computing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.3.2 Android operating system . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.4 Summary and main contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
xv
Contents
3 Propofol direct monitoring 45
3.1 State-of-the-art . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Polymeric membrane-coated carbon Screen Printed Electrodes (SPEs) . . . . . . 47
3.2.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2.2 Electrode preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.2.3 Results and limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.3 Boron Doped Diamond (BDD) and Pencil Graphite Electrode (PGE) electrodes . 50
3.3.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.3.2 Fouling characterization at PGE and BDD electrodes . . . . . . . . . . . . 52
3.3.3 Cleaning procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.4 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.3.5 Serum detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.4 Different compositions of PGEs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.4.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.4.2 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.5 Summary and main original contributions . . . . . . . . . . . . . . . . . . . . . . 69
4 Midazolam and Paracetamol direct monitoring 73
4.1 State-of-the-art . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.2 Carbon-based nano-structured electrodes . . . . . . . . . . . . . . . . . . . . . . 75
4.2.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.2.2 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4.3 Interference study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.3.1 Interference at different PGEs . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.3.2 Interference at C-Screen Printed Electrode (SPE) . . . . . . . . . . . . . . . 89
4.4 Summary and main original contributions . . . . . . . . . . . . . . . . . . . . . . 90
5 Electronic platform 93
5.0.1 System architecture of the electronic platform . . . . . . . . . . . . . . . . 94
5.1 Multi-channel potentiostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.1.1 Front-end design for drug monitoring . . . . . . . . . . . . . . . . . . . . . 96
5.1.2 Front-end optimization process . . . . . . . . . . . . . . . . . . . . . . . . 98
5.1.3 Improved read-out signal by hardware filtering . . . . . . . . . . . . . . . 105
5.2 Measure of pH and temperature for calibrations . . . . . . . . . . . . . . . . . . . 107
5.2.1 System calibration and drug measuring processes . . . . . . . . . . . . . 110
5.2.2 Preliminary calibration procedure . . . . . . . . . . . . . . . . . . . . . . . 110
5.2.3 Validation of the pH-T module with propofol calibrations . . . . . . . . . 110
5.3 Graphical User Interface on the RPi . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.4 System validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
5.4.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
5.4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.5 Summary and main original contributions . . . . . . . . . . . . . . . . . . . . . . 122
xvi
Contents
6 Overall IoT system architecture 125
6.1 State-of-the-art . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
6.2 IoT cloud-based network & Android development . . . . . . . . . . . . . . . . . . 126
6.2.1 Smart-watch as paradigm-shifting player in medical IoT . . . . . . . . . . 127
6.2.2 Cloud-based architecture for anesthesia monitoring . . . . . . . . . . . . 133
6.3 Realization of the sensing platform with fluidics integration . . . . . . . . . . . . 139
6.3.1 Fabrication of fluidic chambers in Poly(di-methyl siloxane) (PDMS) (Cham-
bers nr.2 and nr.3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
6.3.2 Characterization of the fluidic device . . . . . . . . . . . . . . . . . . . . . 144
6.4 Overall system validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
6.4.1 Validation of the system in undiluted human serum . . . . . . . . . . . . 147
6.5 Infusion pump integration: towards closed loop delivery . . . . . . . . . . . . . 149
6.5.1 Raspberry Pi-driven Flow-Injection System (FIS) . . . . . . . . . . . . . . . 150
6.5.2 FIS set-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.5.3 Injection dose calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
6.5.4 Flow-Injection System (FIS) validation . . . . . . . . . . . . . . . . . . . . . 153
6.6 Summary and original contributions . . . . . . . . . . . . . . . . . . . . . . . . . 155
7 Conclusions and future work 159
A Micro-controller firmware 163
A.1 main.c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
A.2 Twi_protocol.h . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
A.3 Setup_twi.c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
A.4 Setup_timer.c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
Bibliography 188
Curriculum Vitae 189
xvii

List of Figures
1.1 Classification of drug administration errors in anesthesia . . . . . . . . . . . . . 1
1.2 Anesthetics sites of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Midazolam pH dependency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4 PK/PD phases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.5 PK/PD curves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.6 Three-compartmental model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.7 Bispectral index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.8 Visual index of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.1 Electrochemical cell configurations . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.2 Energy process of a RedOx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.3 Helmholtz planes theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.4 Electrochemical cell as a "black box" . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.5 ChronoAmperometry (CA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.6 Cyclic Voltammetry (CV) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.7 Differential Pulse Voltammetry (DPV) . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.8 Calibration line parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.9 Carbon-based nano-structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.10 General scheme of a potentiostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.11 Potential control unit: grounded CE . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.12 Potential control unit: grounded WE . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.13 SPI communication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.14 Readout circuit for a grounded WE configuration . . . . . . . . . . . . . . . . . . 31
2.15 Equivalent circuit of an electrochemical cell . . . . . . . . . . . . . . . . . . . . . 32
2.16 IoT reference model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.17 IoT applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.18 Economic impact of IoT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.19 Modular structure of data storage in PrYv middle-ware . . . . . . . . . . . . . . . 38
2.20 Android OS versions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.21 Android architecture stack . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.22 Android activity life-cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.23 Project files in Android Studio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
xix
List of Figures
3.1 Propofol chemical structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Electrochemical CV characterization of propofol (from literature) . . . . . . . . 47
3.3 Spin coating of the PVC membrane on the electrode . . . . . . . . . . . . . . . . 48
3.4 Calibration curve for propofol detection in PBS at PVC-modified electrode and
fouling effect evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.5 SEM image of the PVC membrane . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.6 Pencil graphite electrode (PGE): the configuration . . . . . . . . . . . . . . . . . 51
3.7 SEM image of boron dopped diamond (BDD) electrode . . . . . . . . . . . . . . 52
3.8 SEM image of PGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.9 pH and scan-rate studies for PGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.10 Sensitivities without cleanings for propofol detection at PGE and BDD . . . . . 54
3.11 Propofol calibration lines affected by fouling . . . . . . . . . . . . . . . . . . . . . 55
3.12 Optimization process of the cleaning parameters . . . . . . . . . . . . . . . . . . 56
3.13 Sensitivities with cleanings for propofol detection at PGE and BDD . . . . . . . 57
3.14 Propofol calibration lines with cleanings . . . . . . . . . . . . . . . . . . . . . . . 58
3.15 SEM imaging of PGE after cleanings . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.16 Ferro(ferri)cyanide CV analysis at PGE . . . . . . . . . . . . . . . . . . . . . . . . 58
3.17 Efficacy of PBS cleaning also in presence of propofol . . . . . . . . . . . . . . . . 59
3.18 Long-term electrochemical propofol monitoring . . . . . . . . . . . . . . . . . . 59
3.19 pH and scan-rate studies for PGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.20 Propofol monitoring at PGE in human serum over time . . . . . . . . . . . . . . 61
3.21 Lead composition scale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.22 Pencils set . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.23 Sensitivity variations in propofol detection among different PGE leads . . . . . 64
3.24 CV calibration curves from different PGE leads . . . . . . . . . . . . . . . . . . . 65
3.25 Intra-electrode PGE sensitivity variations over 5 calibrations . . . . . . . . . . . 66
3.26 Fouling evaluation of different PGE leads . . . . . . . . . . . . . . . . . . . . . . . 67
3.27 Propofol in-time monitoring at different PGE leads . . . . . . . . . . . . . . . . . 67
3.28 SEM images of different PGE leads . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.29 EIS analysis for 3H and 3B PGEs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.1 Paracetamol and midazolam chemical structures . . . . . . . . . . . . . . . . . . 73
4.2 SEM images of C-SPE, MWCNTs and Fullerene surfaces . . . . . . . . . . . . . . 77
4.3 Electrochemical characterization of midazolam (from literature) . . . . . . . . . 78
4.4 Midazolam CV calibration in PBS (10 mM, pH: 2.5) at bare C-SPE . . . . . . . . 79
4.5 Electrochemical characterization of APAP (from literature) . . . . . . . . . . . . 80
4.6 APAP CV calibration in PBS (10 mM, pH: 7.4) at bare C-SPE . . . . . . . . . . . . 80
4.7 Typical voltammograms for APAP and MZ detection in PBS (10 mM, pH: 7.4) at
bare, C60- and MWCNT-modified electrodes . . . . . . . . . . . . . . . . . . . . . 81
4.8 APAP and MZ CV calibrations in PBS at C60- and MWCNT-modified WEs . . . . 82
4.9 APAP and MZ detection in human serum at MWCNT- and C60-modified WEs . 84
4.10 APAP interference study CV at PGE . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
xx
List of Figures
4.11 DPV PGE 3H PBS (10 mM, pH:7.4) . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.12 DPV PGE 3H PBS (10 mM, pH:2.5) . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.13 Interference study at different PBS pH conditions (7.4 and 2.5): DPV curves at
PGE 3H in solutions containing APAP, propofol or a mix of the two drugs . . . . 87
4.14 Interference study: CV comparison plots for midazolam detection in PBS (10
mM, pH: 2.5) at PGE 3H and C-SPE WEs . . . . . . . . . . . . . . . . . . . . . . . 88
4.15 CV interference analysis at C-SPE for midazolam detection in PBS pH 2.5 due to
APAP and propofol drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.16 CV SPE midazolam calibration lines interference APAP and Propofol PBS (10
mM, pH: 2.5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.1 Sketch of the Raspberry Pi (RPi)-based overall system . . . . . . . . . . . . . . . . 94
5.2 Architecture of the RPi-based electronics . . . . . . . . . . . . . . . . . . . . . . . 94
5.3 Potentiostat interfaced with three SPE-based electrochemical cells . . . . . . . 96
5.4 Schematic of the electronic front-end for multi-panel drug monitoring . . . . . 97
5.5 First version PCB front-end for drug monitoring . . . . . . . . . . . . . . . . . . . 98
5.6 Different read-out transimpedance topologies being tested . . . . . . . . . . . . 98
5.7 CV plots from first-version electronic platform . . . . . . . . . . . . . . . . . . . . 99
5.8 Igor Pro low-pass FIR filter design window . . . . . . . . . . . . . . . . . . . . . . 100
5.9 Signal noise comparison of the fixed gain and the programmable gain read-out
circuits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5.10 Noise evaluation and comparison at first and second stages of programmable
gain read-out circuit at different DPOT gains . . . . . . . . . . . . . . . . . . . . . 101
5.11 Noise propagation schematic for mixed-signal design . . . . . . . . . . . . . . . 102
5.12 Grounding practice in mixed-signal on a single PCB . . . . . . . . . . . . . . . . 103
5.13 Layout of the second version custom-built potentiostat in star ground configura-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5.14 Screen-shot of the schematic details with the Atmel XMEGA micro-controller . 104
5.15 Final schematic of the custom-built potentiostat . . . . . . . . . . . . . . . . . . 106
5.16 Sketch of the overall system including pH and T measurement module . . . . . 108
5.17 Schematic of the pH and T sensing module . . . . . . . . . . . . . . . . . . . . . . 108
5.18 Process flows for pH-T calibration and drug monitoring . . . . . . . . . . . . . . 109
5.19 Preliminary calibrations of the pH sensor at different T values . . . . . . . . . . 111
5.20 Propofol calibrations at different pH and T conditions . . . . . . . . . . . . . . . 111
5.21 Graphical User Interface (GUI) implemented on RPi . . . . . . . . . . . . . . . . 113
5.22 TCP/IP server on RPi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5.23 System validation: CV, DPV and CA curves from custom-built potentiostat in
comparison with commercial Autolab instrumentation . . . . . . . . . . . . . . 118
5.24 System validation: CV, DPV and CA calibration curves from custom-built poten-
tiostat in comparison with commercial Autolab instrumentation . . . . . . . . . 119
5.25 CV and DPV calibrations for propofol and APAP with custom-built potentiostat 119
xxi
List of Figures
5.26 Gaussian decomposition analysis on Igor Pro 6.22 for propofol and APAP simul-
taneous detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
5.27 Interference study for APAP and propofol . . . . . . . . . . . . . . . . . . . . . . . 121
5.28 Scan-rate analysis for propofol drug with CV and DPV techniques with custom-
built potentiostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
5.29 Scan-rate analysis for APAP drug with CV and DPV techniques with custom-built
potentiostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
6.1 Overall IoT bio-electronic system for on-line monitoring of anesthesia delivery 125
6.2 Smart-wearable unit sales prospective . . . . . . . . . . . . . . . . . . . . . . . . 127
6.3 Smart-watch based IoT architecture . . . . . . . . . . . . . . . . . . . . . . . . . . 129
6.4 Client Android app . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.5 Server Android app and Smart-watch Android-Wear app . . . . . . . . . . . . . . 131
6.6 Communication protocol between smart-watch app, intermediary server app
and client app . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
6.7 Cloud integration for anesthesia monitoring . . . . . . . . . . . . . . . . . . . . . 133
6.8 Different cloud-based tested architectures . . . . . . . . . . . . . . . . . . . . . . 134
6.9 Data packet between RPi and Android app . . . . . . . . . . . . . . . . . . . . . . 136
6.10 Main activities of the AnControl Android app for anesthesiologist . . . . . . . . 137
6.11 WebApp cloud interfaces for patient and doctor . . . . . . . . . . . . . . . . . . . 137
6.12 Work-flows for patient-side and doctor-side to access the cloud . . . . . . . . . 138
6.13 Sketch of the sensing platform with the modular fluidic chambers . . . . . . . . 140
6.14 Metrohm standard flow cell for SPEs . . . . . . . . . . . . . . . . . . . . . . . . . . 141
6.15 Comsol fluidic chambers simulation results . . . . . . . . . . . . . . . . . . . . . 142
6.16 PDMS process flow . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
6.17 Sandwich structure of the fluidic device . . . . . . . . . . . . . . . . . . . . . . . . 143
6.18 Test of the fluidic chamber with dye . . . . . . . . . . . . . . . . . . . . . . . . . . 143
6.19 CA measurements for fluidic characterization . . . . . . . . . . . . . . . . . . . . 145
6.20 Propofol DPV calibrations in human serum under flow conditions . . . . . . . . 147
6.21 Overall system validation: mixing test . . . . . . . . . . . . . . . . . . . . . . . . . 148
6.22 Overall system validation: in-time monitoring test . . . . . . . . . . . . . . . . . 149
6.23 Automatic flow-injection system set-up . . . . . . . . . . . . . . . . . . . . . . . . 150
6.24 Communication protocols between RPi-syringe pump and RPi-Matlab . . . . . 151
6.25 Example of dose calculation and injection for the RPi-driven FIS . . . . . . . . . 152
6.26 FIS dye test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
6.27 FIS test in reproducing APAP time-trend . . . . . . . . . . . . . . . . . . . . . . . 154
7.1 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
A.1 Micro-controller firmware work-flow . . . . . . . . . . . . . . . . . . . . . . . . . 163
A.2 Data packet adopted in the communication protocol from RPi to PCB . . . . . . 164
xxii
List of Tables
1.1 Table of correspondence: thesis chapters - publications . . . . . . . . . . . . . . 15
3.1 PVC membrane composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.2 CV and DPV procedures for BDD and PGE . . . . . . . . . . . . . . . . . . . . . . 51
3.3 Comparison table for propofol sensing . . . . . . . . . . . . . . . . . . . . . . . . 71
4.1 Sensitivity and LOD values for APAP and MZ detection in human serum at
MWCNT- and C60-modified WEs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.2 Sensitivity values (S-interf-APAP and S-interf-Prop) from MZ calibration in so-
lutions containing only midazolam and in presence of interferent compounds
(interf1 is 50 µM APAP and 19.6 µM propofol, interf2 is 100 µM APAP and 80.5
µM propofol). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.3 Comparison table of MZ detection with literature . . . . . . . . . . . . . . . . . . 91
4.4 Comparison table of APAP detection with literature . . . . . . . . . . . . . . . . . 92
5.1 LUT for propofol oxidation in human serum under different pH and T conditions112
5.2 Electrochemical measurement parameters for APAP detection at C-SPE . . . . . 115
5.3 “Feasibility study” Printed Circuit Board (PCB) hardware parameters for APAP
detection at C-SPE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.4 Electrochemical measurement parameters for propofol and APAP detection at
PGE WE with the “feasibility study” PCB. . . . . . . . . . . . . . . . . . . . . . . . 115
5.5 “Feasibility study” PCB hardware configuration for propofol and APAP detection
at PGE WE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.6 Noise evaluation table for front-end PCB . . . . . . . . . . . . . . . . . . . . . . . 116
5.7 Comparison table for propofol detection using various electrochemical ap-
proaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
6.1 Fluid parameters for Comsol simulations . . . . . . . . . . . . . . . . . . . . . . . 141
6.2 Fluidics flux velocities evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
6.3 Electrochemical parameters for DPV, and CA measurements of APAP and Propofol146
6.4 Comparison among different Internet of Things (IoT) solutions in health-care . 156
A.1 Technique tag table . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
A.2 Electrode index table . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
xxiii

1 Introduction
In recent years, studies have been made of how personal variability in response to drugs is
determined by genetic factors, and influenced by habits, age, health status, environmental
exposures, and concomitant therapies [2]. These factors make highly challenging to the
identification of an effective and personalized drug dosage for optimizing the outcome of a
given therapy by limiting side-effects [3]. Therefore, the new paradigm in personalized drug
therapy aims to administer “the right drug, with the right dose at the right time to the right
patient” to avoid lack of response or toxicity effects [4]. This is extremely valuable especially
in the practice of anesthesia, where several potent anesthetic compounds characterized by
a fast action are delivered to the patient within a relatively short time-period. These drugs
would lead to severe side effects if administered without paying maximum attention to dose
balance, delivery time and administration order [1]. According to the NationalCoordinating
Council for Medication Error Reporting and Prevention (NCCMERP) categorization, the higher
incidences (%) of errors in anesthesia practices are due to a wrong choice of drug or an
Wrong route
(3%)
Wrong order
(8%)
Wrong dose
(39%)
Wrong drug
(50%)
Figure 1.1 – Classification of drug administration errors in anesthesia malpractice cases ac-
cording to the NCCMERP taxonomy (reprinted from [1]).
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incorrect dosage, as shown in Fig. 1.1. To reduce these occurrences of malpractice, Therapeutic
Drug Monitoring (TDM) systems are key concept that has to be introduced to tune the drugs
delivery according to each patient’s metabolic response [5]. The main function of a TDM
system is to measure the actual concentration of each infused drug in a patient’s veins, to
provide the medical doctor with the real value of the individual metabolic response and
treatment effect in real time. These TDM systems can be made even more effective if supported
by the new paradigms of Information and Communications Technologies (ICT) [6]. In this
context, the Internet of Things (IoT) concept, according to which any device able to access
the Internet can be interconnected in a network for an easy exchange of data from any
place and at any time, is gaining popularity also in medical applications [7]. Medical IoT
solutions are paving the way towards the realization of “Smart Hospitals”, where an optimized
quality care of the patients with a more personalized approach, and a reduction of medical
errors, are[8]. In the scenario of general anesthesia, medical IoT solutions would provide the
anesthesiologist with a powerful tool to remain always connected with all the anesthetized
patients under his/her superviusion. Nowadays, in fact, the anesthesiologists oversee more
than one operating room at once. Therefore, an IoT equipment for medical applications,
which is able to make accessible the measured data of each patient from any hospital areas at
any time, would guarantee a safer and reliable anesthesia. Moreover, the remote monitoring
of data through cloud solutions, would also lead to the realization of telemedicine networks.
The next section will provide a broad introduction to general anesthesia medical practice and
will describe the actual state-of-the-art of current technologies for DOA monitoring.
1.1 General Anesthesia (GA)
Nowadays, we refer to the term anaesthesia (from Greek "an"-, "not" and "aísthe¯sis", "sensa-
tion") as temporary and reversible state of unconsciousness characterized by loss of sensation,
which is induced before undergoing some medical practices, such as surgery, to make the
patient unresponsive to external stimuli [9]. This state is characterized by three periods: (i)
induction, (ii) maintenance and (iii) emergence. During the anesthesia induction the patient
is put to sleep, and he is maintained asleep for all the time of the surgery. At the end of the
medical intervention, the patient is woken up, emerging from the sedation. Three different
anesthesia categories are available [10]:
• General Anesthesia (GA) suppresses the activities of the Central Nervous System (CNS)
leading to a totally unconscious state. The person can be induced to the anesthetized
state by intravenous (IV) administration of by inhalation of gases.
• Sedation has a weaker suppression of the CNS activities, resulting in an inhibition of
anxiety and of long-term reminiscences formation. The patient is put in an undisturbed
and lethargic state.
• Local or Regional Anesthesia causes loss of sensation in a desired part of the body part
2
1.1. General Anesthesia (GA)
Anesthetic
GABACl
-
GABA
BZD
Molecules
Submolecule
Synapses
Cells
Networks
Cerebellum
Spinal Cord
Cerebral CortexCorpus Callosum
Thalamus
Hypothalamus
Hypophysis
System
Neural structure
and process
Amnesia, Unconsciousness,
Immobility, Antinociception
Cortex, Thalamus, Spinal Cord, 
Thalamocortical loops
Microcircuits
Neurons, Glial Cells, Myocytes, 
Endocrine Cells
Inhibitory synaptic transmission
Excitatory synaptic transmission
Ligand-gated ion channels
Neurotransmitter receptors
Second messenger systems
Lipid bulayer
Resting -70 mV Depolarization Repolarization Hyperpolarization Resting -70 mV
Pumps maintain 
balance
Pumps move Na+
 out K+ in to
 
K+ exceeding
accelerate pumps
Na+ channels close
K+ channels open 
K+ 
Na+ channels open
 channels close
Na+
Threshold = -55 mV
Sub-threshold
Time (ms)
Voltage (mV) Absolute Refractory Period Relative Refractory Period
Inhibition of the Post-Synaptic Potentials
Cl -
Anesthetic 
Agent
Anesthetic agent binds the receptor on GABAA channels 
causing the entrance of Chloride (Cl-).
This hyperpolarizes the cell membrane potential 
and inhibits the post-synaptic potential.
a.
b.
restore balance
K+
Figure 1.2 – a) Anesthetic sites of action at different levels of biological organization, b) hyp-
notic action on action potential due to inhibition of the Cl– channels (inspired by [11, 12, 13]).
by blocking the nerve impulses between the desired area and the spinal cord. It can
block peripheral nerves, nerve plexus or central neuraxial areas (e.g. spinal or epidural).
During this practice the patient remains fully conscious.
In this thesis only GA by IV administration will be considered. We will describe the design,
realization and validation of a TDM system for the continuous monitoring of IV anesthetics
over time.
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1.1.1 Cocktail of drugs
During GA a cocktail of anesthetic compounds with different synergistic actions is adminis-
tered [14]. It normally consists of a hypnotic, such as propofol, an analgesic, such as fentanyl
(opioid) or paracetamol, and a muscle relaxant, such as midazolam. This cocktail of three
agents is referred as the "triad of anesthesia" [9]. It is of vital importance to reach a correct bal-
ance of the "triad" to reach the desired levels of sedation with reduced side-effects. The choice
of each component depends on the kind of surgical operation and on the characteristics of the
patient. The anesthetic compounds have an action on the entire hierarchy of the biological
organization, from cellular level where they alter the activity of neurons by interacting with
ion channels, to an organism’s behavior, as summarized in Fig. 1.2.a [13, 15].
Propofol (2,6-diisopropylphenol) is a highly lipophilic hypnotic agent normally administered
to induce and maintain anesthesia [16]. It ensures a fast onset and a short predictable time
of effect [17]. It produces its hypnotic action by an augmentation of the inhibitory function
of the synaptic transmission binding with the receptors of the gamma-amino-butyric acid
type A (G AB A A) chloride channels. Fig. 1.2.b describes the process of this inhibition due to
the activation of the Cl– channels. G AB A A are involved in the regulation of anxiety, vigilance,
memory, and muscle tension and are the most abundant fast inhibitory neurotransmitter
receptors in the CNS [13]. Hence, they have an important role in the regulation of several
neuronal structures, including the hippocampus, thalamus, spinal cord, and cortex [18, 19, 20].
Midazolam is an imidazobenzodiazepines highly preferred to other benzodiazepines because
of its short-acting time and fast metabolic clearance. It is available as midazolam Hydrochlo-
ride (HCl) salt insoluble in water. Only its acid formulation is soluble in water and highly
lipid soluble in vivo [21]. In acidic conditions midazolam is present as an equilibrium mixture
Fig. 1.3.a of its closed-ring and open-ring structures due to acid-catalysis of the diazepine ring.
The percentage of open-ring form depends on the pH of the solution, as shown in Fig. 1.3.b
[22]. From the graph, the best pH range ranges from 2.5 to 4.
It acts as a depressant of the CNS by increasing the G AB A neurotransmitters inhibitory activi-
ties. Therefore, midazolam produces a calming effect, relaxing skeletal muscles, and inducing
sleep. Also in this case, benzodiazepines bind to the benzodiazepine site on G AB A A receptors
facilitating the entrance of chloride [23].
Acetaminophen, also known as Paracetamol (APAP) (N-acetyl-p-amino-phenol), is a largely
used analgesic and antipyretic drug. It primarily acts at the CNS level with an increase of
the pain threshold due to an inhibition of all the cyclooxygenase isoforms (COX-1, COX-2,
and COX-3) that are involved in the synthesis of the prostaglandins (PGs) [24]. It can be
administered intravenously to treat mild and moderate postoperative pain in place of opioids
to avoid their adverse effects [25]. It can be administered to reduce the pain associated with
propofol injection, referred as Pain On Propofol Injection (POPI), that still induces pain or
discomfort in large percentage of patients (28% - 90%) [26].
Analgesic opioids, such as fentanyl, are narcotic analgesics administered in combination in the
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Figure 1.3 – a) Midazolam close- and open-ring structures equilibrium; b) Dependency graph
between pH variations of the solution and % of open-ring form of midazolam structure
(inspired by [22]).
anesthesia cocktail [27]. They combine with the opiate receptors on the G-protein modulating
calcium and potassium ion channels on the G-protein complex. Following guanosin-trifosfato
(GTP) to guanosine diphosphate (GDP) hydrolysis there is a channel deactivation of the in-
wardly rectifying potassium channel. Further, the intracellular cyclic AMP (cAMP) is reduced
since adenylate cyclase is inhibited. Therefore, the membrane results hypopolarized and
neuronal excitability is reduced. The opioids’ coupling with the receptors affecting potas-
sium and calcium channels has been demonstrated in different neural structures, as in the
hippocampus, locus coeruleus, and ventral tegmental area to the dorsal root ganglia [28].
Fentanyl, an example of opioid, has an effect that is a hundred times stronger than a dose of
morphine. Due to its potent action it may lead to serious side-effects and its therapeutic blood
concentration has to remain very low (0.6 to 3 ng/ml) [29].
1.1.2 PharmacoKinetics (PK) and PharmacoDinamics (PD)
After the administration of a drug, metabolic processes occur before the drug reaches the target
site. This drug-body interaction process is the object of study of the PharmacoKinetics (PK)
and it can be sub-divided into four distinct phases, known as ADME: Absorption, Distribution,
Metabolism and Excretion of the drug. The PK principles are fundamental to dosing the drug
in an effective and safe manner enhancing its therapeutic effects and decreasing its toxicity.
Once the drug has reached its target site, the attention goes to the PharmacoDinamics (PD) of
the drugs that describes the relation between its concentration and the out-coming effects.
The full PK/PD process is schematized in Fig. 1.4.
Fig. 1.5.a depicts a time trend of a typical plasma concentration of an administered drug. From
the curve, some typical and crucial PK parameters can be extracted. As first, we can identify
the Minimum Effective Concentration (MEC) and the Maximum Tolerated Concentration
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Figure 1.4 – PharmacoKinetic/PharmacoDinamic (PK/PD) metabolic pathway of an adminis-
tered drug.
(MTC), which are very important in defining the therapeutic range of the drug [30]. If the
drug concentration is maintained within its therapeutic range, its effects will be beneficial.
Below the MEC threshold, the drug will probably not manifest its therapeutic benefits. On
the contrary, if the drug concentration overcomes the MTC threshold, toxic effects may arise
[31]. Following this, by intersecting the MEC threshold with the time-trend, we can identify
the onset time when the drug action starts to be effective. The duration of action of the drugs
corresponds to the time between the onset time and the time when the trend declines back
to MEC. Cmax is the highest obtained concentration obtained after a time tmax . It is strictly
related to the rate of the drug absorption. Finally, the Area Under the Curve (AUC) depends on
the drug absorption and indicates the overall action of the drug [30]. The PK model of a drug
is extremely important in identifying the correct and personalized dosage administration to
achieve a desired therapeutic effect.
As PD model the Hill equation [32], also known as "Emax model", is recognized as the best
adapted to describe the relationship between concentration and reversible drug effects. It is
based on the assumption that the plasma drug concentration quickly reaches the equilibrium
with respect to the effect site. It has been deduced by empirical observation of the dependency
between the drug effect (E) and its concentration (C), and it follows this formula:
E = E0± Emax ·C
EC50+C
(1.1)
Where Emax is the maximum effect obtained by the drug, EC50 is the drug concentration
that results in half of the maximum effect and E0 is a baseline effect when applicable. These
parameters are visible in Fig. 1.5.b where the drug effect is plotted versus the logarithm of the
drug concentration. Emax is the plateau reached at high concentrations; EC50 is evaluated as
0.5 ·Emax [33]. In PK context it is possible to define two important properties of the drug: the
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Figure 1.5 – PK/PD model (c.) combines the PK model (a.) describing "what the body does to
the drug" (ADME) and the PD model (b.) defining "what the drug does to the body"; hence the
effects.
Volume of Distribution (DL) and the Clearance (Cl) of a drug. The VD refers to the apparent
volume into which the drug is distributed with respect to the administered dose and the
plasma concentration subsequently observed [34]. The Cl is defined as the sum of the different
drug elimination processes and it is calculated as the volume of plasma completely cleared
from the drug per unit time (i.e. ml/min). Main eliminated pathways are through kidneys
and liver (occasionally also lungs). By knowing these drug properties and the desired plasma
concentration (Cp in mg/ml), it is possible to calculate the required dose (Dr equi r ed in mg) as:
Dr equi r ed =Cp · I ·
C l
f
(1.2)
Where I is the interval between two subsequent doses (min) and f is the fraction of the dose
that enters into the systemic circulation [35].
The PD model aims to define the drug- and system-specific properties that regulate the
biological responses to drugs, meaning the therapeutic effects and not the toxic adverse
reactions. Combined PK/PD models quantitatively describe the relationship between dose,
exposure and response by integrating the PK time-trend of the concentration dosage regime
with the PD observed response, occurring at variable drug plasma concentrations. Therefore,
PK/PD models represent the time-course and the intensity of beneficial and/or non-beneficial
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effects resulting from a certain drug dose [33].
1.1.3 Three-compartment model
The PK observations after a drug dose administration can be theoretically described and
simplified by modeling the in-vivo behavior of the drug through a compartmental model [36].
Three-compartment models, as in Fig. 1.6.a, are normally considered to describe anesthetic
compounds [37].
In the case of anesthesia, the drug is intravenously administered in the central compartment
(principally plasma) characterized by a volume V1 and it is then distributed into two compart-
ments, with volumes V2 and V3, respectively. One corresponds to well-perfused tissues, such
as muscles, and the other to areas with slower perfusion, like fatty tissues [36]. k12 and k13
are the distribution rate constants between compartment 1 and compartment 2 and between
compartment 1 and compartment 3, respectively; k10 is the distribution rate from the central
compartment [35]. The distribution volumes (Vi and V j ) and the rate constants ki j and k j i
are linked to each other according to this formula [38]:
Vi =
ki j
k j i
×V j with i > j (1.3)
The drug diffuses from plasma to brain (target site) following an exponential trend char-
acterized by a first-order rate ke0; hence, there is a lag between the blood and effect site
concentration [36]. The dimensions of the compartments and the inter-compartmental rates
come from the properties of the administered drug (e.g. lipid solubility and patient factors)
[37]. The typical decline time-trend of the plasma concentration obtained for an intravenous
bolus administration is a descending exponential, as represented in Fig. 1.6.b. After the bolus
administration, there is a first sharp reduction (α) of the concentration due to tissue with rapid
redistribution, followed by a second concentration reduction (β) due to the slower tissues and
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then a third concentration reduction (γ) mainly due to elimination. It is possible to deduce
the actual concentration (Cp ) at the time t by this equation [35]:
Cp =G ·e−γt + A ·e−αt +·e−βt (1.4)
1.2 Current state-of-the-art of Total Intra-Venous Anesthesia (TIVA)
Total IntaVenous Anesthesia (TIVA) is a method for inducing GA with a combination of anes-
thetic agents administered through an intravenous route. The first form of intravenous infu-
sion was reported in the seventeenth century when Christopher Wren created a syringe from
pig bladder fixed on a goose quill to inject opium into the veins of a dog (1650s). Afterwards,
Johann Daniel Major from Kiel and Johann Sigismund Elsholtz from Berlin were the first to
practice intravenous injections on people (1660s). Nevertheless, these experimental injections
were not successful and only in the 1800s did this kind of drug administration begin to be
popular. It has been continuously improved up until modern times [39].
1.2.1 TCI pump: principles and limitations
Nowadays, the increase in popularity of TIVA is related with two main factors: first, the
improvement of PK/PD models for the most largely adopted IV drugs, such as propofol;
secondly, the advances in new infusion pump technologies that implement mathematical
algorithms to evaluate the dosage regime, such as TCI pumps [40]. The software of the TCI
pump incorporates the PK model of the infused drug and drives the syringe pumps accordingly.
By solving the complex equations coming from drug distribution in the compartments it
allows dynamic drug-dosage adjustments to achieve and maintain a certain level of sedation
in the patient [41]. The TCI follows the Bolus - Elimination - Transfer (BET) principle to
approximate the plasma level of the drug. According to this principle, to achieve a desired
drug concentration at the target site, a loading bolus dose is given to completely fill the
central volume V1. The subsequent infusion regime then compensates the rapid and the
slow diffusions (k12 and k13) of drug into the peripheral compartments (V2 and V3) and
the drug elimination rate (K10). The loading dose (Dloadi ng ) is calculated as Dloadi ng =
Cp xV1; where V1 is the initial volume of distribution (central compartment) and Cp is the
desired concentration for clinical effect. The infusion rate after the bolus injection helps in
maintaining a steady state plasma concentration of the drug [42]. The TCI system estimates
the initial bolus dose and calculates the speed of subsequent infusion every 10 s to adjust the
rate to reach and maintain the desired Cp . As soon as the target Cp decreases, the infusion is
arrested until the plasma concentration reaches the indicated value and is then restarted with
a lower rate [36].
The PK/PD model for propofol administration has been one of the most studied the imple-
mentation in the TCI pump. Two propofol models are implemented in the actual TCI systems:
the Marsh and the Schnider. The Marsh model fixes all the rate constants, and evaluates the
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Figure 1.7 – The bispectral index is scaled to correlate with important clinical end points during
the administration of an anesthetic agent (inspired by [45]).
compartment volumes and clearances depending on the patient’s weight. The Schnider model
fixes values for V1, V3, k13, and k31, while it adjusts the values of V2, k12, and k21 according to
the patient’s age, and of k10 considering the patient’s total weight, lean body mass (LBM), and
height [43]. Up to now, no evidence has yet been provided to favour the use of one model over
the other. The principal difference between the two methods concern the volume V1 that is
set to 19.4 l and 4.27 l for Marsh and Schnider, respectively for a patient of 85 kg. Therefore,
depending on the operation mode of the TCI pump one is more suitable than the other. In
plasma targeting mode, where the user selects the target plasma drug concentration Cp , since
the Schnider central volume is smaller than the Marsh one, lower doses of propofol are re-
quired to achieve the desired Cp . This bolus dose is often insufficient, leading to inadequate
clinical effects. On the contrary, if the TCI works in effect-site targeting mode, where the user
sets the desired drug concentration at the effect site, the Schnider model is recommended as
larger bolus doses are infused compared to the Marsh model [36].
Even if these TCI system are now commercially available and widely used to administer
anesthesia, there are still important limitations to keep into account. The PK/PD models
implemented on the TCI pump have been developed starting from the observations of the drug
effects on a population that did not cover all individuals. Therefore, they cannot reproduce the
inter-patient variabilities in metabolism. Furthermore, no reliable technique for monitoring
drug plasma concentration during TIVA has been presented yet [44].
1.2.2 Bispectral Index (BIS) monitoring: use and limitations
One of the main challenges in TIVA practices is the monitoring of the Depth of Anesthesia (DOA)
in the patient. By providing an accurate evaluation of the DOA it would be possible to tune the
drug administration according to the individual response. In this way, over- and under-dosing
10
1.2. Current state-of-the-art of Total Intra-Venous Anesthesia (TIVA)
would be avoided and side effects minimized. The need for monitoring anesthesia depth has
lead to the creation of a system based on ElectroEncephaloGram (EEG) or Acoustic Evoked
Potentials (AEP) signals [46]. As stated above in Section 1.1.1, the large majority of anesthetics
(e.g., propofol, paracetamol and midazolam) have an inhibitory effect on the G AB A A recep-
tors in the brain, leading to a progressive diminution of the EEG activity with increasing drug
concentrations [47].
AEP is evaluated by providing the patient with an auditory stimulus and by calculating the
average of the EEG periods immediately after the stimulus, hence considering the evoked
auditory potential. Normally, to measure the DOA, an intermediate latency AEP of 40 ms - 60
ms after stimulation is considered; it corresponds to the neural activity within the thalamus
and primary auditory cortex [46]. Compared to the raw EEG, AEP is a less sensitive method
[47].
Since the measured EEG waveforms are hard to be interpret, some analyses have been in-
troduced to reduce the data into a single number [48]. One of the most widely used indices
for DOA monitoring in Europe is the BiSpectral Index (BIS), as introduced in 1992 by Aspect
Medical Systems. It is statistically evaluated combining the contribution of key EEG signal
features (bispectral analysis and others) recorded every 15-30 s [47]. The four EEG features
that are taken into account for BIS extraction are: (i) the degree of high-frequency (14 to 30
Hz) activation, (ii) the amount of low-frequency synchronization, (iii) the presence of almost
suppressed periods, and (iv) the presence of fully suppressed periods (i.e., flat-line). The
algorithm is represented in Fig. 1.7.a [45]. The BIS index ranges between 0 and 100, as shown
in Fig. 1.7.b: if near 100 the patient is awake, while if 0 the EEG signal is iso-electric. To perform
sedation, the BIS is maintained over the value 70 (> 70) to noticeably decrease the memory
functions, but with probable risk of consciousness [49].
To ensure efficient hypnosis during GA, the BIS values has to be kept between 45 and 60. Lower
values than 40 show an high impact of the anesthetic on the EEG. If very low BIS values are
reached, the risk for iso-electric EEG signals increases [45].
Even though BIS monitoring is a widely used DOA monitoring tool, which helps the anesthe-
siologist in regulation of the anesthesia dosage in induction, maintenance and emergence
phases, there are some crucial limitations that have to be mentioned and considered.
First of all, the evaluation of the BIS value is not instantaneous with respect to the clinical
status variations of the patient. The latency linked with the BIS value evaluation limits the
efficacy of the monitoring.
In addition, also the placement and adherence of the EEG electrodes affect the BIS measure.
Moreover, the BIS can be affected by artifacts due solely to interference from other electrical
devices [50]. Finally, differences in a patient’s age and administered anesthetics modify the
range of BIS values [51].
According to recent studies [52, 53], EEG signal can be complemented by Near-InfraRed Spec-
troscopy (NIRS) hemodynamic signals that optically measure the variations in Cerebral Blood
Flow (CBF), related with the DOA. Nevertheless, even if extremely promising, a combined
monitoring of EEG and NIRS during anesthesia has been not reported yet. This is due to the
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wide different dynamic ranges of the NIRS signal (10 pA - 10 nA), and because the variabilities
due to diverse patients and/or to environmental conditions are not controllable [52].
As a conclusion of these drawbacks, the BIS has to be considered as additional datum to
evaluate DOA and has to be interpreted in the context of other clinical data and monitors [45].
1.2.3 Anesthesia side effects and risks
One of the main advantages of performing TIVA/TCI practices is the reduction of Post-
Operative Nausea and Vomiting (PONV) effects facilitating the GA recovery. To be able to
provide these GA benefits, it is imperative to guarantee a dynamically balanced and personal-
ized dosage of the administered "anesthetic triad". In fact, there is a large variability in the
metabolism of a patient population: some have faster metabolisms, others slower. To achieve
the same state of sedation, the former will need a larger dose of drugs, the latter a lower dose
(Fig. 1.5).
However, there is still no mature monitoring system providing the doctor with the actual
anesthetics concentrations in patient’s plasma. As a consequence, a major concern is that
the patient may suffer from undetected awareness [54]. The reported incidence of Accidental
Awareness under General Anesthesia (AAGA) during TIVA varies between 0 and 1.1%—poten-
tially a higher incidence than during volatile anesthesia [55]. AAGA consequences include
psychological symptoms and Post-Traumatic Stress Disorder (PTSD) [56].
While AAGA is an undesired effect of the under-dosage of the anesthetic compounds, over-
dosing must also be prevented to avoid serious GA complications. These range from PONV
common effects to critical ones like brain damage and death which are, luckily, extremely rare.
The risk of death has been reported to be approximately 0.001% for the American Society of
Anesthesiologists (ASA) evaluated for healthy or with moderate systemic disease patients. The
risk increases with more critical patients’ health status [57].
In the light of this, a continuous measurement of the anesthetic concentrations should be
taken to prevent an incorrect GA dosage.
1.3 Research contributions and thesis outline
Nowadays, as described in Chapter 1, the anesthesia IV infusion is achieved by the use of
TCI pumps. TCI software implements PK/PD mathematical models for each administered
drug to predict and adjust the dose rate on the basis of some physical characteristics of
the patient, such as age, gender etc.. However, these mathematical models are affected by
inaccuracy due to inter- and intra-patients’ variability [58] and due to the impossibility of
predicting the direct relationship between kinetics and the clinical effects of the drug [59].
Therefore, monitoring tools are needed to keep the DOA of the patient under control. Among
these monitoring tools, the BIS, evaluated from the EEG signal, is most frequently used in
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actual practices. Nevertheless, this index is evaluated in an indirect manner, hence, it can
be affected by external factors and is influenced by a delay with respect to variations in drug
concentration [60, 61]. The limitations of the actual technologies for anesthesia practices have
been described in Section 1.2.1. The introduction of TDM systems being able to continuously
provide a real measurement of the drug concentration in the patient would overcome the
restrictions of the actual anesthesia delivery devices. The yield and efficiency of the infusion
TCI pumps would be highly improved by the integration of such TDMs as are able to correct
the mathematical models with real measurements, hence, guaranteeing a safer and more
personalized infusion rate. The objective of this thesis is the design, the realization and the
validation of a complete IoT system for the continuous monitoring of anesthetic compounds
over time.
A sketch of the overall system is depicted in Fig. 1.8 and consists of: (1) a central low-noise,
custom-built electronic potentiostat driven by a RPi that from one side interfaces with (2)
an electrochemical multi-sensing platform integrated into (3) a fluidic device for directing
the sample towards the sensing sites, while from the other side it drives (4) an infusion
pump to withdraw the anesthetic drugs based on the output of (5) a Matlab software running
on laptop for data processing and drug concentration estimation. Finally, the system is
enriched by (6) an IoT cloud-based network developed in Android to keeping the doctor and
the anesthetized subject constantly connected, offering a continuous on-line and remote
sharing and visualization of the measured data.
The development of these systems has to keep in consideration several requirements. From
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one side, the sensing part must guarantee high sensitivity and selectivity for the detection of
several different anesthetics at the same time, and it must be robust to resist deterioration over
time. In fact, a normal anesthesia lasts for up to several hours. On the other side, the electronic
part has to guarantee good performance in terms of easy integration with the sensors, and in
terms of noise rejection.
Concerning the presented state-of-the-art, this thesis presents innovative contributions on:
• Multiple drug detection over time The long-time monitoring of several anesthetic com-
pounds at the same time has been achieved by developing optimized electrochemical
sensors from the point of view of high sensitivity and fouling resistance, and by using
appropriate techniques of analysis. Ready-to-use electrochemical sensors have been
proposed to facilitate the measurement procedure, while maintaining effective on-line
monitoring performance.
• Monitoring of different parameters In addition to the sensors for monitoring anes-
thetic compounds, further sensors have been included in the developed system to
measure pH and temperature parameters in parallel. Combining electrochemical sen-
sors with pH and temperature measures is an advantageous strategy, optimizing per-
formance in different physiological conditions, since these two parameters affect the
electrochemical behavior of drugs.
• Multi-channel portable potentiostat We created a low-noise, powerful and portable
custom-built potentiostat by exploiting the RPi computer. The RPi plays a central role
in the system architecture being able to: (i) drive several electrochemical measurements
in parallel for drugs detection, (ii) control the pH and T module, (iii) communicate with
the Android-based IoT network and (iv) with the syringe pump. We proved the high
quality performance of our portable multi-channel electronic system by referring to the
bulky, commercially available Autolab potentiostat by Metrohm as control.
• Medical IoT network We realized “smart” solutions to provide a compelling tool to be
adopted in hospital monitoring scenarios, such as in anesthesia. The data measured by
our TDM system are sent by the RPi to an Android-based app running on smart-devices
of the anesthesiologist, such as a tablet, a smart-phone or a smart-watch. Through the
application we developed the medical doctor can require specific parameters or receive
alerts of critical conditions registered by one or more of the sedated patients connected
to the IoT network.
• System integration and characterization We integrated the different parts of the sys-
tem and we proved that our system was able to successfully monitor multiple anesthet-
ics’ concentrations over time in complex biofluids, such as undiluted human serum.
Following the Introduction, this thesis is organized in the following way.
Chapter 2 provides an overview of the theoretical background at the basis of this thesis. In
particular, general anesthesia practices will be described in detail and limitations will be
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highlighted. Afterwards, electro-chemistry and electronics notions will be provided together
with important aspects of Android development for IoT.
Chapter 3 presents the design, characterization and validation of the optimum electrochemical
sensor for propofol detection in terms of sensitivity and resistance to undesired fouling, over
time. We demonstrated the continuous long-time monitoring of the drug for more than 4
hours and, in human serum, in presence of its main interferent compound, e.g. APAP.
Chapter 4 shows the implementation and the validation of the electrochemical sensors for
the other two main anesthetic compounds of the cocktail, such as APAP and Midazolam (MZ).
The performances of different carbon nano-allotropes have been compared with respect to
the sensing properties of these two compounds in their pharmaceutical range.
Chapter 5 describes the process for the realization and validation of a custom-built portable
electronic platform for the simultaneous monitoring of several compounds at the same time,
together with pH and temperature. To this aim, the platform has been designed with three
independent channels and a pH-T module all driven by a RPi unit. The data are made available
to external devices by exploiting Wi-Fi technology. The optimization process was focused on
improving the board performances in terms of interfacing with electrochemical sensors and
noise reduction.
Chapter 6 reports on the integration of the different parts of the overall system, together
with the realization of the IoT network and the fluidic device to drive the sample directly
on the sensing sites. The complete system has been validated by proving the simultaneous
monitoring of the concentration trends over time of two main anesthetics, e.g. APAP and
propofol, in human serum.
Finally, Chapter 7 sums up with the conclusions and presents possible future improvements
of the system.
The work described in these chapters follows several publications obtained within this thesis.
Therefore, the text and images in the chapters are often extracted from my published papers.
The Table 1.1 makes a correspondence between the various parts of this thesis with the related
citations.
Table 1.1 – Table of correspondence between the thesis chapters and my published works.
Chapter Section Ref.
3
3.1, 3.3 [62]
3.4 [63]
4 - [64]
5
5.1, 5.4 [65] and [66]
5.2 [67]
6
6.2 [68] and [69]
6.1, 6.3, 6.4 [70]
6.5 [71]
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2 Background
2.1 Drug monitoring with electrochemical sensors
Personalized drug dosage is crucial to optimizing benefits in patients’ treatments. TDM is
the clinical practice of measuring the drug concentration in patient’s bloodstream at certain
time-intervals and then correlating it to maintain the drug concentrations constant within a
targeted therapeutic range, thereby optimizing individual dosage regimens [72]. TDM systems
are of vital importance especially for drugs with narrow therapeutic ranges, drugs with marked
PK variability, medications for which target concentrations are difficult to monitor, and drugs
known to cause therapeutic and adverse effects [73]. This is the case of anesthesia practices
where a cocktail of three difficult-to-handle drugs are infused in a patient’s veins.
A reliable sensing platform is needed to develop a TDM system. To this end, electrochemical
sensors are considered as ideal devices due to their high sensitivity and specificity, small
dimensions and portability, low costs and simplicity, which allow an accurate, rapid and
quantitative detection of drugs [74] and an easy integration within electronic platforms and
read out circuits. The monitoring system we have designed and implemented integrates
electrochemical sensors for simultaneously detecting the three main anesthetic compounds:
the hypnotic, propofol; the analgesic, paracetamol and the muscle relaxant, midazolam.
Hereafter, an overview of the adopted voltammetric techniques is provided.
2.1.1 Electrochemical sensing techniques: an overview
Electrochemistry is the branch of chemistry which studies the interrelation between electrical
and chemical effects. This includes chemical reactions caused by an exchange of electrons
(current), and vice-versa, the production of electrical energy by chemical reactions [75] . These
processes happen in an electrochemical cell which consists of an electronic conductor (an
electrode) and an ionic conductor (an electrolyte) made by water-based or other solvents in
which ions are solvated, e.g. human body fluids.
The typical electrochemical cell unit can be designed in two- or three-electrode configurations
depending on the needs of the experiment. Fig.2.1 depicts the two different electrochemical
17
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Figure 2.1 – Schematic representation of the a) two-electrode and b) three-electrode configu-
rations (inspired by [76]).
architectures. The two-electrode configuration consists of a Working Electrode (WE) and a
Reference Electrode (RE), while the three-electrode configuration also includes an additional
auxiliary electrode, the Counter Electrode (CE).
The overall chemical reaction in the cell is based on two half-reactions happening at the two
electrodes as a consequence of the potential difference at the interface (electrode/electrolyte).
Normally, the interest is only in one of the two half-reactions, and the electrode at which
it occurs is the WE. To standardize the other half of the cell, the RE is created by constant
composition so that it is kept at a fixed and known potential. Hence, the potential of the WE
can be read and controlled with respect to the RE. By driving the electrode to more negative
potentials the electrons’ energy increases up to a higher level where it will be transferred to
the electrolyte. In this case, a reduction current from the electrode to the solution occurs,
shown in Fig. 2.2.a. On the other hand, if the electrons’ energy is decreased by imposing a
more positive potential, the electrons of the electrolyte will be energetically facilitated to flow
from the solution to the electrode creating an oxidation current, represented in Fig. 2.2.b.
The potentials at which these electron transfers occur are related to the standard potential,
E0, which is characteristic for each chemical species. The internationally accepted primary
reference is the Standard Hydrogen Electrode (SHE), which has a standard electrode potential
(E0) of zero volts at all temperatures. A common-used RE is the silver-silver chloride electrode:
Ag/AgCl/KCl (saturated in water), with a potential of 0.197 V vs. SHE. In the two-electrode
configuration, the RE acts as electron supplier and as a reference for the potential at the
same time; therefore, it is very difficult to maintain a constant potential to refer to [77]. For
this reason, the three-electrode configuration is normally adopted. In this architecture, an
additional CE is introduced to close the current circuit and is usually made of inert material
(e.g. Pt) to not give contribution in the electrochemical reaction. The current flows between
the WE and the CE; hence the CE must have a higher surface area with respect to the WE, not
to limit the RedOx kinetics.
The potential difference is controlled between the WE and the CE and it is measured between
18
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Figure 2.2 – Explanation of electron flow from electrode to solution, and vice-versa, in case of
a) reduction and b) oxidation processes, respectively.
the RE and the WE. This configuration allows the potential across the electrochemical interface
at the WE to be controlled with respect to the RE.
This configuration has been chosen for the design of the anesthesia monitoring system, the
object of this work. The current from the cell is the result of two main contributions: Faradaic
and non-Faradaic processes. The Faradaic reaction comprises the RedOx where electrons are
transferred across the metal-solution interface. However, whenever an electrode is immersed
in an electrolyte, adsorption and desorption of ions happens at the interface affecting the
potential. More specifically, there will be a separation and re-distribution of charges on the
metal electrode and in the solution, which has been shown experimentally to behave like
a capacitor and is called electrical double layer (Cdl ). However, Cdl is often a function of
potential across it, differently by the real capacitors. The formation of this Cdl at the electrode
interface once in contact with the electrolyte solution is described by the Helmholtz theory.
As shown in Fig. 2.3, at the electrode/electrolyte interface the ions in the solution tend to
organize themselves in several "layers":
• Inner Helmholtz Plane (IHP), which contains solvent molecules and other species that
are specifically adsorbed on the electrode’s surface;
• Outer Helmholtz Plane (OHP), which contains solvated ions that are NON-specifically
adsorbed on the electrode’s surface;
• diffuse layer (DL) , which extends from the OHP into the bulk of the solution.
Although the Faradaic processes are of primary interest to the investigation, the non-Faradaic
contribution can not be neglected.
The potential of the cell, which corresponds to the potential difference between WE and RE
(E , Vcel l in Fig. 2.1), can be expressed by the Nernst equation:
E = E0+ RT
nF
· ln( Cox
Cr ed
) (2.1)
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Figure 2.3 – Simplified illustration of the Helmholtz double layer planes where the potential is
developed in the area of interface between negatively charged electrode and the electrolyte.
where E0 is the standard RedOx potential referred to the SHE, R is the gas constant (8.314472 J
K-1 mol-1), T the absolute temperature, n the number of electrons exchanged in the RedOx
reaction, F the Faraday constant (96485.33289 C mol-1), and Cox and Cr ed are the concentration
of the oxidized and reduced species, respectively. The equilibrium potential is achieved when
the RedOx reaches the equilibrium, which means that the concentration of oxidized species
equalizes the concentration of reduced species.
The concentration of the species Cox and Cr ed at the electrode’s surface are not the same as
those in the bulk solution. Therefore, a gradient is established and a driving diffusion force
transports the analyte towards the electrode surface or the bulk solution. The current ampli-
tude produced by the RedOx reaction of the analyte, once in contact with the electrode surface,
is affected by this diffusive transport phenomena. The concentration gradient established
between the solution near the electrode surface and the bulk solution depends on the applied
potential, according to the Nernst equation (Eq. 2.1).
To have a complete understanding of the phenomenon at the electrode/electrolyte interface,
we can combine Faraday’s law (the observed current is related to the concentration of the
analyte) with Fick’s first law of diffusion (flux is proportional to the concentration gradient) as
follows:
m = QM
F z
(2.2)
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Where m is the mass, Q the charge (96485 coulombs), M the molar mass, F Faraday’s constant
and z the valence number.
J =−D
(
∂ϕ
∂x
)
(2.3)
Which describes the diffusion process in terms of a flux (J); hence as the amount of substance
flowing through a given area in a determined period of time.
By combining Eq. 2.2 and Eq. 2.3 a fundamental general relationship to calculate the diffusion-
limited current at the WE is obtained [78] :
i (t )= dQ
d t
=−nF (F lux)= nF AD
(
∂C
∂x
)
x=0
(2.4)
Where n is the number of electrons involved in the half-reaction, A is the electrode’s area (cm2),
D is the analyte’s diffusion coefficient (cm2/s), and
(
∂C
∂x
)
x=0 is the concentration gradient at
the surface of the electrode.
If we consider an electrochemical cell as a "black box", a particular excitation function (e.g.
a potential waveform) can be applied as input, and a particular response function (e.g. the
resulting variation of current with time) can be measured, as sketched in Fig. 2.4. To apply the
desired potential waveform, the electrochemical cell is connected to a potentiostat instrument
that controls the voltage across the WE and the CE adjusting it so that the desired potential
is applied between the WE and the RE. The aim of the experiment is to obtain information
about the electrolyte, with which the electrodes are in direct contact.
Several different electro-analytical techniques are available depending on the applied wave-
form, but the most common are potentiostatic and potentiodynamic methods.
In the next section the methods that were employed in this thesis will be described, in par-
ticular: ChronoAmperometry (CA), as potentiostatic method, and Cyclic Voltammetry (CV)
and Differential Pulse Voltammetry (DPV), as potentiodynamic methods. The main objective
of these investigative techniques is to measure the concentration of specific electro-active
analytes; e.g. anesthetic compounds.
2.1.2 ChronoAmperometry (CA)
To perform a CA measurement, a fixed potential is applied at the time t0 to the electrochemical
system and the current is measured as a function of time, as in Fig. 2.5.a. The applied potential
Electrochemical 
Cell
Exitation
Waveform
Observed
Response
Figure 2.4 – Electrochemical cell SEEN as a "black box"
21
Chapter 2. Background
Applied Potential Current
Time Timet0
Ei,Ef
Es
t1 t0
t1
Ca
th
od
ic
A
no
di
c
decay as 1/t1/2
Time (s)
Cu
rr
en
t (
nA
)
a. c.b.
Figure 2.5 – Double potential step chronoamperometry (CA): a) exciting waveform and b)
measured current. b) CA trend over time: current variations due to increased concentrations
of the target analyte in the solution.
is chosen as the oxidation or the reduction potential of the target analyte, so that it is possible to
monitor the variation of the current from the electrochemical cell in time, as in Fig. 2.5.b. The
current (i) flowing through the electrochemical cell is proportional to the analyte concentration
and it is described by the Cottrell equation:
i =
nF AcOj
√
D j
p
pit
(2.5)
Where n is the number of exchanged electrons, F is the Faraday’s constant, A is the area of the
electrode (cm2), cOj is the initial concentration of the reducible analyte j (mol/cm
3), D j is the
diffusion coefficient for species j (cm2/s) and t is the time (s). This current also includes the
contribution of the double layer phenomena at the interface, which generates a capacitive
current iC . This iC decays as a function of 1/t ; therefore, it is only visible during the initial
instant (a few ms) of the application of the potential step, as shown in Fig. 2.5.a. It is normal
practice to measure the current given by the solution without the analyte (blank solution) and
then subtract this value from the measured i-t data [79].
Cyclic Voltammetry (CV)
CV is a most popular electroanalytical tool for obtaining rapid quantitative information on a
RedOx process: (i) electron-transfer kinetics, (ii) diffusion coefficients, (iii) thermodynamic
and (iv) subsequent chemical reactions or adsorption processes. To perform a CV measure-
ment a linear sweep-potential scan is applied as an input waveform to the electrochemical
system, as shown in Fig. 2.6. The applied potentials are ranged in a determined interval of
values (E0 and E1) so as to provide the RedOx potential at which the target analyte reacts. This
technique is usually performed as a first investigation of the electrochemical system.
As soon as the applied potential reaches a sufficient negative or positive value, the target
analyte in the solution may gain/transfer electrons from/to the electrode’s surface; afterwards,
the voltage is reversed towards its first value E0. The measured current amplitude is propor-
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Figure 2.6 – A linear sweep potential scan is applied in real time to the electrochemical system;
a voltammogram is obtained by plotting the measured current from the cell vs. the applied
potential.
tional to the concentration of the analyte in the solution; therefore, it is possible to analytically
evaluate it.
The measured current from the electrochemical cell can be plotted as a function of the applied
potential obtaining a voltammogram (potential is plotted on the x-axis while current on the
y-axis). The voltammogram may reveal several peaks; each of them denotes a particular
electrolytic process in solution. It is possible to decide the initial direction of the first sweep,
depending on the characteristic of the analyte: if the analyte is oxidable, the first sweep starts
in the positive direction; whereas if the analyte is reducible, the first sweep begins in the
negative direction.
Another information provided by the voltammogram refers to the electrochemical reversibility
of the RedOx couple. If the reaction is reversible, two peak potentials from the anodic sweep
(oxidation), Epa , and from the cathodic peak (reduction), Epc , can be read from the voltam-
mogram, and their difference ∆Epeak can be related, through the Nernst equation (Eq.2.1),
with the number of electrons taking part in the RedOx (n). The relationship is given by:
n∆Epeak = 59mV (2.6)
To evaluate the reversibility of the process, it is possible to estimate the ratio of the peak
currents
ipc
ipa
. If the ratio is equal to 1, it is an indication of reversibility. If the ratio is < 1 but
a return peak is present, then the electrochemical reaction is said to be pseudo-reversible.
Finally, if only one peak is visible in the voltammogram, the process is irreversible. The peak
current amplitudes are measured vertically from the peak down to a background baseline,
which is extrapolated from the steady-states before the peaks area in the CV plot (as shown in
Fig. 2.6).
The quantitative information regarding the analyte concentration is obtained by using the
23
Chapter 2. Background
Randles-Sevcik equation:
ipeak = 0,4463 ·nF AC
√
nFνD
RT
(2.7)
Where n is the number of transferred electrons, ν is the scan-rate for the potential sweep
(V/s), F is Faraday’s constant, A is the electrode area (cm2), R is the gas constant, T is the
absolute temperature (K) and D is the diffusion coefficient of the analyte(cm2/s). Thanks to
this equation it is possible to calculate the peak current, ipeak (either anodic or cathodic), in
terms of the concentration C of the analyte. Moreover, if the analyte concentration is known,
then this formula can be used to evaluate the diffusion coefficient of the analyte [78].
Differential Pulse Voltammetry (DPV)
In the differential pulse techniques, two potential steps with similar short duration are super-
imposed on the potential waveform. The main advantage introduced by these techniques
is that the non-Faradic current due to double layer effect is eliminated (or nearly); therefore
higher sensitivity of the measurements is ensured. As a result of this advantage, these kinds
of method are widely used in chemical analysis [80]. In the DPV, the potential waveform is
generated by superimposing small pulses of constant amplitude upon a staircase waveform,
as shown in Fig. 2.7. The measured current is evaluated as the difference between two currents
sampled before and at the end of a pulse, respectively. That is why the non-Faradic current
contribution is eliminated. Therefore, each pulse period will produce one point according to
the equation in2− in1 =∆in,d p ; where n corresponds to the pulse number and ∆in,d p is the
output current. The differential pulse voltammogram represents the ∆in,d p as a function of
the applied potential. In case of a reduction, as soon as the applied potential reaches a value
near the RedOx potential, the differential current reaches a maximum, and decreases to zero
as the current becomes diffusion-controlled; hence obtaining a symmetric peak [81].
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Figure 2.7 – DPV potential wave form and recorded voltammogram.
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2.1.3 Sensor calibration
The design and the development of a sensor strongly depends on the requirements of the final
application. Main sensor features that need to be evaluated are:
• Selectivity: the sensor must be selective toward the desired analyte;
• Sensitivity: ability to discriminate small variations of the analyte concentration;
• LOD: the minimum analyte concentration that can be detected by the sensor;
• Dynamic Linearity Range: ability to follow rapid changes in the input parameter (e.g.
variations of the analyte concentration).
Therefore, before using a sensor, it is fundamental to calibrate it in order to characterize
its performance. A calibration process provides a calibration curve which gives the relation
between the sensor output and the analyte concentration. To build the calibration line, it is
necessary to measure the sensor response (in voltammetric sensor it is a current), at increasing
and known concentrations of the analyte. As shown in Fig. 2.8, the sensitivity can be evaluated
as the slope of the calibration curve, while the LOD can be defined, according to International
Union of Pure and Applied Chemistry (IUPAC) standard, as:
LOD = 3 ·σb
Sensi t i vi t y
(2.8)
Where σb is the standard deviation from the signal obtained from the blank (a solution
identical to that analyzed but without the analyte) and the factor 3 maintains the required
confidence level of 99% between the observed signal and the blank response [82].
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Figure 2.9 – Example of carbon nano-scale structures for enhancing the sensing performance
(adapted form [84]).
Since this thesis is focusing on electrochemical sensors, the calibration has to consider pH
and temperature variations of the analyzed solution. Indeed, according to the electrochemical
theory, these two factors may vary the voltage at which the RedOx reaction is happening in
the electrochemical cell and the amplitude of the measured current signal. These effects are
visible if considering the full version of Nernst equation (Eq. 2.1):
E = E0+ RT
nF
· l n( Cox
Cr ed
)− RT
nF
·pH (2.9)
It is evident that there is a dependence on pH and temperature (T) variations [83]. For this
reason, monitoring pH and temperature is crucial to ensuring reliable electrochemical mea-
surements. Moreover, by considering the final application where biological fluids represent
the analyzed solution, if pH and temperature are also detected, additional information on the
health-status of the patient can be revealed (e.g. fever, alkalosis, acidosis etc.).
2.1.4 Enhancement of electrode performance
Electrochemical methods are promising technologies for clinical use. The main challenge
in the fabrication of electrochemical devices resides in the improvement of their sensing
performance. To that aim, nanomaterials can be employed to enhance their electron-transfer
properties. Indeed, nanomaterials offer high electrical conductivity, improved surface-to-
volume ratio, structural robustness, catalytic features and excellent stability characteristics
[85].
Carbon nano-scale allotropes can be exploited for their outstanding chemical, mechanical
and electrical properties, such as high stability at environmental conditions, strong covalent
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bond formation etc. [86]. Main carbon nano-scale allotropes are represented in Fig. 2.9 and
listed hereafter [87].
• Graphite is a natural allotrope with an extended sp2-hybridized carbon atoms network,
organized in a hexagonal honeycomb structure. It is extremely conductive and with low
dissipation power. It consists of countless layers of carbon atoms lying on top of each
other, weakly bonded together. The material is extremely soft and it is employed for
creation of graphite pencils [88].
• Diamond is a natural allotrope with a C-sp3 hybridization and tetrahedral bonding
atom network. It is extremely hard, chemically inert and with high electrical resistivity.
To be used as electrode material, it has to be doped to become conductive. P-doping
with boron is a common practice, and the obtained BDD conductive material is highly
resistant to surface biofouling and chemical degradation [89, 90].
• Fullerene C60 is a synthetic allotrope consisting of a spherical network of sixty struc-
turally equivalent sp2-hybridized carbon atoms in the shape of a sphere [87].
• Graphene is a single isolated layer of graphite in sp2-hybridization form. It has extraor-
dinary electrical, thermal, and physical properties [91].
• Carbon NanoTube (CNT) have properties similar to graphene since it is also in sp2
configuration. It can be created in Single-Walled Carbon NanoTube (SWCNT) or Multi-
Walled Carbon NanoTube (MWCNT) structure. The former consists of a single graphene
sheets wrapped into a cylindrical tube shape (diameter between 0.4 and 2.5 nm); the lat-
ter derives from more than one graphene sheets rolled in a cylindrical shape (diameters
up to 100 nm) [88].
Carbon-based nano-materials have been widely adopted to modify electrodes in order to
obtain improved sensing performance. For instance, ion selective sensors based on a nanos-
tructures as solid-contacts showed superior performance when compared to other conductive
polymeric sensors [92]. In addition to this, since nano-structures provide a larger electrode’s
area, it was also proven that they enhance the electron-transfer properties as well, as they
provide a more favorable adsorption of bio-functionalization structures, such as enzymes [93]
and proteins [94].
In this thesis, diamond and graphite have been investigated for propofol detection to exploit
their hardness and high conductivity properties, as described in Chapter 3, while fullerene-C60
and MWCNTs have been used in modified carbon-based electrodes to enhance the sensitivity
performance in midazolam detection, as reported in Chapter 4.
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2.2 Electronics for electrochemical sensing
2.2.1 Potentiostat
Potentiostat instruments are fundamental tools for performing electrochemical measure-
ments. The general structure of a potentiostat is illustrated in Fig. 2.10. The main functionali-
ties of a potentiostat are:
• Driving the sensor electrodes by applying the desired excitation waveform to the cell
(VC ELL),
• Ensuring that the applied voltage remains stable in order to supply the current necessary
for the electrochemical reaction to occur (Potential Control block in Fig. 2.10),
• Measuring a current as output signal from the electrochemical cell (Current Readout
block in Fig. 2.10).
Power 
Supply
PC
Control Logic,
Waveform Signal
Generation
ADC,
Data Processing
Data Transmission
Potential 
Control
Current
Readout
Potentiostat
Electro-
chemical
Cell
Figure 2.10 – Main blocks of a potentiostatic measurement.
Potential control configurations
To control the voltage applied between WE and RE two different configurations are feasible:
the grounded counter electrode and the grounded working electrode. The former is depicted
in Fig. 2.11, but the latter is normally preferred. As illustrated in Fig. 2.12.a, the basic imple-
mentation is obtained by keeping the WE at the ground (GND) while an operational amplifier
(Driving Amplifier controls the cell current IC ELL , so that the cell potential VC ELL corresponds
to the desired excitation potential VI N .
This architecture is extremely simple to implement; however, some limitations have to be
considered. Indeed, the functionalities of the potentiostat depend on the Driving Amplifier
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Figure 2.12 – a) General schematic of a grounded WE configuration and b) schematic with
voltage buffers to isolate driving amplifier and RE.
characteristics. To ensure zero-current flowing in the RE to avoid polarization effects, the
driving amplifier input bias current has to be small while the input resistance should be very
large. Furthermore, since the electrochemical cell is the load and feedback network of the
amplifier, it is possible to isolate the driving amplifier and the RE from whatever currents the
load may produce by adding two buffer amplifiers in its input, as shown in Fig. 2.12.b. The
voltage gain and the input offset voltage of the driving amplifier define the accuracy and the
linearity of the potential control unit [95].
Waveform generator The various voltammetric techniques differ from one another accord-
ing to the excitation waveform being applied to the electrochemical cell. Therefore, a waveform
generator is a crucial block to be included in an electrochemical circuit instrumentation. A
multi-mode waveform generator is desired to produce signals of various shapes, amplitudes
and frequencies.
Direct Digital Synthesizer (DDS) architecture can be designed to generate all the needed
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Figure 2.13 – Typical SPI bus: bidirectional communication between a master and three
independent slaves.
excitation waveforms for different electrochemical measurements (e.g. CA, CV and DPV). DDS
is a mixed-mode circuit consisting of a Digital to Analog Converter (DAC) digitally-controlled to
implement all shapes and multiple frequencies from a reference frequency, which is provided
[96].
In this thesis, the DDS has been developed by a micro-controller unit that sends, with a certain
frequency, an increasing or decreasing digital value to the DAC, which converts it in an analog
voltage to be applied to the electrochemical cell. The communication between the micro-
controller and the DAC unit exploits the high speed Serial Peripheral Interface (SPI) interface,
which only needs an external clock to generate the desired waves, as shown in Fig. 2.13. The
micro-controller acts as the master while the DAC as the slave. Further, since the SPI bus can
operate with a single master device and with one or more slave devices, it is possible to let
the micro-controller control several DAC in parallel (three slaves architecture in Fig. 2.13).
This is of high interest for the actual application since the system has to monitor up to three
drugs (composing the anesthesia cocktail) at the same time. If more than one slave device
is connected to the micro-controller, the Slave Select (SS) line is used to address the DAC of
interest.
Current read-out architecture
As soon as the driving signal is imposed on the electrochemical cell, RedOx reactions happen
in the solution at the WE interface. Therefore, custom circuits for reading out the RedOx
current have to be implemented. Also in this case, different approaches can be adopted.
However, for the purposes of this thesis, only voltage-mode circuits will be described [95].
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Figure 2.14 – General schematic with TIA.
TransImpedance Amplifier (TIA) In this configuration the measured current from the elec-
trochemical cell is directly converted into a voltage signal by the use of a TransImpedance
Amplifier (TIA), as shown in Fig. 2.14.a.
The Faradic current IC ELL from the RedOx reaction flows in the single resistor in the feedback
RT I A of the TIA and is converted into a voltage Vout ,T I A according to the equation:
Vout ,T I A =−IC ELL ·RT I A (2.10)
Therefore the output signal Vout ,T I A is proportional to the Faradic current IC ELL . In addition
to the TIA stage, it is possible to include in cascade further amplification stages to enhance
the electrochemical signal. The final amplification would be provided by the product of
the amplification stages. Programmable Gain Amplifier (PGA) can be used for this further
amplification stage since it offers the possibility to test different gains, ensuring the flexibility
of the circuit.
If we consider the equivalent circuit of the operational amplifier, as in Fig. 2.14.b, we can
notice that the input impedance is equivalent to the impedance between the positive and the
negative inputs. This impedance is affected by some leakage currents (Io f f set ), which could
cause problems both in IC ELL current readout and VC ELLtracking, especially if low Faradic
currents are generated by the RedOx and a very high value of RT I A is required. This error can
be minimized by choosing an amplifier with low offset and bias current guaranteed by very
high input impedance RI N .
Furthermore, flicker and thermal noises of the TIA have to to be considered for the design.
These noises can manifest themselves as:
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• Output voltage (Vnoi se ): VOU T =Vout ,T I A +Vnoi se
• Input current (Inoi se ): Inoi se = Vnoi seRT I A so that the minimum Signal to Noise Ratio (SNR) of
the TIA is established as:
SN R = IC ELL
Inoi se
(2.11)
2.2.2 Equivalent circuit for an electrochemical cell
A largely adopted approximation of the equivalent circuit for the three-electrode cell is shown
in Fig. 2.15. Passive components of the circuit are RSW , RSR and RSC that take into account the
distances from the electrodes and can be evaluated according to the Ohm’s second Law as:
R = ρ · d/2
A
(2.12)
Where A is the area of the electrode, d is the distance between the electrodes, and ρ is the
resistivity of the solution.
A similar equation to Eq. 2.12 can be adopted for evaluating the charge transfer resistances
for CE and WE branches; e.g. RC E and RW E , respectively. In this case, the d corresponds to
the thickness of the electrode and ρ is the resistivity of the electrode’s material. Normally,
the area of the CE is designed to be very large, so as to observe a low resistance, which only
depends on the material used for the fabrication. The resistance related to the RE branch
RRE is absent because both the resistance and the capacitance of the reference must be very
large to ensure zero-current flow. Finally, the capacitances CW E and CC E model the double-
layer capacitance effect at the WE-/CE-electrolyte interfaces, respectively [98]. In the circuit
represented in Fig. 2.15 an active component is also present. This Faradaic-current generator
iW simulates the current deriving from the chemical reaction happening at the WE. According
to electrochemical conventions, positive currents (oxidation) flow from the WE to the CE, and
vice-versa for negative currents (reduction). This WE current iW can be considered as the sum
RSCRSW
RSR
RE
WE CE
RCERWE
CWE CCE
Solution
Vcell
Potentiostat
iW
Figure 2.15 – Equivalent circuit for the three-electrode amperometric configuration, modified
from [97].
32
2.3. IoT in medical applications
Figure 2.16 – Structure of the IoT reference model. (Reprinted from [101].)
of Faradic (iF ), non-Faradic (inon−F ) and noise (inoi se ) currents [83]:
iW (t )= iF (t )+ inon−F (t )+ inoi se (t ) (2.13)
If a constant bias potential drives the electrochemical cell, as in CA measurements, then the
current iW does not depend on the bias, and it is possible to define IW = IF as the average
value of the Faradic current obtained for a certain analyte concentration [98].
2.3 IoT in medical applications
IoT is a growing topic of common interest since it is having a great impact on several aspects
of everyday-life and the behavior of users, in private and business contexts [99]. According
to the definition provided by Recommendation ITU-T Y.2060 (06/2012), [100] IoT is a “global
infrastructure for the information society, enabling advanced services by interconnecting
(physical and virtual) things based on existing and evolving interoperable information and
communication technologies”. "Any THING" that able to connect to the Internet is enabled
to exchange data and interact with other devices within the network and access information
at "any TIME" and from "any PLACE". Therefore, an IoT network consists of a large number
of heterogeneous devices that are dynamically interconnected so as to exchange data and
services of different kinds. In this context, it is crucial to provide standard and flexible architec-
tures able to handle and sustain this traffic. The IoT reference model, represented in Fig. 2.16,
is based on four layers, including also management and security capabilities [100].
1. Application layer includes the IoT applications
2. Service support and application support layer consists of generic and specific capabili-
ties. The former can be used by different applications; the latter are detailed capabilities
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Figure 2.17 – Schematic representation of the IoT possible fields of application. (Reprinted
from [102].)
to provide different support functions to specific target applications.
3. Network layer relies on networking and transport capabilities to provide control over
network connectivity functions (e.g access and authentication, etc.) and the transport
of IoT service and data.
4. Device layer is categorized into device and gateway capabilities. The device capabil-
ities include direct and indirect interaction (including "sleeping" and "waking-up"
mechanisms to save energy) with the communication network even through ad-hoc
networking in some specific scenarios. The gateway capabilities refer to the ability to
interface different kinds of wired or wireless connectivity technologies (e.g. ZigBee,
Bluetooth or Wi-Fi) and to communicate through various network technologies (e.g. 2G
or 3G networks, digital subscriber lines (DSL), Ethernet or others). Furthermore, the
gateway capabilities are also needed in protocol conversion when different device layer
protocols are used (e.g. Wi-Fi and Bluetooth protocols), or when different protocols are
used at the device and network layers (e.g. ZigBee protocol at the device layer and a 3G
protocol at the network layer).
5. Management capabilities can be either generic or specific. The generic management
capabilities include the general management of the device ((de)-activation, diagnostics,
updating), and the management of the local network topology and of the traffic and con-
gestion. The specific management capabilities are related with the specific requirements
of the application.
6. Security capabilities are of two kinds: generic and specific. Generic security capabilities
are independent of applications and are applicable to different IoT layers, such as
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Figure 2.18 – Projected economic impact market of IoT applications by 2025. (Reprinted from
[102].)
the application, the network and the device layers, handling the authorization, the
authentication, the confidentiality and integrity protection. Specific security capabilities
follow the application requirements.
There are several domains and environments in which IoT solutions can be adopted playing
a remarkable role. These applications range from transportation and industrial automation
to health-care and smart-environments [102], as in Figure 2.17. In particular, the adoption
of IoT solutions in the medical field lead to the realization of powerful tools for medical staff
and patients providing optimized monitoring even remotely, improved management of the
health-care systems and advanced solutions to diffuse medical services with the respect to the
specific policies and regulations.
If we have a look at the economic impact of IoT by 2025, shown in Figure 2.18, it is evident that
health-care applications cover one of the largest markets (41% of impact). The whole annual
economic impact caused by IoT is estimated to be in the range of $2.7 trillion to $6.2 trillion
by 2025, of which $1.1−2.5 trillion annual growth is from the health-care market [103]. Within
this development of IoT, medical IoT applications are gaining increasing popularity paving
the way towards the realization of Smart-Hospitals. Smart-Hospitals are supported by IoT
technologies to provide advanced diagnosis, treatment, management and decision services
by enabling device interoperability and fluent exchange of information [104]. Additionally,
medical IoT solutions also include remote medical services, such as remote diagnosis and
monitoring of patients, which are grouped under the concept of Telemedicine [105].
To guarantee high performance in an IoT network, some requirements has to be guaranteed
[102, 106]:
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1. Scalability - The IoT network has to guarantee the possibility including new devices,
services and functions without negatively affecting the quality of the existing services.
To do that, a ground-up approach has to be followed. The challenges related to this
requirement are due to the fact that diverse hardware platforms and communications
protocols have to be interfaced. Furthermore, it is very difficult to create a testing set
with such highly-scalable networks.
2. Heterogeneity - End-to-end interoperability challenges IoT networks since a large num-
ber of heterogeneous devices has to be connected together. This should be kept in
consideration by both application developers and IoT device manufacturers in order
to deliver services for all customers regardless of the specifications of the hardware
platform that they use.
3. Reliability - The proper operation of the system should reflect the specification. There-
fore, the availability of information and services has to be guaranteed over time. This
is especially true in the case of medical applications. Reliability must be implemented
throughout all the IoT layers.
4. Mobility - A key role of IoT is to provide services continuously to the connected users
while on the move. Therefore, it is fundamental to handle such mobility and dynamism
within IoT networks.
5. Security and Privacy - In IoT heterogeneous networks security and privacy represent
two main challenges that have to be faced. Data must be protected from unauthorized
access and has to be transmitted and received without any modifications, hence ensur-
ing its integrity. In particular, for medical IoT networks, the main security challenges are
related to: (i) confidentiality, (ii) authentication, (iii) access control, (iv) privacy, (v) trust
and (vi) policy enforcement. The confidentiality ensures that the data is readable only by
the target receiver. Authentication ensures the validity of an user and normally requires
the generation of a session key. Access control algorithms provide new connections only
after the verification of the quality of communication. These algorithms are a protection
against “man in middle” attacks. Privacy is concerned with different aspects such as
devices, communication, storage and processing. Trust management systems estimate
the dynamic trust scores for all the cooperating nodes for handling misbehavior. Finally,
policy enforcement governs the access rights of users for specific services [107].
2.3.1 Cloud computing
An IoT network connects a large number of physical objects through the Internet. Therefore, an
enormous amount of data is exchanged among the devices in the network. We normally refer
to this as “big data”. To handle and manage these loads of information correctly, efficient data
storage and process mechanisms have to be provided. Due to the fact that “big data” normally
exceeds the capability of commonly used hardware and software, emerging technologies like
cloud computing and data analytics are spreading. Cloud services allow users to use software
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remotely, as well as hardware components and services provided by third parties. According
to Marston et. al. cloud computing features can be summarized by this definition: ‘‘It is an
information technology service model where computing services (both hardware and software)
are delivered on-demand to customers over a network in a self-service fashion, independent
of device and location. The resources required to provide the requisite quality-of-service
levels are shared, dynamically scalable, rapidly provisioned, virtualized and released with
minimal service provider interaction.” [108]. Therefore, cloud solutions represent a powerful
tool for the IoT “big data” handling. There are a lot of free and commercially-available cloud
platforms and frameworks available to host IoT services. In this thesis, the PrYv middle-ware
solution was used. It enables organizations to collect, store and use data to spark new and
innovative projects, enhance existing services and improve consumers’ services [109]. The
term “middle-ware” refers to a software layer placed between applications and objects. It is a
“network-oriented” vision that aims to provide solutions to frequently encountered problems,
such as heterogeneity, interoperability, security, etc., and facilitates the interfacing of new
services with previous technologies to produce novel and advanced services [110]. The main
features offered by middle-ware are the transparency and the abstraction that offer a solution
to architecture mismatch problems. In the following section PrYv middle-ware solution will
be presented.
PrYv e-health middle-ware
PrYv S.A. is a Swiss Company founded by Pierre-Mikael Legris in 2012 and located in the Ècole
Polytechnique Fèdèrale de Lausanne (EPFL) Innovation Park (Lausanne). It is a middle-ware
solution that offers services and functionalities for the secure and private transmission and
storage of sensible data on cloud platform. They adopt a privacy-by-design approach to
meet the requirements established by regulations, such as General Data Protection Regulation
(GDPR), Health Insurance Portability and Accountability Act (HIPAA) and Software as a Medical
Device (SaMD). The decentralized design of the middle-ware ensures that the standards of
other governmental or company-wide legislations and policies regarding sensitive data are met
as well. This middle-ware was built to work with medical devices, and integrates easily with
existing systems software. The highly sensible data are transmitted from the local browser to
the cloud by exploiting HyperText Transfer Protocol Secure (HTTPS) which adopts an encrypted
communication. Different kinds of data can be handled, stored, manipulated and visualized
by the offered cloud-based tools. Stored data are private by default, the users can share the
data by explicitly opening read-only or collaborative access to specific parts of their data.
Data, which are called events in PrYv, are organized in a modular structure similar to files in
computer folders, as shown in Fig. 2.21. Therefore, we can consider events as the primary
units of content in PrYv. They can be defined as a timestamped piece of typed data belonging
to a given context. Contexts are the circumstances in which events occur. The context of an
event is the combination of a stream and tags. Streams are the fundamental contexts in which
the events occur. They follow a hierarchical structure (streams and sub-streams). Tags provide
further context to the event. Each event can be labeled by one or more tags [111].
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Stream:
Sensor
Sub-stream:
Heart
Event:
Pressure
Type: pressure/mmhg
Content: 128
Event:
Pulse
Type: frequency/bpm
Content: 87
Figure 2.19 – Modular structure data organization in PrYv middle-ware solution.
Three different libraries are offered by the Company for interacting with PrYv middle-ware: (i)
Java-script (browser & Node.js), (ii) Apple Cocoa (iOS & OSX) and (iii) Java (Android & desktop).
In this thesis the PrYv Java library for developing a dedicated Android-based IoT solution was
adopted. Indeed, Android is an open-source and widely diffused Operating System (OS), highly
attractive for realizing custom solutions.
2.3.2 Android operating system
Android is a mobile Operating System (OS) developed by Google, based on a modified version
of the Linux kernel. It offers the first complete and open-source platform for developing
mobile applications. Starting in 2008, several versions and updates have been provided. The
different versions, listed in Fig. 2.20, are indicated at the official level with a version number
according to the computer standard accompanied by the most used "codename" inspired
by traditional pastries and strictly in alphabetical order: Cupcake (Android 1.5), Donut (1.6),
Eclair (2.0), Froyo (Frozen Yogurt i.e. 2.2), Gingerbread (2.3), Honeycomb (3.0), Ice Cream
Sandwich (4.0), Jelly Bean (4.1), KitKat following an agreement with Nestlé (4.4), Lollipop
(5.0), Marshmallow (6.0), Nougat (7.0) and the recent Oreo (8.0) [112]. The Android OS system
Figure 2.20 – Android OS versions (reprinted from [112]).
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architecture is organized in the form of a software stack consisting of applications, operating
system, run-time environment, middle-ware, services and libraries. It is typically divided into
four layers [113, 114], as shown in Fig. 2.21.
Figure 2.21 – Android OS system architecture (reprinted from [115]).
1. Linux Kernel, at the bottom of the stack, provides a level of abstraction between the
device hardware and the upper layers. The kernel is based on Linux version 2.6, and
it provides multitasking, low-level core system services (such as memory, process and
power management), and device drivers to control the hardware components such as
the device display, Wi-Fi and audio. Since Linux kernel provides multitasking execution,
then multiple processes can be executed in parallel directly on the Linux kernel. This
is possible because every Android application runs in its own process, with its own
instance of the Dalvik Virtual Machine (DVM), which is a register-based VM included in
the Android OS [116]. Running applications in VMs presents several advantages. First,
applications cannot negatively interfere (intentionally or otherwise) with the operating
system or other applications, nor can they directly access the device hardware. Secondly,
this enforced level of abstraction makes applications platform neutral so that they are
not tied to any specific hardware.
2. Android Core Libraries, also considered as Dalvik Libraries, can be divided into three
main categories:
• Dalvik VM Specific Libraries used for interacting directly with an instance of the
DVM.
• Java Interoperability Libraries are a subset of the Standard Java core libraries that
have been adapted and transformed for use by applications running within a DVM.
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These libraries provide support for tasks such as string handling, networking and
file manipulation.
3. Application Framework is a set of services that collectively form the environment for
running and managing Android applications. It includes the following key services:
• Activity Manager controls all the aspects of the application life-cycle and the
activity stack.
• Content Providers allows applications to publish and share data with other applica-
tions.
• Resource Manager provides access to non-code embedded resources such as
strings, color settings and user interface layouts.
• Notifications Manager to display alerts and notifications.
• View System used to create different kinds of views and layout for specific user
interfaces.
• Package Manager able to find out information about other applications currently
installed on the device.
4. Applications, at the top of the stack, comprise both the native applications provided
with the particular Android implementation (e.g. web browser and email applications)
and the developed applications installed by the users.
Application components
The application components are the essential building blocks for developing an Android ap-
plication. There are four basic types of component with different roles within the application,
own life-cycle and individual activation time. These components are:
• Activity is a single screen of the user interface through which the user can interact with
the application to perform operations. Typically, an application consists of several Activ-
ities among which one is the Main Activity that is displayed as soon as the application is
launched. An Activity can start another Activity by the use of the startActivity(intent)
command in order to accomplish different tasks. Whenever an Activity is started it is
inserted in the stack (Black Stack), while the previous one is suspended and maintained
in a stack. Since the stack data adopts the Last iIn - First Out (LIFO) structure, if the
button “Back” is pressed, the last suspended Activity is shown again.
• Service is an application component that performs operations in the background and
does not provide any user interface. A service can take two basic forms: started and
bounded. The started service is when the service is called by using the call startService().
Once it is started, it runs in the background until it is destroyed. It performs the re-
quested operations and usually does not return anything to the caller. A bounded service
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Figure 2.22 – Schematic of the life-cycle of an Android activity (reprinted from [118]).
takes this form when it is started by an application calling the bindService(). It offers
a client-server interface to the components that want to interact with it and it lasts for
as long the specific component runs.
• Content Provider manages access to a set of structured data. It offers data encapsulation
and some mechanisms for defining the security. Content Providers are the standard
interface for sharing secure information among different applications in read-only, read
or write mode. An example of a Content Provider is the list of contacts on the phone.
Applications, with the required permissions, can access the list of contacts for reading
and writing information.
• Broadcast Receiver is a component that responds to the broadcast advertisement of
the system. Most of the broadcasts are generated by the system, such as a warning when
the charge level of the battery is low or when the screen has been turned off.
Three of the four application components - Activity, Service and Broadcast Receiver - are
triggered by an asynchronous message called Intent. It associates the various components with
each other in runtime either if they belong to the same application or to different applications.
Thanks to the Intent, Android becomes an interconnected system composed of independent
components that can communicate with each other [117].
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Activity life-cycle
The fundamental component of an Android interface is the Activity, which allows the user
to interact with the application. The displayed window, through which the user interacts,
is known as View and it is possible to place the different User Interface (UI) elements by
using the command setContentView(View). Activities in the system are managed in a stack:
whenever a new activity is started it is placed on the top of the stack and becomes the running
activity, while the previous activity is kept below in the stack, remaining in the foreground
until the new activity exits.
An activity has essentially three states: if it is in the foreground of the screen (at the top of
the stack), it is active (or running), if it has lost focus but it is still visible (when, for example,
a new non-full-sized or transparent activity is placed on top of it), it is paused and if it is
completely obscured by another activity, it is stopped. When an activity is paused or stopped,
the system can drop the activity from the memory by either asking to finish it, or simply by
killing its process. While, if it is displayed again to the user, it must be completely restarted
and restored to its previous state. To enable these processes, three key life-cycle loops have to
be considered:
1. The entire lifetime of an activity begins with the first call to onCreate(Bundle), which
contains all the setup "global" states, and ends with the final call to onDestroy(), that
releases of all the remaining resources.
2. The visible lifetime of the activity happens between a call to onStart() until a corre-
sponding call to onStop(). During this time the activity is visible on the screen, though
it may not be in the foreground.The resources that are needed to show the activity to
the user are maintained in memory.
3. The foreground lifetime of the activity starts with an onResume() call till the corre-
sponding onPause() call. During this time the activity is in front of all the other activities
and is interacting with the user.
Fig. 2.22 shows the entire Activity life-cycle with the important state paths. All the mentioned
methods are hooks that it is possible to override in order to obtain personalized features when
the activity changes the state. On the other hand, onCreate(Bundle) must be implemented
by all the activities in order to ensure a proper initial setup. All these overridden methods
always need to call up superclass in order to make effective their changes or initializations.
Android Studio
Android Studio is the official Integrated Development Environment (IDE) for Android or An-
droid Wear applications development. It offers advanced features to enhance the developer
productivity when building Android apps, such as: flexible Gradle-based build system, exten-
sive testing tools, smart editor suggestions etc.. Each project in Android Studio is organized
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Figure 2.23 – The project files in Android Studio view (reprinted from [119]).
in modules containing code and resource files. These modules, visible in Fig. 2.23, are: (i)
Android app modules, (ii) library modules and (iii) Google App Engine module. The Android
app module consists of three folders:
• manifests that contains the Android Manifest.xml file. This file declares all the com-
ponents included in the Android application. The Android framework consults the
Manifest to obtain the essential information about the developed interface in order to
run any part of the code. It also contains also other details, such as descriptions of the
Application Programming Interface (API) libraries, description of the intent filters and
the permissions list, if any.
• java that contains the Java source code files.
• res that includes all the non-code resources, such as XML layouts, UI strings, and bitmap
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images.
Android Studio uses Gradle build system to automate the process of program compilation.
This build system is a plug-in that runs as an integrated tool from the Android Studio. The
build files are named build.gradle [119].
2.4 Summary and main contributions
The creation of a complete IoT system for anesthesia monitoring requires the involvement and
application of a range of different scientific disciplines, such as electro-chemistry, electronics
and software development. This chapter contains important and fundamental notions for
each of these fields. We can summarize the most crucial information of each part as follows:
• Electrochemical sensors are a valid option for accurate and reliable on-line drug sens-
ing due to their advantageous characteristics, such as high sensitivity and specificity,
small-dimensions and portability, low costs and the simplicity of their integration with
electronics. The electrochemical set-up normally consists of a three-electrode cell
(WE-RE-CE) in which RedOx reactions occur as a consequence of excitation potential
waveforms. The excitation potentials vary depending on the electrochemical technique
required. For instance, constant potential is applied for chronoameperometry, while a
linear sweep potential ramp is imposed in case of voltammetric measurements. The
chemical reaction is then converted in a measured current signal that contains the
information about the presence and the amount of the target analyte in the solution.
• Potentiostats are fundamental tools for electrochemical measurements. They drive
the electrochemical cell by applying the excitation potential waveform, ensure a stable
applied voltage between WE and RE in order to provoke the electrochemical reaction to
occur and read out the current signal generated by the RedOx reaction in the electro-
chemical cell. Different architectures can be implemented, such as grounded working
and grounded counter electrodes.
• IoT solutions in medical applications are able to provide powerful tools to support the
medical staff in their daily responsibilities. The great amount of data generated by IoT
networks, named as “big data”, can be handled by cloud-supported structures that also
make them accessible at any time and from any place. Any device that can connect to
the Internet and wirelessly share data can be connected to these IoT networks.
• Android is a widely used mobile operating system that offers the first complete and
open-source platform for developing mobile applications. It is therefore considered as a
powerful tool for the creation of ad-hoc networks to be adopted in medical monitoring
scenarios.
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2,6-diisopropylphenol (propofol), chemical structure in Fig. 3.1, is a well-known hypnotic
agent used in many surgical and critical care settings. Its administration and correct dosage
is of vital importance to prevent Propofol Infusion Syndrome (PRIS), due to high doses and
prolonged administration [120]. PRIS is a sudden complication that, in the majority of the
cases to the death of the patient. The main effects are: metabolic acidosis, rhabdomyolysis of
skeletal and cardiac muscles, arrhythmias, myocardial failure, renal failure, hepatomegaly and
death [121]. Only the early recognition and the immediate cessation of propofol infusion may
prevent the fatal outcome of PRIS syndrome.
3.1 State-of-the-art
Various technologies have been already presented in the literature for propofol detection. For
example chromatographic methods exploiting High Performance Liquid Chromatography
(HPLC) [122] and Chromatography-tandem Mass Spectrometer (C-MS) [123] were used for
accurate and efficient drug detection. However, despite the advantages of these techniques,
the instrumentation is costly, requiring large quantities of expensive organics, not portable
and requires experienced technicians [124, 125].
Figure 3.1 – 2,6-diisopropylphenol (propofol).
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Another widespread technique is based on the detection of propofol in human breath. In
this case real-time monitoring is based on Proton Transfer Reaction Mass Spectrometry (PTR-
MS) and Solid-Phase Micro-Extraction coupled with Gas Chromatography Mass Spectrometry
(SPME-GC-MS) [126, 127, 128, 129]. However, by using the MS technique, the same disadvan-
tages listed above are encountered, furthermore, there is still no evidence of strict correlation
between propofol concentrations in blood and in breath. Therefore, serum samples are still
preferred as background media for propofol monitoring [130].
To assess anesthesia delivery monitoring, including propofol hypnotic agent detection, an
easy- and ready-to-use sensor able to guarantee reliable, on-line and accurate measurements
over long periods of time has to be provided. This is because a common surgical operation, on
average, lasts for up to several hours (∼4 h). To meet this need, electrochemical sensors have
been found to be exceptionally advantageous for the development of drug monitoring tools
[131]; hence their use for propofol detection has already been investigated [132, 133, 134].
These studies have demonstrated that propofol can be easily oxidized; since it is a phenolic
compound, and, therefore, it can be electrochemically sensed. However, phenolic oxidation
produces free radicals that lead to electro-polymerization processes on the sensor’s surface,
decreasing the sensitivity over subsequent measurements. This phenomenon is referred to as
"electrode fouling" [135, 136]. The electriochemical behavior of propofol and the consequent
fouling effect happening at solid state Glassy Carbon (GC) electrodes have been investigated in
[134]. Fig. 3.2.a shows the ten voltammograms obtained with GC electrodes (ø 3 mm) by con-
secutive scans (scan-rate = 0.1 V/s) at 10−4 M propofol in 10−2 H2SO4. After the first scan (red
in Fig. 3.2.a) four peaks are evident; however, only the peak between 0.7 V and 0.9 V is related
to the propofol direct oxidation. The other growing peaks (between 0.4 V and 0.6 V (oxidation)
and between -0.1 V and 0.3 V (reduction) come from the electrochemically active layer which
is deposited on the GC electrode surface with subsequent CV scans (fouling effect). After these
10 CV measurements, the GC working electrode was cleaned by running CV procedure 10
times in 10−2 H2SO4 without propofol. Fig. 3.2.b shows the obtained voltammograms from
the cleaning procedure. The only two peaks that remained after the cleaning corresponded to
the oxidation and reduction of the deposited layer, while the peak around 0.8 V disappeared
after the third scan (green line). Even if the electrode passivating effect caused by propofol
reaction was not overcome, the effect of this fouling phenomenon has been made clear by this
study [134].
To overcome this unpleasant phenomenon, a recent study proposed the use of a polymeric
membrane-coated electrochemical sensor [137, 133]. The polymeric membrane was realized
by PolyVinil Chloride (PVC) solution (PVC polymer, plasticizer, electrolyte, ion-exchange salt
and solvent composition). They obtained a detection limit of 0.012±0.004 µM for propfol
sensing in serum-like media (containing physiologically relevant levels of albumin (5%) and
Ascorbic Acid (AA) (3 mM) AA and paracetamol (1mM) as interfering agents). However, despite
the promising results in terms of detection limit and resistance to fouling, the membrane
deposition process on the electrode surface is very critical and not straightforward for stan-
dardization since proper thickness and uniformity of the polymeric layer has to be maintained.
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Figure 3.2 – Electrochemical CV characterization of propofol (reprinted from [134]).
Moreover, as an additional hurdle, PVC membrane-coated sensors are not able to ensure
physical and mechanical stability for long-term use [138].
Recently, Molecular Imprinted Polymer (MIP) biosensors have been also investigated for
propofol detection [139]. Promising results have been obtained from this study, but variability
in the fabrication process can lead to heterogeneity in the of pore size and binding sites [140],
resulting in sluggish mass transport - not adequate for drug monitoring over a long period of
time [141]. Therefore, mature systems for the long-term continuous monitoring of proprofol
have yet not been developed.
In the following sections, the analysis to identify an optimal sensor for long-term proprofol
sensing will be described in all its investigative phases. The main objective of this research
activity was to obtain and validate a ready-to-use and robust point-of-care sensor to be inte-
grated in the overall system described in Section 1.3. The effects of different electrode materials
on propofol electro-oxidation and the fouling phenomenon have been widely studied to fully
understand the reaction mechanism.
3.2 Polymeric membrane-coated carbon Screen Printed Electrodes
(SPEs)
As a first attempt for propofol detection while avoiding the fouling effect, we have implemented
the approach presented in [133]. Therefore a PVC coated electrode has been constructed and
tested.
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Table 3.1 – PVC membrane composition.
PVC elements Components Quantities %
polymer PVC 25.5 mg 25
plasticized DOS 49.5 mg 50
electrolyte ETH500 21.5 mg 22
ion-exchange salt NaTFPhB 3 mg 3
solvent THF 2.5 ml -
3.2.1 Materials and methods
Propofol was purchased by TCI Chemicals. Stock solution of 5.4 mM was obtained by diluting
the 5µl of pure propofol in 5 ml of NaOH 0.1 M. Subsequent propofol dilutions have been
done in Phosphate Buffer Saline (PBS) (10 mM, pH:7.4) to obtain the concentrations of: [9.9 -
19.6 - 38.5 - 56.6 - 80.5] µM for sensor calibration.
For membrane production, the chemicals are listed in Table 3.1, all the compounds are
selectophore and were provided by Sigma Aldrich (Switzerland).
Two Carbon SPEs from DropSense (DS-110) have been used as electrochemical cells. One SPE
was modified with the PVC membrane following the procedure described in Section 3.2.2 and
used as WE (4 mm Ø), the other SPE as carbon CE and silver RE. A Metrohm Autolab system
(PGSTAT 302N) was used to run the CV experiments applying voltages in the range of [-0.3 - 1.4]
V with 0.1 V/s scan-rate. Scanning Electron Microscopy (SEM) images have been performed
with FEI XL30 (XLF-30) SFEG (Interdisciplinary Center for Electron Microscopy (CIME) at EPFL)
in Secondary Electrode (SE) mode with accelerating voltage of 10 KV, magnitude 1200x and
Working Distance (WD) of ∼ 10.
1. Dipping of the electrode 2. Spin Coating to model the membrane
PVC membrane 
solution
3. Total evaporation of the solvent
Figure 3.3 – Sketch of the process for PVC membrane deposition on C-SPE.
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Figure 3.5 – SEM image of: a) bare carbon (C) SPE and b) PVC membrane coated C-SPE. In the
zoom insertion, the detail of a PVC membrane fracture is shown.
3.2.2 Electrode preparation
Carbon SPEs from DropSense (DS-110, C-WE of 4 mm Ø) have been used as solid electrode
substrate. To deposit the PVC membrane on the electrode the procedure depicted in Fig. 3.3
has been followed. The SPE was dipped in the PVC membrane solution (realized with the
formulation in Table 3.1), then a spin coating action was performed to model the membrane
in order to obtain a thin layer on the SPE surface. For this step a spin coater model SCV from
LOT Quantum Design has been used. Finally the electrode was kept at room temperature until
the total evaporation of the solvent. Before using the electrode for measuring propofol, it was
dipped for 15 minutes in PBS solution as a conditioning step.
3.2.3 Results and limitations
The PVC coated electrode has been characterized both for propofol electrochemical direct
detection and with SEM analysis. Fig. 3.4.a shows the calibration line obtained by testing three
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different electrodes with increasing propofol concentrations in PBS background solution. We
have obtained a sensitivity of 1.63×10−02±1.58×10−01 µA/µM, as the slope of the calibration
line, and a LOD of 6.38 µM. However, even if with the membrane coating on the electrode’s
surface, fouling effect was still visible after multiple measurements as shown in Fig. 3.4.b.
Indeed, if performing multiple CV scans with 80.5 µM propofol solution, the peak current
was increasing and if a blank solution was measured immediately after (labeled as PBS after
measurements in the figure), the current was not coming back to the initial value (PBS before).
This effect derives from the formation of the electroactive passivation layer.
To understand the reason for this fouling effect, we have characterized the electrode surface
through SEM analysis. Fig. 3.5 shows the C-SPE before and after the membrane deposition. As
visible in Fig. 3.5.b, the membrane is not uniformly deposited with evident fractures, resulting
in a non-effective protection against fouling. This is due to the fact that SPEs have not been
left with a smooth surface after their fabrication process, and the spin coating process makes
it extremely difficult to obtain a reproducible membrane that is thin enough. Furthermore, it
is difficult to maintain the physical and mechanical properties of the PVC-coated sensors for
ensuring its performance is long-term detection, as demonstrated by [138]. This is a crucial
point in case of anesthesia monitoring.
For these reasons, alternative sensing platforms have been investigated to provide ready-to-
use, low-cost and reliable propofol detection over long-time monitoring.
In the following section, the effect of BDD electrode and PGE materials on propofol electro-
oxidation and fouling will be deeply analyzed to fully understand the chemical reaction
mechanism and to compare their electrochemical performance in long-time monitoring.
3.3 BDD and PGE electrodes
The performance of BDD electrodes and PGEs were tested and compared in terms of sensitivity
values and resistance to fouling over long-term propofol monitoring.
BDD was chosen for its low catalytic activity for hydrogen and oxygen that allows for a wider
application of potential ranges [142] and because of the elevated mechanical strength and
reduced chemical activity [143].
On the other hand, disposable PGE offers excellent electrochemical reactivity leading to high
sensitivity, good mechanical rigidity, low cost, low background current, wide potential window,
chemical inertness and easy miniaturization [144].
First, we characterized the fouling effect at the bare surface of the two electrodes by performing
several propofol calibrations one after the other. Then we developed, tested and compared two
surface cleaning methods to improve the electrode’s performance over time by preventing the
fouling. The two optimized cleaning procedures were carried out: 1) in Phosphate Buffer Saline
(PBS) and 2) in sodium hydroxide (NaOH). By running one of the two cleaning procedures
every six propofol measurements, we achieved a successful and reliable propofol detection of
over 4 h.
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Electrical connection with tip of
the electrode
Parafilm protection
WE
Instrumentation
connection 
Figure 3.6 – PGE configuration: WE mine inside mechanical holder.
Table 3.2 – CV and DPV procedures for propofol detection at BDD electrode and PGE.
Technique BDD PGE
CV
potential range [+0.75 - +1.4] V [+0.2 - +1.4] V
scan rate 0.1 V/s 0.1 V/s
DPV
potential range
-
[0.0 - +1.1] V
interval time 0.2 s
modulation amplitude 50 mV
modulation time 50 ms
scan rate 0.025 V/s
3.3.1 Materials and methods
Propofol stock solution and subsequent dilution concentrations were obtained as before
(Section 3.2.1). NaOH and KNO3 and heat inactivated human male serum (H3667-100ML)
were purchased from Sigma Aldrich (Switzerland). 10 ml of Ferro(ferri)cyanide 5 mM solu-
tion for electrochemical area evaluation was obtained by mixing 0.0211 gr potassium hexa-
cyanoferrate trihydrate II with 0.0165 gr potassium hexa-cyanoferrate III in PBS (10 mM pH:
7.4). All the chemicals were purchased by Sigma Aldrich.
Rotating disk BDD/Silica substrate (Si) WEs (electro active area of 12.4 mm2, 700 ppm) were
purchased from NeoCoat SA. Before using BDD, a preliminary CA conditioning at +2.2 V for
900 s keeping the electrode in 0.1 M KNO3 solution was recommended by the Supplier for
proper activation of the electrode surface.
Pencil mines with diameter of 0.5 mm were used as PGE WE and a commercial mechanical
holder was adopted and modified by soldering a copper wire to guarantee electrical contact
between the WE tip and the instrumentation connection part, as shown in Fig. 3.6. The PGE
was dipped for 8 mm into the solution to obtain an electro-active area comparable with the
BDD electrode (considering the mine as cilindrical: Abase + Al ater al (pi× (0.5/2)2)+ (2×pi×
(0.5/2)×8)= 12.7 mm2). An Ag|AgCl|3.0 M KCl from Metrohm have been used RE and a Pt wire
as CE. CVs and DPVs were performed with a Metrohm Autolab PGSTAT 302N potentiostat,
and data analysis and plotting were performed in Matlab R2013a and Excel 2011. In particular,
a Matlab script was implemented for the peak height evaluation with respect to a constant
baseline. The constant baseline is selected and set for each calibration as the average value of
the ordinates of the points in the area before the peak (steady state). CV and DPV procedures’
parameters for BDD electrodes and PGEs are summarized in Table 3.2.
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1µm
BDD after CVs in PBS
1µm
BDD after propofol calibration (dirty)
a. b.
Figure 3.7 – SEM images of BDD electrode: a.) bare electrode after 5 cycles of CV in only PBS
(background electrolyte), and b.) after one propofol calibration.
PGE after CVs in PBS
200 µm
a.
PGE after propofol calibration (dirty)
200 µm
b.
PGE after propofol calibration (dirty)
Figure 3.8 – SEM images of PGE: a.) bare electrode after 5 cycles of CV in only PBS (background
electrolyte), b.) after one propofol calibration.
The sensitivity and the LOD values were evaluated for both the electrodes via CV technique
by performing five subsequent sets of 5-point-calibrations. LOD was also experimentally
determined in serum by performing DPV at null and at 0.85 µM propofol concentration and
by registering an increase of the blank signal when propofol was injected. An XLF30-FEG
scanning electron microscope was used for SEM analysis. The Secondary Electrons (SE) images
were taken by applying an accelerating voltage of 20 kV and at a WD of 9.9.
3.3.2 Fouling characterization at PGE and BDD electrodes
Surface characterization of the fouling layer
The electrode-fouling effect at BDD and PGE surfaces was investigated through SEM surface
characterization.
Surface images of the BDD electrode have not shown any evidence of fouling, as visible in
Fig. 3.7. On the contrary, the surface of the PGE shows traces of fouling from SEM analysis, as
visible in Fig. 3.8.b. What is evident from this comparison is that, while in Fig. 3.8.a the bare
PGE is characterized by graphite striae on the lateral surface and small pointed tips at the
base, after a propofol calibration a deposited layer is clearly visible on both the lateral and the
base surfaces of the electrode Fig. 3.8.b. This passivating layer of propofol fouling covers the
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Figure 3.9 – pH and scan-rate studies with 30 µM propofol electro-oxidation at PGE: a.)
CVs in solutions at different pH [2 - 10], b.) linear dependency between peak position and
pH variation, c.) peak current amplitude VS square root of scan-rate, and d.) suggested
mechanism of propofol electro-oxidation reaction..
superficial structures of the electrode and causes the decrease of sensitivity registered by the
electrochemical results.
Electrochemical characterization of the fouling layer
To better characterize the mechanism of propofol electro-oxidation that leads to the formation
of the fouling layer, pH and scan-rate effects were also investigated.
In fact, by studying the effect of pH on propofol electro-oxidation it is possible to deduce the
number of electrons exchanged in the reaction. Two cycles of CV were performed in 30 µM
propofol solution at different pH values in the range between 2 and 10. As it is evident from
Fig. 3.9.a, the CV peak current (height) and peak potential (position) are highly influenced by
the pH of the solution. In particular, although there is not a trend for peak current, it is clear
that the peak potential shifts to more negative values for higher pH values. A plot of the anodic
peak (Ep A) potential versus pH exhibits a slope value equal to 62 mV (Fig. 3.9.b) that is close
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Figure 3.10 – a) Typical CV curves at increasing propofol concentrations ([9.9 - 80.5] µM) at
PGE and BDD surfaces; (b) change in sensitivity (S) values for BDD and PGE with respect to
subsequent propofol calibrations performed in PBS (pH:7.4). Error bars represent the standard
deviation from the linear regression analysis performed for S evaluation (n = 5, points in each
calibration).
to the 59 mV predicted by the Nernst equation for the process involving an equal number of
protons and electrons [145]. This result demonstrates that propofol electro-oxidation involves
the exchange of one proton and one electron [146]. In addition to pH, the effect of different
scan-rate values [0.025; 0.05; 0.1; 0.15; 0.2] V/s was also investigated by performing CVs in 30
µM propofol solution. In Fig. 3.9.c, the peak current is plotted versus the square root of scan-
rate obtaining a non-linear trend. This proves that the reaction is not a diffusion-controlled
process, since it is characterized by a combination of adsorption and fouling phenomena at
the electrode’s surface, in agreement with the previous characterization results.
Therefore, considering the results obtained from electrochemical and surface characteriza-
tions of the electrodes, and congruently with previous works [147], the chemical oxidation of
propofol is illustrated in Fig. 3.9.c. When the positive potential is applied, propofol is oxidized
by one electron and one proton removal; three types of intermediate phenoxy radicals would
possibly form and initiate the polymerization process that results in electrode fouling (in the
dashed frame).
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Figure 3.11 – The effect of fouling on calibration lines for a) BDD and b) PGE without interme-
diate cleanings. The lines were drawn for five concentrations [9.9 - 19.6 - 38.5 - 56.6 - 80.5]
µM.
After having characterized electrochemical and surface properties of the fouling effect at both
PGE and BDD electrodes, we wanted to estimate the fouling resistance and the sensitivity of
these two different C-based materials.
Electrochemical behavior of the two electrodes have been studied by performing five CV
propofol calibrations (five points each) one after the other. Typical voltammograms are de-
picted in Fig. 3.10.a, while the sensitivity values obtained over the five calibrations are reported
in Fig. 3.10.b. A higher sensitivity of (2.3±1.0)×10−07 A/µM is obtained by the PGE compared
to the one of (5.3±1.2)×10−08 A/µ evaluated for the BDD electrode. Nevertheless, both the
electrodes appear to be affected by the fouling effect due to propofol oxidation reaction. The
undesired phenomenon is more evident in PGE measurements where a sharp reduction of the
sensitivity is visible after the third calibration. However, the BDD sensitivity, even if it obtains
similar values in all the consecutive calibrations, is affected by a high variability limiting the
reproducibility. To further underline this phenomenon, the obtained calibration lines are also
reported in Fig. 3.11.
3.3.3 Cleaning procedures
Two cleaning procedures have been implemented and tested for eliminating the effects of foul-
ing caused by propofol oxidation at BDD and PGE electrodes. The electrochemical cleaning
was performed after every six CV measurements.
• NaOH cleaning: ten CV cycles in 10 ml of 0.1 M NaOH solution. The applied potential
range is the same as the one for drug sensing ([+0.75 - +1.4] V for BDD and [+0.2 - +1.4]
V for PGE).
• PBS cleaning: CA in 10 ml of 10 mM PBS (pH: 7.4) performed by applying +1.4 V for 30 s
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Figure 3.12 – Cleaning optimization process for PGE (left) and BDD electrode (right). PGE
cleaning tests: a.) anodic CV scan without (blue) and with (red) propofol in solution; b.) NaOH
cleaning procedure by increasing the number of CV scans; c.) PBS cleaning by increasing the
applied voltage and keeping constant the CA time. BDD cleaning analysis: a) effect of number
of CV cycles for NaOH cleaning, b) effect of applied potential for CA based PBS cleaning.
without stirring.
The cleaning criteria were obtained from an optimization process in which the effect of
different combinations of parameters was investigated. As concerns the NaOH cleaning
procedure, the effect of number of scans (2, 5 and 10) has been tested; while for the PBS
cleaning procedure different fixed potentials have been applied (+1, +1.2 and +1.4 V) for a
constant duration (30 s). Results from the optimization study for PGE and BDD electrode are
reported in Fig. 3.12.
3.3.4 Results and discussion
To avoid the formation of the passivating layer at BDD and PGE surfaces (Fig. 3.10 and Fig. 3.11),
and to stabilize the sensitivity values over time, two kinds of electrochemical cleaning proce-
dures have been introduced between one calibration and the subsequent one.
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Figure 3.13 – Sensitivity (S) values evaluated for PGE and BDD with respect to calibration
number (nr) and type of intermediate cleaning (PBS and NaOH). Error bars are the standard
deviation from the linear regression analysis for S evaluation (n = 5, points per calibration).
Fig. 3.13 shows the results of sensitivity for BDD and PGE electrodes over each calibration
curve (up to five) with cleaning procedures; i.e. PBS or NaOH cleaning, applied in between
two subsequent calibration curves. It is clear that, even if both PBS and NaOH cleanings have
an improvement against the fouling effect, NaOH guarantees the best maintenance of the
electrode over time. In particular, the sensitivity values after NaOH cleaning are higher and
characterized by the lowest variability compared to use without cleaning or after cleaning in
PBS. To underline further the success of the intermediate cleaning procedures, calibration
lines for PGE and BDD electrodes are shown in Fig. 3.14.
We have also studied the cleaning effects by performing SEM analysis at PGE, since for BDD the
fouling was not evident. After performing NaOH or PBS intermediate cleanings the passivating
layer that was covering all the PGE surface in Fig. 3.8.b is removed and the morphology of the
PGE is recovered back to its original bare structure, as visible in Fig. 3.15.
As support of SEM imaging observations, variations in PGE Electro-Active Surface Area (EASA)
were evaluated by performing CVs in 5 mM ferro(ferri)cyanide (K3[Fe(CN)6]/K4[Fe(CN)6])
[148] before and after the cleanings. Fig. 3.16 shows the voltammograms acquired during
this analysis. The EASA of the electrode has been evaluated from Randles-Sevick equation as
follow:
A = ip
286.6×n3/2×D1/2×C ×ν1/2 (3.1)
Where ip is the anodic peak currents from CV plot, D is the diffusion coefficient (cm2/s), C is
57
Chapter 3. Propofol direct monitoring
10 20 30 40 50 60 70 80 900
2
4
6 x 10
6 cleaning PBS
[Propofol] (µM)
Cu
rr
en
t (
A)
 
 
1cal
2cal
3cal
4cal
5cal
10 20 30 40 50 60 70 80 900
0.5
1 x 10
5 cleaning NaOH
[Propfol] (µM)
Cu
rr
en
t (
A)
 
 
1cal
2cal
3cal
4cal
5cal
10 20 30 40 50 60 70 80 900
0.5
1
1.5
2 x 10
5 cleaning PBS
[Propofol] (µM)
Cu
rr
en
t (
A)
 
 
1cal
2cal
3cal
4cal
5cal
10 20 30 40 50 60 70 80 900
1
2
3 x 10
5 cleaning NaOH
[Propofol] (µM)
Cu
rr
en
t (
A)
 
 
1cal
2cal
3cal
4cal
5cal
PGEBDDa. b.
Figure 3.14 – Effect of intermediate cleanings (PBS and NaOH) in calibration lines for: a)BDD
electrode and b)PGE. The lines were drawn for five concentrations [9.9 - 19.6 - 38.5 - 56.6 -
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Figure 3.15 – SEM images of PGE: a) after NaOH and d) after PBS cleanings.
−0.5 0 0.5 1−4
−3
−2
−1
0
1
2
3
4
x 10−4a.
Voltage (V)
Cu
rr
en
t (
A)
−0.5 0 0.5 1−4
−3
−2
−1
0
1
2
3
4
x 10−4b.
Voltage (V)
Cu
rr
en
t (
A)
before calibration
after calibration
after NaOH cleaning
before calibration
after calibration
after PBS cleaning
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Figure 3.18 – Long-term electrochemical propofol monitoring with best electrode-cleaning
combinations: a) BDD electrode with NaOH cleaning and b) PGE with PBS cleaning. The
arrows indicates the points where the propofol concentration was changed and where cleaning
procedure was implemented. Successive cycles have the same trend in concentration as the
one in first cycle, then demonstrating the success of the intermediary cleanings being used.
the concentration of the electro-active species in the bulk solution (mol/cm3), and ν is the
scan-rate (V/s). As visible in Fig. 3.16 the ferro(ferri)cyanide peaks decrease after propofol
calibration with 5 concentrations. That shows the effect of propofol polymerization on the
active area of the electrode. After PBS and NaOH cleaning the peaks are recovered again. This
is because the cleaning procedures are effectively regenerating the surface of the electrode.
According to the results before and after cleanings, it is concluded that the EASA is recovered of
99.6% and 71.2% for PBS and NaOH cleanings, respectively. From this analysis, we concluded
that BDD electrode sensitivity values were more stable, especially if applying NaOH cleaning
step, while PGE is more sensitive to propofol (shown in Fig. 3.13) and, therefore, by adopting a
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Figure 3.19 – pH and scan-rate studies with 30 µM propofol electro-oxidation for PGE: a.)
CVs in solutions at different pH [2 - 10], b.) linear dependency between peak position and
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proper cleaning procedure, it is favorable for performing direct propofol detection in human
serum. Moreover, since it could be more convenient to avoid extra chemicals, such as NaoH,
so as not to complicate the system design and reduce the measurement time, the use of PBS
cleaning is preferable for the final application. To that aim, we also tested the cleaning in
PBS with 80 µM propofol concentration inside and comparable results with only PBS solution
are obtained, as in Fig. 3.17. We proved that the cleaning is successful also in presence of
the analyte itself. Therefore the two best electrode-cleaning combinations are: i) PGE with
PBS cleaning, identified as the most suitable in view of the final application, and ii) BDD with
NaOH cleaning, which was providing the best performance.
We finally demonstrated the long-term monitoring properties for both these two selected
combinations by performing five calibrations (5-concentrations each) resulting in 25 subse-
quent measurements adding up to 4 h of total measurement time. According to the diagnostic
definition in [42], we have achieved a continuous monitoring system by measuring one sample
every 10 minutes (6 measurements for one hour). However, if we estimate the time required by
combining cleaning and measuring procedures, the system provides a sample every minute
that is even better in the case of drugs with fast clearance, such as propofol. In Fig. 3.18 we
have reported the measurements in time both for PGE with PBS cleaning and for BDD with
NaOH cleaning. Therefore, we demonstrated the success of the used cleaning processes.
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Figure 3.20 – Reproducibility of propofol measurements in serum with PGE: a) propofol
oxidation peak trend in time of three different PGE sensors running DPV procedure at various
concentrations (9.9 - 19.6 -38.5 - 56.6 - 80.5) µM, b) change in oxidation peak current by time
and c) bar graph of RSD% (<15%).
3.3.5 Serum detection
After the optimization of the cleaning parameters, the analysis of pH and scan-rate effects
and the identification of the best electrode-cleaning combination (considering the final ap-
plication, PGE with PBS cleaning was preferred for the highest prpofol sensitivity), it was
possible to verify the detection of propofol inside human serum. PGEs and DPV electrochem-
ical technique have been used for this aim. In particular, DPV was preferred to CV since
it is a more sensitive technique [149]; hence, more suitable for serum measurements. The
same PBS cleaning procedure was run every 6 measurements as for CVs. As preliminary step,
propofol calibration was carried out in PBS to identify the oxidation peak position and the
best potential range, as shown in Fig. 3.19.a. The same set of calibrations was then carried out
in undiluted human serum. Fig. 3.19.b reports a visible oxidation peak in the same potential
range within PBS. The peak current values are linearly related with the increase of the propofol
concentrations. Therefore, a linear calibration equation with an R2 of 0.99 was evaluated by
the regression analysis (n = 3). The slope of the calibration lines corresponds to the electrode’s
sensitivity: 1.2×10−1 µA/µM and 1.1×10−2 µA/µM for PBS and serum detection, respectively.
Evidently, there is a drop (one order of magnitude) in sensitivity in serum solution compared
to the one in PBS. This is due to the fact that propofol is highly lipophilic drug and binds to
human serum components more than 95%, in particular to albumin [150]. Therefore, only a
small fraction (called "free drug concentration") is electrochemically detectable. Furthermore,
serum is a complex solution rich in components that also affect the electrode’s performance by
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reducing the sensitivity. However, from the obtained calibration curve, the LOD was calculated
to be 0.82 µM with 9.3 (%) Relative Standard Deviation (RSD) and this concentration is in the
physiological range ([1 - 60] µM).
Fig. 3.20 compares the performance over time of three different PGEs. It is evident that
the three trends are very similar proving the reliability and the stability of the monitoring.
Measurement reproducibility was evaluated by estimating the RSD(%) values for every step of
the calibration considering the three tested PGEs, reported in Fig. 3.20.c. An average value of
8.6 (%) RSD was obtained, which is considered acceptable for medical applications [151]. This
reflects the precision across the three different electrodes that were tested.
3.4 Different compositions of PGEs
As a consequence of the results obtained in the previous Section 3.3, it emerged that PGE is
the most suitable electrode for propofol detection since it ensures reliable monitoring over
long time periods. Since the pencil graphite is a composition of graphite, clay and a binder
(typically wax, resins or high polymer) in various percentages, we decided to investigate which
composition guarantees the best performance in terms of sensitivity and fouling resistance,
considered as the ability to remain unaffected by fouling agents that gradually cause the
formation of the passivating layer on the electrode’s surface [152]. In fact, the lead composition
influences both the chemical (e.g., ion exchange) and structural properties (e.g., the degree of
disorder and surface morphology) of the pencil graphite mine used as WE. According to the
European Letter Scale, graphite pencils are marked with letters H (hardness) and B (blackness)
and numbers indicating the degree of hardness or blackness. B type leads contain more
graphite and are softer, and the harder H type leads have more clay. Therefore, we could test
20 different leads spanning from 9H (the hardest) to 8B (the softest), as in Fig. 3.21.
3.4.1 Materials and methods
The 3-electrode electrochemical cell consisted of a PGE, with different lead compositions, as
WE, a K0265 Ag/AgCl electrode from Ametek Scientific Instruments as RE and a Pt wire as
Graphite (%)
Clay (%)
Wax (%)
  41  44  47  50  52  55   58   60  63  66  68  71   74   76  79  82  84   87  90  93
  53  50  47  45  42  39   36   34  31  28  26  23   20  18  15   12   10   7    5    2
    5    5     5    5     5    5     5      5    5    5    5     5      5    5     5     5      5    5    5    5
9H   8H  7H  6H  5H  4H  3H   2H   H    F    HB    B    2B   3B   4B   5B   6B   7B   8B   9B
SoftHard
Figure 3.21 – WE lead compositions in wt% of: wax, clay and graphite.
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Figure 3.22 – Staedtler Mars Lumograph Wood Pencil Set of 20.
CE. A Staedtler Mars Lumograph Wood Pencil Set of 20 (Fig. 3.22) was purchased from Cult
Pens (United Kingdom) and used as WEs with different graphite-clay compositions, with wax
as binder. The electrode was made by peeling the two ends of the pencil in order to expose
the internal lead. One pencil extremity has been used to provide electrical contact with the
potentiostat. The other has been cut so as to guarantee a flat surface before being immersed
in the analyzed solution.Carbon (C)-SPE (DS-110) from Metrohm has been used as a control
electrode to highlight the PGE performance.
CV measurements with applied potentials in the range [+0.2 - +1.4] V and scan-rate of 0.1
V/s were carried out with the PGSTAT 302N Metrohm Autolab. Data analysis and plotting
were carried out in Matlab R2013a. The propofol oxidation current peak was identified as the
maximum current value recorded in the voltage range [+0.7 - +0.8] V.
Two main tests were performed in order to compare the performance in propofol monitoring
of different PGE compositions as WE:
• three calibrations with three different WEs with the same composition to verify inter-
electrode variability.
• five subsequent calibrations with the same WE to test intra-electrode variability with
time, and fouling resistance;
Since the lead diameter varies according to the pencil graphite compositions, the immersed
height of the PGE inside the solution has to be regulated to guarantee a constant EASA of
∼ 12.6 mm2. To further characterize the surface properties of the tested electrodes, also
Electrochemical Impedance Spectroscopy (EIS) and SEM analysis ware carried out. EIS was
performed in 5 mM ferro(ferri)cyanide solution by using the Autolab Frequency Response
Analyzer (FRA), with a frequency range of 0.1 Hz to 100 KHz and AC amplitude of 5 mV. The
measured impedance spectra were analyzed in Nova 1.11 software with the Electrochemical
circle fit tool. SEM was done with both the XLF30-FEG and the Zeiss Gemini microscopes,
with accelerating voltages of 10 kV and 3 kV, respectively.
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Figure 3.23 – Different representation of electrode sensitivity. a) Diagram of the inter-electrode
sensitivity for different PGE compositions andC-SPE. b) Comparison in sensitivity for different
wt% of graphite and clay in lead compositions
3.4.2 Results and discussion
To investigate the inter-electrode variation we have repeated a 5-points CV propofol calibration
three times, for all the twenty types of PGEs. From this investigation we found out that no
signal was obtained from 7B, 8B, 9B PGEs because they present an immediate fouling effect
due to their very soft lead compositions.
Fig. 3.23.a summarizes the resulting sensitivity values estimated for all the other PGE compo-
sitions. There is an evident growing trend of sensitivity values with an increase of the graphite
content (wt%) in the lead composition. We can notice that the sensitivity values evaluated for
5B and 6B PGEs are affected by high standard deviation that can be justified with their soft
composition. Indeed, due to the high graphite content, these leads are extremely soft and
fragile so that it is very challenging to obtain the same EASA as the others.
Looking at the sensitivity values, it is possible to identify a range where the S±σ is approxi-
mately constant. This range is between 3B and 5H PGE leads.
Another representation of the sensitivity variance upon percentage of clay or graphite content
is depicted in Fig. 3.23.b. The sensitivity clearly increases with higher wt% of conductive
material (graphite), while it decreases with higher wt% of insulating material (clay) in the
composition. Therefore, while the graphite-content of the electrode is the key for the electro-
chemical activity, the clay within it could provide a sort of protective shield against fouling.
To confirm these results, we have evaluated the fouling-resistant properties of the electrodes
by performing five subsequent calibrations (n = 5) with the same WE. Typical CV calibration
curves are reported in Fig. 3.24 for the PGE lead compositions 9H (hardest), F, 3H (intermedi-
ate) and 6B (softest). From Fig. 3.24.a and Fig. 3.24.c it is possible to notice that the oxidation
propofol peak height current decreases by half the magnitude due to an increase in clay
content. Indeed, the clay has an insulation effect on the PGE lead. Conversely, the oxidation
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Figure 3.24 – CV curves for the 1st and the 5th propofol calibrations at PGE: a.) and b.) 6B, c.)
and d.) F, e.) and f.) 9H, g.) and h.) 3H lead compositions.
peak becomes more well-defined at higher graphite contents. Furthermore, from Fig. 3.24.b,
Fig. 3.24.d and Fig. 3.24.f we can see that all 9H, F and 6B PGEs lose their sensitivity in time.
Unlike these, the intermediate 3H lead provides more stable and reproducible results, so that it
stands out as a suitable compromise between sensitivity and fouling resistance. Indeed, even
if the shape of the oxidative peak varies during successive calibrations, due to modification
of the capacitive current after hours immersed in the solution, the peak amplitude, which
correlates to the drug concentration, does not change significantly, as shown in Fig. 3.24.g and
Fig. 3.24.h. By plotting the change in sensitivity upon five calibrations for various PGE leads,
as in Fig. 3.25, the first observation is that when the graphite (wt%) is reduced and the clay
(wt%) is increased in PGE lead, it is possible to identify a switch-point in clay to graphite ratio
for which the fouling effect is less evident in the electrochemical analyses. As a consequence of
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Figure 3.25 – Intra-electrode sensitivities obtained by 5 subsequent propofol calibrations
performed on each PGE. Trend for all the different lead compositions are reported.
this, it can be said that, with a certain clay content, pre-treatment or regeneration of electrodes
are not needed due to the fact that fouling does not occur - thanks to the properties of the
lead. Therefore, these PGEs can be selected as the best substrate for a direct electrochemical
detection of propofol. The identified optimum point of clay/graphite ratio is set for a value of
0.4, which corresponds to the lead composition having 66% w/w in graphite and 28% w/w in
clay (assuming a fixed amount of wax at around 5% w/w). In other words, for achieving the
reliable long-term propofol monitoring, the clay/graphite ratio has to be between 0.4 and 1.5.
This range corresponds to the PGE leads between F and 9H. Among the lead compositions in
the selected range, we wanted to identify the optimum candidate in terms of fouling preven-
tion and stability properties over time. Hence, two principal analyses have been conducted.
First, we drew the bar graph with the normalized standard deviations from the inter-electrode
sensitivity analysis (Fig. 3.23.a) with respect to sensitivity (Standard deviation/S), as shown in
Fig. 3.26.a. Secondly, the bar graph was drawn with the normalized fouling standard deviation
with respect to the intra-electrode sensitivity (Fouling standard deviation/intra--electrode
S), in Fig. 3.26.b, based on the analysis of subsequently run calibration curves in Fig. 3.25.
Both figures, Fig. 3.26.a and Fig. 3.26.b show the trends of PGEs for resistance to fouling effect
and stability. It can be deduced from these figures that, 3H PGE composition (58% graphite,
36% clay and 5% wax, with clay-graphite ratio of 0.62, calculated as 36%58% , and indicated by the
green arrow in the figures) has the best performance by providing the minimum normalized
standard deviation values in both the analyses.
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Figure 3.27 – Continuous monitoring experiments with four different kinds of PGE (6H, 3H, 2B
and 4B) with respect to a carbon-SPE. Five calibrations (with five rising propofol concentra-
tions each) were carried out resulting in 25 subsequent measurements, for a total of 4 hours,
without any intermediate cleaning.
The best performance of 3H PGE in terms of stability and current amplitudes is also evidenced
by Fig. 3.27 where different PGEs were compared for long-term (up to 4 h) propofol moni-
toring, repeating the same experiment as in the previous section but without intermediate
electrochemical cleanings. A carbon (C) SPE has been used as control electrode in the com-
parison. C-SPE was affected by fouling already from the third calibration (Fouling effect zone
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Figure 3.28 – SEM images of 3H, 2H, H, HB, F PGEs before (Not-used) and after 5-points
propofol calibration measurement (Used).
in Fig. 3.27) and no further detection was possible afterwards. This limited performance was
overcome by all the PGEs. Considering the PGEs’ time trends, it is visible that 4B PGE lead,
despite its higher current amplitude values, had a strong fouling that made it unsuitable for
long-term monitoring. The same is also visible for the 2B PGE, even if it seemed to have better
performance than 4B PGE. Regarding 6H PGE, although the fouling effect is not evident due
to its higher clay content, it has the lowest current values and less reproducibility, making it
unattractive for the final application. Therefore 3H composition turned out to be the best
trade-off between sensitivity and fouling resistance properties. Moreover, the LOD of the opti-
mum PGE was evaluated to be 7.79±2.17×10−07 µM, which is lower than lowest concentration
in the physiological range of propofol (1 - 60 µM).
Surface characterization
To support the electrochemical investigation of the different lead compositions, SEM and
EIS analyses were performed to compare the electrodes’ surfaces properties before and after
propofol detection. SEM images were taken for all types of electrodes; Fig. 3.28 compares
the clean PGE surface before performing propofol sensing (Not-used PGE) with the used one
after the measurement (Used PGE (after calibration)for PGE leads from F to 3H. F PGE has
been identified as the critical point for fouling and sensitivity, while 3H was the optimum lead
composition for propofol monitoring.
From Fig. 3.28, a fouling layer is visible on the surface of HB and F PGE leads after their usage.
This layer seems to be reduced by increased clay content. Indeed, lead compositions of H, 2H
and 3H do not present evidence of this undesirable effect. Moreover, since the hardness of
the PGE lead increases, the surface is cut in an easier and more efficient way, ensuring flatter
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Figure 3.29 – EIS analysis comparison between Not-used and Used PGEs: Nyquist plots of a) 3H
and b) 3B, c) bar graph with error bars representing standard error (n = 3) for Rct (%) variance.
and more homogeneous surfaces. We further analyzed the electrodes surface by performing
EIS. Charge-transfer resistance (Rct ) values of 3H and 3B PGEs were compared before and
after propofol monitoring. Looking at Fig.3.29.a and Fig.3.29.b, the Rct value of the unused
3B PGE is lower that the 3H one since it contains less clay. It is also evident that, propofol
sensing resulted in fouling and hence increased Rct value for 3B, while the surface for 3H
seems almost not affected. Bar graph in Fig. 3.29.c shows normalized changes in Rct values
(%), evaluated by the formula:
Rct% = 100× RctUsed −Rct NotUsed
Rct NotUsed
(3.2)
This value is extremely high for 3B PGE compared to the one of 3H.
3.5 Summary and main original contributions
In this chapter we have exposed the steps of the development process of an electrochemical
sensor for propofol detection during anesthesia practices. Propofol is a widely-used hypnotic
agent, which is intravenously administered during anesthesia induction and maintenance
phases. The correct and balanced dosing of this compound is crucial to avoid over- or under-
dosing that might lead to serious health damages/syndromes or to experiences of awareness,
respectively. Only a continuous monitoring of its concentration in patient’s veins would enable
a personalized and dynamic adjustment of the infusion rate.
Bare carbon-based materials were identified as suitable and ready-to-use substrates to make
propofol RedOx to happen. However, the fouling effect due to free radicals produced by
propofol oxidation reaction results in an electro-active polymeric layer on the electrode’s
surface, preventing continuous detection. We selected boron-doped diamond and pencil
graphite working electrodes for their properties: from one side BDD for its low catalytic activity
and elevated mechanical strength and reduced chemical activity, from the other side PGE for
its excellent electrochemical reactivity and sensitivity, good mechanical rigidity, low cost, low
background current, wide potential window, chemical inertness and easy at miniaturization.
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The main steps and contributions of our research process in propofol detection can be sum-
marized as follows:
• Characterization of the fouling phenomenon at both BDD and PGE. They appear to
be both affected by the fouling effect due to propofol oxidation reaction, even if the
undesired phenomenon was more evident in PGE measurements after the third 5-point
calibrations performed in rows. However, the PGE sensitivity for propofol detection was
evaluated to be one order of magnitude higher that the one from BDD.
• We defined and validated two electrochemical cleaning procedures (in PBS and NaOH
solutions) to be run alternately with propofol measures as an intermediate step between
one 5-point calibration and the subsequent one. We identified two best electrode-
cleaning combinations: (i) PGE with PBS cleaning, the most suitable in vision of the
final application since PGE has higher sensitivity, and (ii) BDD with NaOH cleaning,
providing the best performance but requiring an external compound, e.g. NaOH, to
be flushed. Therefore, we demonstrated the success of both of these combinations in
propofol long-term monitoring (up to 4h).
• Table 3.3 summarizes and compares the obtained results with the literature. We can
conclude that both our sensors are suitable for reliable propofol detection. This is true
also for propofol monitoring in undiluted human serum where we obtained a LOD in
human serum by performing DPV technique with PGE, obtaining the lowest sensitivity
of 0.011 µA/µM. The main advantage of our technology is that it can be adopted as
propofol sensors in an extremely easy- and ready-to-use procedure.
• PGE and PBS cleaning were selected as the most suitable electrode/cleaning combi-
nation in view of the final application in detecting the concentration of propofol in
human serum. Indeed, PGE electrodes registered a higher sensitivity to propofol and
PBS cleaning does not add any non-physiological chemical to the measurement. The
DPV propofol detection in undiluted human serum resulted in a LOD of 0.82 µM with
9.3 (%) RSD, which is below the propofol physiological range ([1 - 60] µM).
• PGE composition is made of graphite, clay and wax (binder) in different percentages.
We investigated and compared the performance in propofol long-term detection of
different lead compositions in terms of: (i) propofol sensitivity and (ii) fouling resistance
properties. The electrodes were characterized by electrochemical analysis, EIS mea-
surements and SEM imaging. By electrochemical analysis, we demonstrated that the
higher the graphite content (wt%), the higher the sensitivity, whereas the higher the clay
content (wt%), the smaller the fouling effect. This is also reflected by EIS results where
higher charge-transfer resistance (Rct ) values characterize the PGE with the higher clay
content.
We identified a significant value of clay-to-graphite ratio, as equal to 0.4, for which
the fouling effect is not significant in the time-series of measurements. This values
corresponds to the F lead composition (66% w/w in graphite, 28% w/w in clay and
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5% w/w in clay). Therefore, we identified a range of clay/graphite ratios suitable for
reliable long-term propofol monitoring, such as from 0.4 to 1.5 (from F to 9H). Within
this selected suitable range, we discovered that the 3H lead (58% graphite, 36% clay and
5% wax, with clay-graphite ratio of 0.62) was providing the optimum material substrate
in terms of preventing the fouling effect, electrode stability, and detection sensitivity, for
measurements of propofol over a period of time of 4 hours in continuous monitoring.
The higher performances of this PGE composition have been confirmed and validated
further by SEM and EIS analysis.
Table 3.3 – Comparison of the performance of the sensors for propofol sensing presented
in the literature: ready to use (RtU), electrochemical technique (T), LOD (error limits are
evaluated as standard deviation of the dataset n = 5), Long-Term Monitoring (LTM), possibility
to detect in human serum background electrolyte (HS) and on-line electrochemical cleaning
procedures implemented (CPI) in which solution (CS) are taken in consideration.
Ref. WE RtU T LOD (µM) LTM HS CPI CS
[134] GC SPE × CV 3.2 ± 0.1 − − × −
[132] PVC WE × CV 0.08 ± 0.05 3 h − × −
PVC WE × CA 0.012 ± 0.004 − X × −
This Thesis BDD X CV 2.38 ± 0.5 > 4 h − X PBS
BDD X CV 2.4 ± 0.9 > 4 h − X NaOH
PGE X CV 8.1 ± 5.6 > 4 h − X PBS
PGE X CV 3.1 ± 1.1 > 4 h − X NaOH
PGE X DPV 0.82 ± 0.08 − X − −
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4 Midazolam and Paracetamol direct
monitoring
In Chapter 3 the complete analysis to identify the best electrochemical sensor for direct long-
term propfol detection, the hypnotic agent of anesthesia cocktail, has been explored. In
this chapter, to complete the array of electrochemical sensors required for full monitoring
of the anesthesia cocktail, two other drugs, the analgesic (APAP) and the muscle relaxant
(midazolam), have to be investigated. As mentioned in Section 1.1.1, both midazolam and
APAP, whose chemical structures are reported in Fig. 4.1, are common drugs extensively used
in sedation procedures. On the one side, APAP treats mild to moderate pain and reduces fever.
It is often administered in place of opioids to alleviate pain resulting from POPI that still affects
between 28% and 90% of patients [26]. Therefore, it is still considered as one of the most
critical problems in the current anesthesia practices [153]. Since, APAP is metabolized primary
by the liver, overdose may lead to hepatotoxicity. After 1 h of ingestion, the drug concentration
in plasma ranges from 2 to 20 mg/L, whereas levels of 30 - 300 mg/L are often observed in
overdosed patients [154, 155].
b) Midazolam a) Paracetamol
Figure 4.1 – Chemical structures of: a) paracetamol and b) midazolam.
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On the other side, MZ is a water-soluble benzodiazepine in its acid formulation with a rapid
onset of action and high metabolic clearance. It is largely adopted in anesthesia induction
and maintenance, as well as in sedation [21]. Since it affects CNS activity, serious breathing
problems may be encountered if a dose of 0.15 mg/kg is administered [22].
Finally, we will conclude the chapter with the results obtained in an electrochemical interfer-
ence analysis among propofol, midazolam and paracetamol drugs.
4.1 State-of-the-art
Different approaches have been used for APAP and MZ detection in human fluids, such as
titrimetry [156], spectrophotometry [157], flow-injection spectrophotometry [158] and chro-
matographic methods [159], liquid chromatography with mass spectrometric [160], electron-
capture gas chromatographic [161, 162], RadioImmunoAssay (RIA) [163], and potentiometric
electrodes [138]. However, alternative methods of detection still need to be investigated in
order to develop reliable point-of-care to avoid any over dosage of such invasive compounds.
As stated above, electrochemical sensors are suitable candidates since they offer high sensitiv-
ity, low cost, easy manufacturability and fabrication reproducibility, as well as the possibility
to be miniaturized and easily integrated in electronic circuits and read-outs [164]. Moreover,
the electron transport performance of electrochemical sensors, in terms of sensitivity and
specificity, can be highly improved with the integration of nano-materials [165, 85]. This
enhancement of detection sensitivity is extremely beneficial in case of drugs with a narrow
therapeutic range, and with small differences between therapeutic effects and toxic doses of
the administered concentrations [166].
As far as the electrochemical detection of APAP and MZ is concerned, direct sensing with
carbon electrodes has been already extensively verified in the literature [167, 168, 169].
Faced with the vast literature about nano-structured electrochemical sensors, we have in-
vestigated and compared the performances obtained by different nano-allotropes of carbon
materials, namely fullerene (C60) and MWCNTs, with respect to bare C-SPE, in order to esti-
mate the enhancement in MZ and APAP sensing due to C-nanostructures deposition. The
objective of this analysis is to identify the best nano-composite substrate for APAP and MZ
monitoring in human serum.
In order to guarantee a proper and reliable comparison among tested electrodes, we used
the approach (developed by our group) described in [170] for sensor functionalization to
obtain equal EASA among different nano-structured electrodes. It is based on an a-priori
evaluation of the EASA for each material that is used to know the amount of nano-material to
drop-cast on the WE surface. In this way, it is possible to exclude the EASA effect on sensing
enhancement and, therefore, to highlight the contribution only related to the electron-transfer
and electro-catalytic properties of the nano-materials, by excluding the increased effect that is
purely related to the catalytic area of the surface.
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4.2 Carbon-based nano-structured electrodes
4.2.1 Materials and methods
APAP has been purchased in powder from Sigma-Aldrich (Switzerland), as well as the human
serum heat inactivated (H3667-100ML). APAP 30 mM stock solution has been obtained by
dissolving 5 mg of powder in 1 mL PBS (10 mM, pH: 7.4). Subsequent concentrations of [50 -
100 - 150 - 200 - 250 - 300] µM were obtained by injecting 16.6 µL of stock solution in 10 mL
PBS or human serum background electrolytes. The range of concentration was chosen in
agreement with the pharmaceutical formulation of the drug [169].
Midazolam Hydrocloride (MZ HCl) was provided in powder from Lipomed AG. A 15 mM stock
solution was prepared by diluting 10 mg of powder in 2 mL distilled water to reach the desired
solution. Sample aliquots of 1 mL were prepared by diluting the stock solution in acidic PBS
(10 mM, pH: 2.5) and undiluted human serum to desired concentrations of [0.45 - 1.35 - 2.25 -
3 - 4.5] mM. The range of concentration was chosen in agreement with the pharmaceutical
formulation of the drug [171]. The acid formulation was used to increase the solubility of
midazolam as described in Section 1.1.1.
10 ml of ferro(ferri)cyanide 1 mM solution for experimental EASA evaluation was obtained by
mixing 0.0042 gr potassium hexa-cyanoferrate trihydrate II with 0.0033 gr potassium hexa-
cyanoferrate III in PBS (10 mM pH:7.4). All the chemicals were purchased by Sigma Aldrich.
Commercial C-SPEs (WE, 4 mm Ø) were purchased from Metrohm (DRP-110). Powder of
MWCNTs (90% purity; 0.05% functionalized with NH2) with diameter of 10 nm and length
of 1 to 2 µm was purchased from DropSens (Spain) and was dispersed in chloroform to a
final concentration of 2 mg mL−1, and was sonicated for 1 hour to achieve a homogenous
solution. Fullerene, C60 powder (average diameter: 60-80 nm) was provided by Nanoshel
Company (India) and was dispersed in methanol to the final concentration of 1 mg mL−1, and
was sonicated for 1 hour to achieve a homogenous solution.
Autolab potentiostat (PGSTAT128N) by Metrohm was used to carry out experiments. The
data analysis was performed in Excel and Matlab, where a dedicated script for peaks height
evaluation was implemented.
Surface characterization has been carried out using a Zeiss Merlin scanning electron micro-
scope with accelerating voltages in the range of 1.2 kV to 3 kV. The nanostructure solutions
were deposited on Copper (Cu) foils by standard drop casting.
Nano-structured electrode preparation and theoretical EASA calculation
For electrode functionalization the amount of nanomaterials to drop-cast on the electrode’s
surface was evaluated a-priori by using Specific Surface Area (SSA) calculation, as in [170], in
order to obtain an equal additional EASA by different nanomaterials. The SSA (m2/g) of a
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sample can be evaluated as [172]:
SS Ananopar ti cle =
ar ea
mass
(4.1)
For MWCNT, assumed to have cylindrical shape, the SSA has been evaluated in [170] as 215.7
m2/g, according to this calculation:
SS AMW C N T = SS AGS ×de
n×de −2×ds−s∑n−1i=1 i (4.2)
Where de is the MWCNTs diameter (10 nm), ds−s is the inter-shell distance (0.34 nm), SS AGS is
the SSA of one side of the graphene sheet (1315 m2/g), and n is the number of shells (calculated
to be 8).
The SSA of C60 sample, assumed as spheres, was calculated as equal to 29.0 m
2/g.
SS AC 60 = 3
r ×ρ (4.3)
Where r is the radius of a fullerene spherical nanoparticle (60 nm) and ρ is the density (1.72 g
cm−3).
According to [173], the optimum additional-EASA of MWCNT is 4314 mm2. Therefore, to
guarantee an appropriate comparison between the electrochemical properties of the two
different carbon nano-scale allotropes, the gain in terms of EASA has to be the same. The
required amount of MWCNTs and C60 in µg to achieve the same optimum additional-EASA
can be evaluated from Equations 4.4 and 4.5, respectively:
4314mm2 = 215.7 m
2
/
g ×XMW C N T =⇒ XMW C N T ≈ 20µg (4.4)
4314mm2 = 29 m
2
/
g ×XC 60 =⇒ XC 60 ≈ 149µg (4.5)
Surface characterization
We have performed SEM analyses of bare C-SPE, MWCNTs and C60 samples to observe and
compare the morphological characteristics of the nano-structures also with respect to a
bare electrode, in Fig. 4.2. As visible from Fig. 4.2.b, MWCNTs present high homogeneity in
morphology and a dense 3D coverage of the surface. The diameter of the nano-structures is
estimated and confirmed to be about 10±2 nm.
On the other hand, the C60 sample turned out to be assembled in globular aggregates, as
shown in Fig. 4.2.c. The dimensions of the structures vary and are not perfectly homogeneous,
as due to the fabrication method. The average size of these nanostructures is estimated to
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a.
b.
1µm
100 nm
200 nm
200 nm
100 nm
20µm
5µm
c.
Figure 4.2 – SEM characterization of a) bare C-SPE, b) MWCNT- and c) fullerene-modified
surfaces.
be around 120 nm, indicating a quite high standard deviation of 40 nm, as previewed from
repeated SEM imaging obtained on different areas of the modified surface. In some cases,
even larger structures are found with a diameter up to 200 nm, mainly due to an intense
clustering occurring between neighboring smaller structures.
4.2.2 Results and discussion
APAP and MZ characterization at bare C-SPE
The electrochemical behavior of MZ have been investigated with glassy carbon electrode by
[169] in Britton–Robinson (BR) buffer containing 0.1% cationic surfactant. Typical voltam-
mogram (900 µg/mL midazolam) exhibited four well defined peaks, as shown in Fig. 4.3.a.
However, they found that peak 0 was not registering any signal enhancement after increasing
the analyte’s concentration in the solution unlike the other peaks (peak 1, 2 and 3). Therefore,
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a. b.
Figure 4.3 – a) Cyclic voltammogram of midazolam (900 µg/mL) shows peak 0, 1, 2 and 3
in presence of 0.1% cationic surfactant indicating the irreversibility of electrode process. b)
Sketch of the reaction mechanism for midazolam reduction (reprinted from [169]).
they supposed that peak 0 might correspond to a pre-adsorption step not affected by the
analyte concentration. Concerning the other peaks, they assigned the peak 1 to the 2-electron
reduction of the –C=N– bond of the seven membered ring, peak 2 to the 2-electron reduction
of –C=N– bond of the five membered ring and peak 3 to the 2-electron reduction of –C=C– of
the five membered ring of midazolam structure. Since no peak is observed in the reversed CV
scan, these reactions are irreversible processes. On the basis of these results, they postulated a
reduction mechanism for midazolam as in Fig. 4.3.b.
We started from these findings and we characterized the electrochemical response of midazo-
lam at C-SPE by performing CV in the range of potentials between -1 V and 0 V with 0.1 V/s
scan-rate. Typical CV plots obtained for increasing midazolam concentrations are shown in
Fig. 4.4.a. Three reductive peaks are visible from the plots, corresponding to the first three
peaks detected by [169]. Also in this case, peak 0 seems to be unaffected by variations of the
drug concentration. For the calibration analysis, the CV area with the peaks has been isolated
and rendered in absolute value, as seen in the Fig. 4.4.b (to have a more easy intuition of the
relationship between increase in concentration and corresponding augmentation of the peak
current). Both peak 1 and peak 2 have been considered for the analysis (blue and orange areas
in the figure, respectively). Fig. 4.4.c shows the calibration lines obtained from three C-SPEs
for both the considered peaks. For peak 1 a sensitivity of 1.60−05±1.7−06 mA/mM and an LOD
of 0.29 mM were evaluated, while for Peak 2 the sensitivity was of 1.94×10−02±2.16×10−03
mA/mM and the LOD 0.20 mM. We can notice that both the peaks gives very similar responses
in midazolam calibration procedure.
As far APAP direct detection is concerned, [174] reported its electrochemical characterization
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calibration line plots obtained from peak 1 and peak 2 at three different C-SPEs, errors bar
represents the standard deviation.
with bare Glassy Carbon (GC) electrode. It has been found that in the pH range between 3 and
11 (containing the physiological pH: 7.4) the chemical reaction is characterized by a reversible
process since both an oxidation and a reduction peaks are visible in the voltammogram at
+0.1 V and +0.5 V (vs. Ag/AgCl), respectively. The typical CV plot and the reversible reaction
mechanism for APAP have been reported in Fig. 4.5. Starting from this study, we characterized
the detection of paracetamol at C-SPEs by running a CV procedure between -0.1 V and +1.1
V with a scan-rate of 0.1 V/s. Typical CVs for increasing concentrations of APAP are reported
in Fig. 4.6.a. Both oxidative and reductive peaks are visible confirming the reversibility of
the RedOx process, as predicted by [174]. From the calibration line in Fig. 4.6.b, which was
evaluated for the oxidation peak (green area in the figure), we have found that the sensor
sensitivity was of 6.02×10−02±6.38×10−4 µA/µM and the LOD of 0.58 µM.
After having characterized the electrochemical behavior of MZ and APAP at C-SPE, we investi-
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Figure 4.5 – a) CVs of 1×10−3 M APAP at bare GC electrode in aqueous solutions at pH 3.
Reprinted from [174]. b) Reversible reaction mechanism for APAP at pH 3.
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Figure 4.6 – APAP calibration at bare C-SPE in PBS solution at pH 7.4: a) typical CVs for
increasing concentrations of APAP; all show the oxidation and reductive peaks. b) Calibration
line plot obtained from APAP oxidation at three different C-SPEs, errors bar represents the
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gated and compared the performances obtained from the functionalization of the electrode
with two carbon nano-allotropes, i.e. fullerene (C60) and MWCNTs.
APAP and MZ characterization at carbon nanoscale allotropes modified electrodes
Experimental Determination of EASA We have experimentally evaluated the EASA of bare,
MWCNTs- and fullerene-modified WEs to validate the efficacy of the EASA theoretical cal-
culation for obtaining optimum and comparable surface nano-structuring, as presented in
Section 4.2.1. To this aim, CV procedure between -0.5 V and 1 V and scan-rate 0.1 V/s was
carried out in ferro(ferri)cyanide 1 mM solution. Since the RedOx process for the electro-
chemical couple Fe2+/Fe3+ is well-known, it is possible to evaluate the total EASA (A in the
following equation) from Randles-Sevcik equation as in Eq. 3.1, knowing that n = 1 is the
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Figure 4.7 – Comparison of voltammograms obtained for: a) APAP 300 µM and b) MZ 3
mM at bare, MWCNTs- and fullerene-modified electrodes (PBS blank measurements have
been reported for all the electrodes as control). It is visible how nano-structures improve the
EASA and electron-transfer properties respect to the bare electrode; c) and d) compares the
sensitivity values obtained for the three tested electrodes (calibration performed considering
the peaks in the yellow areas).
number of electrons exchanged in this reaction, D = 6.20×10−6 cm2 is the diffusion coefficient
of ferro-cyanide [175], C = 1 mM is the concentration and ν= 0.1 V/s is the scan-rate adopted
in the CV procedure.
We found that the EASA of MWCNT- and C60-modified electrodes were respectively increased
by 43.9 cm2 and 47.8 cmr (26.5% and 24.3%), respectively, in comparison with the bare C-SPE.
Hence, confirming the the efficacy of the theory for EASA calculation (theoretical assumption
for equal to 43.14 cm2).
Electrochemical characterization We have carried out CV procedures to electrochemical
characterize the performance of MWCNTs and fullerene nanostructured electrodes in deter-
mining APAP and MZ concentrations. Typical voltammograms for 300 µM APAP and for 3
mM MZ obtained by bare C-SPE, MWCNT- and C60-nanostructured electrodes are reported in
Fig. 4.7.a and Fig. 4.7.b, respectively. In dashed lines there are the blank measurements (base-
line currents) measured for every tested electrode, as per control. These measurements were
obtained at a scan-rate of 0.1 V/s in PBS (10 mM, pH:7.4 and 2.5 for APAP and MZ, respectively).
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Figure 4.8 – APAP and MZ CV calibrations at C60- and MWCNT-modified WEs in PBS (10
mM, pH: 7.4): extraction of the peaks area from CVs for increasing concentrations of a) APAP
(oxidation) and b) MZ (reduction); c) and d) are the calibration lines obtained from APAP and
MZ detection considering three different WEs, errors bar represents the standard deviation.
It is clear that a higher capacitive current is measured from MWCNT-modified electrodes. In
agreement with what we have already discussed in Section 4.2.2, the electrochemical response
of all the tested electrodes for APAP detection presented well-defined oxidation and reduction
peaks, while, for MZ detection three reductive peaks are registered (the first one, indicated by
arrows in the figure, is not related to MZ concentration). A preliminary significant observation
on Fig. 4.7 can be done on interference action of the two target drugs, that will be further
discussed in Section 4.3. The two drugs were found not to be interfering each other since MZ
shows only reductive peaks at negative applied voltages, while APAP manifests oxidative and
reductive peaks at positive potentials.
What is more, there is an evident shift of the peaks-position toward smaller potentials when
the RedOx occurs on modified electrodes as explained by the Nernst effect [176]. Fig. 4.7.c
and Fig. 4.7.d. reports the error bar graph with the sensitivity values obtained for all the
tested electrodes (error bars represents the standard deviations, n = 3) considering the peaks
highlighted in yellow (oxidative peak for APAP and peak 1 for MZ). Even if for APAP detection
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in PBS there is no an evident enhancement of the sensitivity with nano-allotropes with regards
to the bare C-SPE, for midazolam both are notably increasing the sensitivity with respect to
the bare electrode. In particular, MWCNTs are almost doubling the sensitivity obtained for
bare SPE.
We then performed CV measurements at different APAP and MZ concentrations, ranging
between [50 - 300] µM and [0.45 - 4.5] mM, respectively, to calibrate the sensors. The peaks
area extracted by the measured voltammograms with MWCNT and fullerene-C60 modified
electrodes are shown in Fig. 4.8.a and Fig. 4.8.b. As concerning APAP detection (Fig. 4.8.a), we
can notice that MWCNTs-modified electrode revealed a second oxidative peak beyond 250
µM APAP concentration. Also in this case, the calibration analysis was carried out considering
the oxidation peak for APAP and peak 1 for MZ, since it is also visible also with the lowest MZ
concentration at MWCNT (yellow areas in the figure). Calibration lines for APAP and MZ on
both modified electrodes are reported in Fig. 4.8.c and Fig. 4.8.d, respectively. The sensitivities
for APAP detection at the two kinds of modified electrodes are close ((2.6±0.2)×10−2 µA/µM
MWCNTs and (4.7±0.2)×10−2 µA/µM fullerene). However, the fullerene electrodes are af-
fected by lower reproducibility, as measured by the larger estimated standard error (σd /
p
(n)
whereσd is the standard deviation and n is the number of evaluated points, n = 3). Indeed, the
average estimated standard error was found to be 3.2 and 5.7 for MWCNTs and fullerene-C60
modified electrodes, respectively.
For MZ detection, the sensitivities of the two kinds of modified electrodes are also comparable:
52.4±9.6 µA/mM for MWCNTs and 32.8±3.7 µA/mM for fullerene.
APAP and MZ detection in Human Serum After having characterized the electrochemical
behavior of the two differently nano-structured electrodes in PBS solution, we have then
performed CV measurements in undiluted Human Serum (HS). This allowed us to validate
the sensor’s efficacy in MZ and APAP detection within the scope of the final application
for anesthesia monitoring. The voltammograms and calibration lines obtained from this
analysis are presented in Fig. 4.9. The first observation we can make is that we were not
able to measure MZ in human serum with C60-modified electrodes. As we have seen in
both surface and electrochemical characterizations, in fact, these electrodes were affected
by inhomogeneous deposition leading to instability. Therefore, we have confirmed their
inefficiency in MZ detection in human serum.
As for the calibration lines we obtained, the current amplitude of the peaks is increasing
Table 4.1 – Sensitivity and LOD values for APAP and MZ detection at MWCNT and fullerene-C60
modified electrodes in human serum.
Sensitivity LOD
APAP MWCNT 0.052±0.001 (µA/µM) 0.352±0.023 µM
C60 0.046±0.001 (µA/µM) 1.179±0.105 µM
MZ MWCNT 10.1±0.4 (µA/mM) 0.319±0.038 mM
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Figure 4.9 – APAP and MZ detection in undiluted HS at MWCNT and fullerene-C60 modified
electrodes. Peak areas extracted by the voltammograms and calibration lines (n = 3) are
reported for increasing concentrations of APAP and MZ.
in linear fashion with the APAP and MZ subsequent concentrations. The sensitivity and
LOD values for all the calibrations were evaluated as summarized in Table 4.1. From this
comparison table, MWCNT-modified electrodes are also shown to be best option for APAP
detection in undiluted human serum.
4.3 Interference study
To sum up the findings in Chapter 3 and previous Section 4.2, we concluded that the sensors
should include:
• For propofol detection: Ag/AgCl RE, Pt wire CE and wood PGE 3H WE;
• For APAP and MZ detection: Ag RE, carbon-based WE and CE.
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Figure 4.10 – APAP interference study: Gaussian decomposition of the CV procedure ([+0.2 -
+1.4] V, scan-rate 0.1 V/s at PGE) belongs to the mixture of APAP (1 mM) and propofol (80.5
µM).
Therefore, the analysis has to be completed by an interference study. Interference will be
considered mainly among the monitored drugs, but also with respect to the main interfering
components, e.g. Ascorbic Acid (AA), Uridic Acid (UA) and cysteine.
4.3.1 Interference at different PGEs
Interferences between APAP and Propofol oxidation processes have been evaluated with PGE
in PBS background electrolyte. Indeed, APAP can be administered to alleviate pain due to
POPI to avoid opioids. Therefore, it can be present in patient’s blood when propofol is infused.
Furthermore, APAP is an electro-active phenol compound as propofol and its oxidation CV
peak appears at around [+0.3 - +0.5] V, which is very close to that of propofol at PGE ([+0.4 -
+0.9] V). Fig. 4.10 shows the oxidation peak resulting from CV procedure applying potentials
between +0.2 V and +1.4 V at 0.1 V/s scan-rate in a solution containing 1 mM APAP and 80.5
µM propofol with background correction. This isolated current peak region was fitted with two
Gaussian functions centered at +0.47 V and +0.60 V. Since the two Gaussian components are
well discriminated, it is possible to identify and separate the contribution due to paracetamol
(gaussian1fit at +0.47 V) from the propofol current peak in the voltammogram (gaussian2fit at
+0.60 V).
Since we confirmed the interference action between APAP and propofol, we further inves-
tigated the optimal conditions (in terms of pH and post-processing analysis) to be able to
monitor both the drugs simultaneously. DPV procedure (potential range between +0 V and
+1.1 V, interval time 0.2 s modulation amplitude 50 mV modulation time 50 ms and scan
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Figure 4.11 – DPV plots from APAP and propofol interference study at PGE 3H in neutral PBS
(10 mM, pH:7.4) background solution.
rate 0.025 V/s) has been performed keeping the concentration of APAP fixed at 200 µM and
increasing the propofol concentration during subsequent measurements. We have considered
the influence of pH since, as discussed in the Chapter 2, it affects the potential at which the
drug reacts (peak position).
Fig. 4.11 and Fig. 4.12 show DPV results at physiological and acid background solutions
(PBS, 10 mM pH: 7.4 and 2.5), respectively. Both the figures report: a) overlapped typical DPV
plots obtained for increasing concentrations of propofol ([9.9 - 80.5] µM) and APAP ([50 - 300]
µM) if separately present in the buffer solution; b) typical DPV plots registered at fixed APAP
concentration (200 µM and 300 µM) and increasing concentrations of propofol (range [9.9 -
80.5] µM).
Regarding Fig. 4.11.a , we can predict an interference action between APAP and propofol
oxidation peaks between +0.4 V and +0.7 V. Indeed, Fig. 4.11.b shows only two peaks, one at
∼+0.35 V (pink area), deriving from APAP and the other from the double contribution of APAP
and propofol oxidations (yellow area).
Conversely, Fig. 4.11.a shows a peak for APAP at∼+0.6 V well separated from the two propofol
oxidation peaks at ∼ +0.39 V and at ∼ +0.75 V. This result in three separated peaks (yellow
areas for propofol and pink area for APAP contributions) also in the DPV measurement in the
presence of both the drugs in the solution. The different contributions from the two drugs are
more easily seen in Fig. 4.13 where single DPV plots resulting from solutions containing only
APAP, only propofol and a mix of the two drugs are overlapped.
As a conclusion of this analysis, the acid pH condition is preferred, in general for sensing
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Figure 4.12 – DPV plots from APAP and propofol interference study at PGE 3H in acid PBS (10
mM, pH:2.5) background solution.
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Figure 4.15 – Interference study: CV plots at C-SPE for midazolam detection in PBS pH 2.5 in
the presence of APAP and propofol drugs.
aims. Fig. 4.13.c reports the calibration lines for the two oxidation peaks of propofol at +0.4
V (red) and +0.8 V (blue) in the presence of 300 µM of its interferent APAP. Sensitivity values
have been evaluated as 0.053±0.012 µA/µM and 0.076±0.002 µA/µM for propofol peaks
at +0.4 V and + 0.8 V, respectively. As far midazolam is concerned, we have performed CV
measurements between -1 V and 0 V at PGE WE for midazolam concentrations 0.45 mM
and 2.4 mM. However, as visible in Fig. 4.14.a, midazolam is not reacting at this electrode’s
substrate. Fig. 4.14.b reports the voltammogram obtained by running the same CV procedure
in the same midazolam solutions to demonstrate the presence and the correct electro-activity
of MZ drug in the analyzed solution. Therefore, we could conclude that no interference action
would derivate from MZ for propofol and APAP detection at PGE.
Finally, other interfering compounds, i.e. AA, UA and cysteine were not investigated further at
PGE since their oxidative peaks are not in the same potential window of propofol. Indeed, AA
and UA oxidation peaks are recorded at +0.1 V and +0.5 V, respectively (at graphite-based WE
and saturated calomel electrode as RE) [177]. Moreover, cysteine had an oxidation peak at 0 V
on modified graphite electrodes (saturated calomel electrode as RE) since the sensitivity of
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Figure 4.16 – Calibration lines for MZ detection in PBS pH 2.5 in the presence of: a) APAP and
b) propofol interference compounds. Error bars represent the standard deviation from the
three tested WEs.
bare electrodes were very low [178].
4.3.2 Interference at C-SPE
Midazolam detection was demonstrated at C-SPE (Metrohm) as WE. In this section the inter-
ference action of APAP and propofol, the other two electro-active drugs administered in the
anesthesia cocktail, will be analyzed. The interference action on the midazolam electrochemi-
cal response has been evaluated in acid PBS (pH: 2.5) background electrolyte in presence of
50 µM APAP and 19.6 µM propofol, separately. Fig. 4.15.a and Fig. 4.15.b show the CV plots
obtained for a reduced applied potential range ([-1.1 - 0] V, blue lines) and for a wider potential
range ([-1.1 - +1.1] V, red lines) in the presence of APAP and propofol, respectively. As we can
observe, in the CV with reduced potential range, only typical MZ reduction peaks are visible
(blue areas in the figures), while, once the potential range is enlarged, the oxidation peaks
from APAP and propofol oxidation reactions at positive potentials also appear (red areas in the
figures). Fig. 4.16.a and Fig. 4.16.b report the calibration lines for MZ detection in the presence
of increasing concentrations of interferent compounds. In particular, Fig. 4.16.a shows the
calibration lines for MZ in the presence of 50 µM and 100 µM APAP, while Fig. 4.16.b reports
the calibration lines for MZ detection in the presence of 19.6 µM and 80.5 µM propofol. The
sensitivity values from the calibration lines are summarized in Table 4.2 and graphically re-
ported in Fig. 4.16.c and Fig. 4.16.d. The sensitivity values are slightly changing in the presence
89
Chapter 4. Midazolam and Paracetamol direct monitoring
of increasing concentrations of interferent compounds in the solution. In case of APAP, the S
from MZ calibration is decreasing of 0.4% and 19.6% in the presence of 50 µM and 100 µM
of APAP, respectively. On the other hand, S from MZ calibration increases of 4.1% and 17.4%
if 19.6 µM and 80.5 µM, respectively, of propofol are added into the solution. Therefore, we
Table 4.2 – Sensitivity values (S-interf-APAP and S-interf-Prop) from MZ calibration in solutions
containing only midazolam and in presence of interferent compounds (interf1 is 50 µM APAP
and 19.6 µM propofol, interf2 is 100 µM APAP and 80.5 µM propofol).
S-interf-APAP (µA/mM) S-interf-Prop (µA/mM)
only MZ 25.75±3.18 25.64±1.86
interf1 25.64±1.86 26.69±2.95
interf2 20.62±1.51 30.09±1.67
could conclude that midazolam detection can be performed on a C-SPE electrode by running
the CV procedure between the reduced range of potentials [-1.1 - 0] V without any interference
action even in presence of propofol and APAP in the analyzed solution.
4.4 Summary and main original contributions
In this chapter the design and the manufacture of the sensors for detecting midazolam and
paracetamol anesthetics in human serum have been reported. In the previous chapter, we
identified the PGE 3H substrate as the optimum for propofol direct monitoring in terms of
sensitivity and fouling resistance. Therefore, in this chapter, we have finally identified the
best sensors for all the anesthesia triad (hypnotic, analgesic and myorelaxant). The main
contributions reported in this chapter can be summarized as follows:
• We have realized and compared the performance of different carbon nano-scale al-
lotropes for APAP and MZ detection. In particular, MWCNTs fullerene-C60 were consid-
ered as nano-materials. By comparing our results for APAP and MZ with the literature,
as summarized in Tables 4.4 and 4.3, respectively, we can notice that, to the best of
our knowledge, we have reported for the first time on a complete measure of MZ in
undiluted HS with MWCNTs-modified SPE. We also obtained excellent LODs for APAP
detection with respect to the only previous works [179] and [180], in relation to its
detection in highly diluted human serum. Hence, we confirmed the superior efficacy
of MWCNT-SPE in MZ and APAP detection in HS. This is also confirmed by the fact
that the reported LOD for the sensor is lower than the minimum concentration of the
therapeutic range of these drugs.
• The two differently nano-structured electrodes, e.g. modified with MWCNTs and
fullerene-C60, were prepared according to theoretical EASA calculation. Indeed, by
performing an a-priori evaluation of the EASA for each material, it is then possible to
know the amount of nano-material to drop-cast on the WE surface in order to have a
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proper and reliable comparison among the tested electrodes. In this way, it is possible
to exclude the catalytic effect due to area enhancement and, therefore, to highlight the
contribution related only to the electron-transfer and electro-catalytic properties of the
nano-materials.
• MWCNT-modified SPE have given satisfactory results for both midazolam and APAP
sensing in undiluted human serum compared with literature. The excellent performance
of MWCNTs nano-structures were also confirmed by SEM imaging analysis.
• We conducted an interference study among propofol, midazolam and APAP compounds.
Main results from the investigation are: (i) APAP and propofol can be detected by
the same PGE WE and (ii) Gaussian decomposition can be used to discriminate the
current contributions of the two drugs, (iii) midazolam neither undergoes nor causes any
interference with the other two drugs since it is characterized by reduction reaction at
negative potentials, whereas APAP and porpofol react by oxidation at positive potentials.
• Acid pH solutions may facilitate the process of discrimination for APAP and propofol
detection since more separated current peaks from the two drugs are recorded. Hence,
Gaussian decomposition turns out to be more straightforward.
Table 4.3 – Comparison of electrochemical performance of previously reported sensors for MZ
detection.
Electrode Detection Method LOD (µM) Stock Biosample Ref.
PVC membrane potentiometry 5
MZ
tetraphenyle
borate
solution
× [138]
CPE (Carbon
Paste
Electrode)
potentiometry 60
MZ
tetraphenyle
borate
solution
Highly
diluted
HS
[181]
GC DPV -
Organic
solvents
and
surfactants
BR buffer [169]
MWCNT-SPE CV 536 PBS
Undiluted
HS*
This
Thesis
*To the best of our knowledge,
this is the only MZ detection in undiluted human serum with a reported LOD.
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Table 4.4 – Comparison of electrochemical performance of previously reported sensors for
APAP detection.
Electrode Detection Method LOD (µM) Stock Biosample Ref.
Fullerene GC DPV 50 PBS Urine [182]
CPE
SquareWave
voltammetry (SWV)
1.6 PBS × [183]
MWCNT DPV 0.6 PBS
Highly
diluted
HS
[179]
SWCNT–
Graphene
NanoSheet
(GNS)/GC
voltammetry 0.038 PBS
Highly
diluted
HS
[180]
SWCNT -
pyrolytic
electrode
(EPPGE)
voltammetry 0.003 PBS Urine [184]
C60-SPE CV 1.18 PBS
Undiluted
HS*
This
Thesis
MWCNT-SPE CV 0.35 PBS
Undiluted
HS*
This
Thesis
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5 Electronic platform
The creation of a complete electrochemical sensor requires the integration of two main
building blocks: (i) the sensing platform to detect and measure the target compounds,and (ii)
the front-end electronics to control and readout the sensors. In Chapter 3 and Chapter 4 we
examined the investigation process to obtain the best electrochemical sensors for anesthetics
monitoring. In this chapter, the design, development and validation of a portable Point
of Care (PoC) electronic system to be integrated with the electrochemical sensors will be
presented and described. This hardware platform will not only be interfaced with the sensors
for drug detection, but also with two other commercial sensors for pH and temperature
monitoring for sensors calibration.
The development of the hardware and the sensing systems was running in parallel, therefore
the final electronic board has been produced through a progression of improved hardware ver-
sions. Two main features were considered for the advancement of the circuitry: (i) optimizing
the interfacing with the sensors that were gradually selected for anesthetics’ detection, and
(ii) improving the performance by reducing the noise and increasing the signal to noise ratio.
The optimization process for obtaining the final electronic system made with Components
Off-The-Shelf (COTS) will be presented in detail throughout the following sections.
A sketch of the custom-built portable potentiostat system is represented in Fig. 5.1. The main
control unit of the system consists of a powerful and low-cost RPi platform (version 3 model B
[185]) that interfaces with a potentiotatic front-end PCB realized with COTS components. A
dedicated Graphical User Interface (GUI), developed using the C++ programming language in
QT Creator 3.2 software1, allows the user to interact with the RPi and, through it, directly with
the PCB circuit. The communication between RPi and PCB exploits the I2C serial protocol. As
it can be seen in the schema, we have interfaced the system with both SPE and PGE-based
electrochemical cells. The rest of the system includes a TCI pump2 connected to the RPi via
serial port communication, to infuse the anesthetic drugs and a laptop for data processing
1The code for RPi system was developed by Abuduwaili Tuoheti, Politecnico di Torino, Italy.
2The Matlab code implemented for driving the pump injections has been developed under my supervision by
Bruno Donato, internship master student at Laboratory of Integrated System, EPFL, Switzerland.
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Figure 5.1 – Sketch of the RPi-based portable system for anesthesia monitoring.
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Figure 5.2 – Architecture of the RPi-driven electronic circuit for monitoring up to three anes-
thetics at the same time.
and for actual drug concentration evaluation.3
In this chapter we will focus on the development and validation of the electronic platform.
All the schematics and layouts of the PCBs were realized in Altium Design Software, while the
fabrication process of the hardware was provided by Eurocircuits Online PCB Prototype and by
Atelier de fabrication de circuits imprimés (ACI) at EPFL.
5.0.1 System architecture of the electronic platform
The schematic representation of the RPi-based electronic architecture is depicted in Fig. 5.2.
RPi has been chosen and integrated in the circuit to exploit its high performance and excellent
hardware and software features. It is in fact based on Quad-Core Broadcom BCM2837 chip
3The algorithms for automatic estimation of the drug concentration were implemented by Alena Simalatsar
and Monia Guidi, our partners in Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland.
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with 1.2 GHz CPUs. It also has 40 GPIO pins that can be configured as I2C, SPI ports and/or
UART ports and some of them can also provide stable 3.3 V and 5 V supply. Hence, the PCB is
powered from the 5 V pins of the RPi. Thanks to the I2C module library, the specific pins have
been configured to be connected with the micro-controller’s Two Wire Interface (TWI) port on
the PCB to enable the exchange of the data packets. A dedicated GUI, that will be describe
afterwards in Section 5.3, has been developed to let the user interact with the electronic system.
The PCB front-end potentiostat offers three independently programmable parallel channels
to guarantee the flexibility of the platform in detecting different target compounds at the same
time. Each channel implements actuation and sensing blocks consisting of: (i) generation
of excitation waveform according to the electrochemical technique to run and (ii) read-
out circuit to collect the response signal from the electrochemical cell. The ATxmega32E5
micro-controller Atmel AVR XMEGA family4 plays a pivotal role in the front-end circuit
since it receives the setup parameters chosen by the user through the GUI from the RPi. It
controls the voltage generator circuit to apply a stable potential between the WE and the
RE to make the RedOx reaction happen, and it digitalizes, through its internal 12-bit Analog
to Digital Converter (ADC) (bandwidth up to 1 MHz), the measured analog signal from the
electrochemical cell to send it back to the RPi unit. The main details on the micro-controller
firmware are reported in Appendix A.
The portability of the system was guaranteed by limiting the dimensions of the electronic
platform (10 × 8 cm), which was included in a containing box (27 × 21 × 13 cm) together with
the RPi to ensure an easy system portability.
In the following sections more details will be provided about the development and optimiza-
tion processes that have contributed to the manufacture of this optimized multi-channel
potentiostat. Finally, the chapter will conclude with the validation of the system.
5.1 Multi-channel potentiostat
The main advantage of a custom-built electronic system resides in the fact that several com-
mercially available potentiostats are bulky and expensive [186], therefore not fully suitable for
providing services in everyday medical practices, where costs are required to be kept as low
as possible [187]. Furthermore, the majority of potentiostatic circuits developed up to now
provide only restricted electrochemical techniques [188, 189, 190] and only few of them are
used for drug monitoring scopes [191, 192].
To overcome these limitations, we focused on the realization of a multi-channel potentiostat
for the simultaneous detection of up to three drugs at the same time to be used for monitoring
the concentrations of the anesthesia triad (e.g. propofol, midazolam and paracetamol) over
time. In addition to the drug monitoring front-end, pH and temperature measurements will
also be included in the electronic platform since they affect the electro-active drug behavior.
4Micro-controller programmed by Abuduwaili Tuoheti, Polytechnic of Turin, Italy
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Figure 5.3 – Sketch of electrochemical cells interfaced with the multi-channel potentiostat
system blocks: the micro-controller unit drives the voltage generation circuits and receives
amperometric signals from the readout circuits.
5.1.1 Front-end design for drug monitoring
First of all, a front-end PCB was realized as a “feasibility study” in order to identify the required
constrains to the final prototype of a custom-built potentiostat. The front-end architecture
was designed to enable the simultaneous monitoring of three different compounds with the
aim of avoiding multiplexing techniques by providing independent channels for each cell.
An ATxmega32E5 micro-controller was used to drive the three independent actuation and
sensing blocks for interfacing with three separated electrochemical cells, as shown in Fig. 5.3.
To provide three independent amperometric sensing channels three voltage generators and
three readout circuits were implemented in the PCB. This is also visible in the schematic of the
multi-channel potentiostat in a grounded-WE configuration, as shown in Fig. 5.4. The building
blocks are: (i) the micro-controller unit (ATxmega32E5 by Atmel), a key component of the
circuit since it controls both the (ii) voltage generator circuit for applying a stable potential
between WE and RE to make the RedOx happen and (iii) the read-out circuit based on a TIA
to collect the current signal from the electrochemical cell.
It is also important to notice, in the schematic in Fig. 5.4, that the circuit is virtually grounded
at half the value of the power supply (Vcc /2) at the non-inverting input of the TIA to allow
positive and negative signals.
The voltage generator circuit was built by implementing a DDS architecture for each channel.
Every DDS consists of the micro-controller and a 10-bit DAC (MCP4911 by Microchip Tech-
nology Inc.). The shape of the excitation signal waveform is first digitally defined inside the
micro-controller and then converted to the correspondent voltage levels through the DAC.
The communication between the micro-controller and the DAC is based on SPI interface. The
analog value, the output of the DAC, is applied to the sensing cell through a control amplifier
that offers high input resistance and zero current suitable for connecting the RE.
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Figure 5.4 – Schematic of the multi-channel front-end for monitoring up to three anesthetics
at the same time.
The RedOx current signal from the electrochemical cell passes through a 3-stage readout
circuit before reaching the 12-bit ADC internal the micro-controller. The first two stages of
the readout are based on: (i) a TIA and (ii) a PGA in cascade. The TIA converts the value of
the RedOx current from the electrochemical cell (Icel l ) into a voltage by the very well-known
relation Vout =V0−R f × Icel l , where V0 is Vcc2 since the circuit is grounded at half the value of
the power supply, R f is the feedback resistance of the TIA (10 KΩ). Furthermore, a capacitor C1
(1nF) is placed in parallel to the resistor to obtain a low-pass filtering effect (1st -order hardware
Low Pass Filter (LPF)) since the electrochemical signal is contained at low frequencies. The
cut-off frequency (16 KHz) was selected as experimental threshold.
The PGA stage is implemented by a programmable digital potentiometer (DPOT, TPL0102 by
Texas Instruments) with 256 wiper positions and an end-to-end resistance of 100 KΩ. The
resulting gain is given by the ratio RH /RL . Therefore, the total gain of these two cascade stages
is given by: Gai n =R f ×RH /RL . Operational amplifiers LMC6482 by Texas Instruments were
used in the circuit since they provide ultra-low input current and excellent Common-Mode
Rejection Ratio (CMRR) and Power Supply Rejection Ratio (PSRR). The configuration of the
readout circuit is set by the user before starting the measurements through the GUI provided
in the RPi. Thanks to the separate channels for each electrochemical cell, it is possible to set
the suitable gain differently for each of them, hence guaranteeing the flexibility of the system.
The final stage of the read-out consists of an offset correction block driven by a trimmer. It
has been introduced to regulate the offset of the amplified signal in order to exploit the full
dynamic of the internal ADC of the micro-controller for the conversion (bandwidth up to 1
MHz).
Once the measured analog voltage has been converted by the micro-controller ADC, the
digital value is sent back to the RPi. The bi-directional communication between RPi and
micro-controller relies on I2C serial protocol.
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Figure 5.5 – First version PCB developed for CV and CA measurements with three independent
electrochemical cells.
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Figure 5.6 – Schematic of the different read-out trans-impedance topologies selectable by a
switch.
In the following sections we will provide a detailed description of the optimization process
being followed, to obtain the final multi-channel potentiostat as “prototype” that will be used
for serum detection in Chapter 6.
5.1.2 Front-end optimization process
The first version of the front-end PCB realized as “feasibility study” is shown in Fig. 5.5 (16
× 6 cm dimensions). This first version did not include the interfacing with the RPi and the
microcontroller autonomously managed the measures5. The read-out circuit was assembled
5Micro-controller programmed by Tamador Elboshra, Khalifa University, Abu Dhabi, KU.
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Figure 5.7 – Cyclic Voltammograms obtained for: a) etoposide, b)propofol and c) paracetamol.
with two trans-impedance topologies selectable via a switch, as shown in Fig. 5.6. The first
topology was based on a fixed-gain TIA (10 KΩ), while the other topology was implemented
with two-stage amplification, e.g. a TIA and a PGA in cascade. Any offset correction stage was
provided in this read-out. The configuration of the readout circuit is set before starting the
measurements so that, during the experiment, the characteristics of the switches are negligible.
To record the signals at different components’ output pins, we have used the Wave Surfer 3000
oscilloscope by Teledyne Lecroy.
The fixed-resistor readout of each on-board electrochemical channel was tested and validated
by performing CV measurements of three different drugs: propofol, APAP and etoposide. It
was considered the case that the patient under anesthesia is also subjected to other thera-
peutic treatments, which is very often the case. Carbon SPEs from Metrohm have been made
to interface with the electronic board through dedicated connectors. Stock solutions for the
three target compounds were obtained as follows: 5 mM propofol in 0.1 M NaOH, 30 mM
APAP by dissolving 5 mg of powder in 1 ml PBS (10 mM, pH: 7.4) and 30 mM etoposide by
dissolving 15 mg of powder in 1 ml Dimetil Sulfoxide (C2H6OS). All chemicals were provided
by TCI (propofol) and by Sigma Aldrich (others).
Voltammograms acquired in PBS background solution (10 mM, pH:7.4) by applying the po-
tential range between −0.8 V and +1.7 V with 0.1 V/s scan-rate are shown in Fig. 5.7. All the
measured data have been post-processed in Igor Pro 6.03A2 software by applying a Finite
Impulse Response (FIR) LPF, characterized in Fig. 5.8 to eliminate the high frequency noise. A
three-point calibration procedure was carried out for each tested compound: (i) etoposide
was measured at 400 mM, 800 mM and 900 mM, (ii) propofol at 450 mM, 500 mM and 530
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Figure 5.8 – Screen-shot of the filter design widows of Igor Pro software with the parameters
for the low-pass FIR filter used in data post-processing.
mM, and (iii) APAP at 300 mM, 500 mM and 700 mM. From these preliminary results, we
could identify the characteristic peaks of each target analyte and demonstrate an increase
of the traces due to subsequent increasing drug concentrations. Furthermore, we could also
observe the propofol fouling phenomenon between 500 mM and 530 mM concentrations
(slight increase of the output traces) due to the use of a C-SPE. This problem was afterwards
solved by using a PGE 3H WE as described in Chapter 3. However, a considerable limitation
of this circuit implementation lay in the design of its layout. In fact, as visible in Fig. 5.5,
there was not a clear division between the analog and the digital parts of the circuit so that
a large noise component from the electronics was affecting the electrochemical measured
signal, especially the variable-resistor read-out channel. Fig. 5.9 demonstrates the overlapped
signals recorded at the output pins of: the DAC and of the readout circuit. It is evident that,
when comparing the two readout circuit configurations, the fixed gain TIA results in better
signal-to-noise ratio (SNR) with respect to the PGA-based read-out. Indeed, by evaluating the
SNR as the maximum signal variance over the maximum deviation of the signal from the mean
value, we obtain a value of 12 (21.58 dB) for the fixed-resistor TIA while only of 1.8 (5.10 dB)
for the variable one. This is due to the fact that the digital potentiometer (DPOT) introduces
noise that, added to the noise on the input signal from the sensing cell, is amplified by the
second stage. To investigate this aspect further, we have compared the output signals of the
first and second amplification stages of the variable-resistor TIA read-out at different DPOT
gains, in Fig. 5.10. Clearly, a big part of the noise component at the output comes from the
second amplification stage due to the digital component (DPOT). This noise increases when
the DPOT gain decreases, in fact the calculated SNR values are: 2.56, 1.9, 1.8, 1.4 (8.16 dB, 5.57
dB, 5.10 dB, 2.92 dB) for 4.12, 1, 0.71 and 0.28 DPOT gains, respectively.
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From this analysis, on the one side we demonstrated that the proposed front-end schematic
was able to detect three different compounds, such as propofol, paracetamol and etoposide
with the same circuitry, but on the other side it was clear that we had to focus on improving
the layout of the PCB front-end to obtain optimized performances and reduce the circuit
noise. Based on these considerations, an improved architecture was implemented with the
aim to provide an optimized system in terms of noise and performance. Hence, the second-
version front-end potentiostat was able to interface with any type of electrochemical cell
and to apply different exciting potentials between RE and WE, to provide all the principal
electrochemical techniques, e.g. CV, DPV and CA. Concerning the noise reduction, we followed
some good-practices in mixed-signal circuit design as reported in the following subsection.
Considerations on practical aspects in mixed-signal circuit design
In order to improve the performance and reducing the noise of the circuit much attention was
paid to the co-design of the mixed signal circuit layout. Indeed, mixed-signal circuits require
very careful consideration of the floor-plan to protect the more noise-sensible analog part
from the noise propagation of the more noisy digital part, as represented by the schematic in
Fig. 5.11. To confine this noise propagation, appropriate circuit design techniques should be
followed; e.g. careful placement of components and input/output blocks, taking into account
the layout routing, powering, grounding and decoupling. In particular, two basic principles of
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Figure 5.11 – Schematic of mixed signal circuit design: the concept of noise propagation
propagation from digital to analog parts.
ElectroMagnetic Compatibility (EMC) should be taken into account [193]:
1. Currents should be returned to their sources locally. Otherwise, an antenna loop is
created.
2. A system should have only one reference plane, as two references create a dipole an-
tenna.
As a consequence of these two principles, grounding is one of the most frequently discussed
subjects. The general recommendation is to split the PCB ground plane into an analog
plane (AGND) and a digital plane (DGND), not overlapping each other in order to minimize
capacitive coupling between the two. Further, the ground plane could be connected to a
single point, which is generally the power supply. This results in a mixed-signal device with
a so called "star" ground configuration [194], as shown in Fig. 5.12. In this way, all noisy
digital currents flow through the digital power supply to the digital ground plane and back
to the digital supply remaining isolated from the sensitive analog portion. In addition, to
guarantee signal isolation, the physical distance between the signal traces should be respected
by following some good practices [195]:
• Minimizing long parallel lines and close proximity of signal traces on the same board to
reduce inductive coupling.
• Minimizing long traces on adjacent layers to prevent capacitive coupling.
• Signal traces requiring high isolation should be routed on separate layers and, if not
possible, they should run orthogonally to one another with ground plane in between to
minimize capacitive coupling. In this case the ground will form an electrical shield.
Concerning the circuit decoupling, performance degradation may be derived from ripple
and/or noise on the power supply pins. Traditionally, the sensitivity of an analog circuit to
102
5.1. Multi-channel potentiostat
Figure 5.12 – Grounding practice in mixed-signal on a single PCB: "star" ground (GND) config-
uration (reprinted from [194]).
power supply variations is specified as Power Supply Rejection Ratio (PSRR). Normally, in
the applications section of data-sheets for practically all mixed-signal components there are
recommended power supply decoupling circuits that should always be used to ensure proper
operation of the device. Some of the main rules can be summarized as follows [196]:
• A large electrolytic capacitor (typically 10 - 100 µF) should be placed close to the chip.
The capacitor acts as a reservoir of charge to supply the instantaneous charge require-
ments of the circuit locally.
• A smaller capacitor (typically 0.01 - 0.1 µF) should be placed as physically close to the
power pins of the chip as possible. The purpose of this capacitor is to short the high
frequency noise away from the chip.
• All decoupling capacitors should be connected to a large-area low-impedance ground
plane through a VIA or short trace to minimize inductance.
• Optionally, one can also place a small ferrite bead in series with the supply pin to obtain
the follow benefits: (i) localize the noise in the system, (ii) keep external high frequency
noise from the circuit and (iii) keep internally generated noise from propagating to the
rest of the system.
Of course, for each application it is important to deeply examine the constraints, noise sources
and signal amplitudes to develop ad-hoc solutions capable of guaranteeing successful circuit
performance. This is especially true in the context of Bio/CMOS co-design, where designing a
high performance circuit does not guarantee correct results from the biological information, if
not properly integrated with the correct sensing transducer. Taking into account the practices
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Figure 5.14 – Screen-shot from Altium with the schematic of the microcontroller. The main
application notes were respected; e.g. Schottky diode, ferrite beads and decoupling capacitors
were included.
suggested above for the co-design of mixed-signal circuits, the resulting layout of the second
version of the custom-PCB potentiostat is depicted in Fig. 5.13. The electronic board measures
10 × 8 cm and was included in a containing box (27 × 21 × 13 cm) together with the RPi
to ensure an easy system portability. As can be visible from the circuit schematic, we have
separated the analog and digital components and protected the areas with guard rings, made of
VIAs placed near to each other in order to obtain a shielding effect. The micro-controller and its
related components have been separated in a further area, as well as the Low-DropOuts (LDOs)
that are used to isolate sensitive loads from noisy power sources [197] since they offer good
voltage ripple suppression and EMC performance [198]. The system star ground architecture
is obtained by providing the ground (GND) signal to the different PCB parts through large non-
overlapping tracks that radiate from the central GND pin of the power supply. Few localized
lines interconnect the different areas of the board to allow the transmission of the signal in the
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potentiostatic circuit. Furthermore, careful attention was paid in placing and connecting the
central unit to the power supply; i.e. the micro-controller, by following the specific application
notes described in Atmel AT01080: XMEGA E Schematic Checklist. In particular, as visible in
the schematic detail in Fig. 5.14, we have placed a Schottky diode for power supply battery
protection and low Equivalent Series Resistance (ESR) decoupling capacitors close to the
device for each supply pin pair. Ferrite beads were also added between the external power and
the VCC for power filtering, since they give a better filtering performance than the common
inductor at high frequency. Indeed, they employ high-frequency current dissipation in a ferrite
ceramic to build high frequency noise suppression devices. We have chosen a bead with 10
µH inductance [199].
5.1.3 Improved read-out signal by hardware filtering
We have redesigned the analog part of the PCB presented as “feasibility study” in the previous
subsection by improving its performances with the aim of providing an even-more robust
system for human serum detection. The main modification of the architecture relies on the
readout circuit that now implements a first TIA stage with fixed gain followed in cascade by a
4th-order Sallen Key LPF to clean the signal directly in the PCB pipeline. The fixed gain of the
first-stage TIA was chosen differently, so each channel could be tuned for its target drug: 10 KΩ,
30 KΩ and 500Ω resistors selected for channel 0, 1 and 2 respectively. The rest of the circuit,
as shown in Fig. 5.15, is still composed of the ATxmega32E5 micro-controller driving the three
independent actuation and sensing blocks for interfacing with three separated electrochemical
cells. Each actuation block includes: a 10-bit DAC (MCP4911) and an operational amplifier
(MAX4475ASA+, chosen for its low noise, low distortion and wide-band properties). Each
sensing block consists of a 3-stage signal processing: (i) current-to-voltage conversion, (ii)
filtering, (iii) voltage-level correction.
(i) Current-to-voltage conversion
This TIA stage (blue square in Figure 5.15) converts the current from the WE into a
voltage signal. To minimize the noise, the MAX4475ASA+ operational amplifier was
chosen for its low noise, low distortion and low input-bias current characteristics [200].
Besides that, a low noise feedback resistor with 0.1% tolerance is used.
(ii) Filtering
This stage (pink square in Figure 5.15) implements a 4th order Butterworth low-pass
filter with unity-gain Sallen-Key topology. The Butterworth low-pass filter is selected
as it gives the maximum passband flatness for the incoming signal [201] and it offers
a higher roll off to the input signals beyond the cut-off frequency compared to lower
order [202]. The smallest pulse period during measurement is 68 ms, as indicated in
Table 5.2, which corresponds to a frequency of around 15 Hz. Therefore, by considering
the stabilization time of the electrochemical signal when the potential is applied to the
cell, the cut-off frequency fc of the filter was set at 200 Hz.
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Figure 5.15 – Schematic of the final version of the portable electronic platform consisting of
the RPi driving the custom-built PCB circuit through I2C serial communication.
Since the 4th order Butterworth filter is designed as 2-stage cascaded Sallen-Key 2nd
order filters, we have derived the overall transfer function starting from the one of the
second-order Sallen-Key filter:
HSK (s)= Vout (s)
Vi n(s)
= 1
[1+ωcC1(R1+R2)s+ω2cC1C2R1R2s2]
(5.1)
Hence, the overall final transfer function is given by:
HBW (s)= 1
[1+ωcC1(R1+R2)s+ω2cC1C2R1R2s2]
× 1
[1+ωcC3(R3+R4)s+ω2cC3C4R3R4s2]
(5.2)
Where ωc = 2pi fc and fc is the cut-off frequency of the filter. By comparing the denomi-
nator with the 4th order normalized Butterworth polynomials:
B4(s)= (s2+a1s+b1)(s2+a2s+b2)= (s2+1.8478s+1)(s2+0.7654s+1) (5.3)
we have that a1 = ωcC1(R1 +R2), b1 = 1, a2 = ω2cC1C2R1R2, therefore, by choosing
appropriate values for C1, C2, C3 and C4 (C2 ÊC1 b1a21 , similarly for C3 and C4) the values
of R1, R2, R3, R4 can be calculated accordingly (R1,2 = a1C2±
p
(a1C2)2−4b1C1C2
4pi fcC1C2
, similarly for
R3,4) [203]. The selected parameters are reported in the inset of Figure 5.15.
Knowing the transfer function H(s) and the cut-off frequency ( fc = 200Hz), that for
Butterworth filters is the same as the f−3dB for all the orders [204], the equivalent noise
bandwidth (ENBW) was evaluated to be: feqnb = 1.13× fc (αBut ter wor th = 1.13 [205]).
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We obtained an feqnb of 226 Hz.
Also in this case simulations in LTSpice XVIII6 were run to characterize the circuit noise.
The root mean square (rms) voltage noise over the bandwidth is 3.6 µV and the rms
current noise is 437.22 pA. At 1 HZ the input referred current noise is 19.5 pA/H z1/2 and
the output referred voltage noise is 195 nV/H z1/2; hence, the gain is estimated to be 10
KΩ.
Finally, at the 5V supply voltage, during the simultaneous measurements on the three
channels, the total current consumption is 78 mA, so the power consumption of the
electronic board is 390 mW.
(iii) Voltage-level correction
The voltage signals at the output of the sensing blocks are measured by the 12-bit ADC
inside the Micro-controller, furthermore, the reference voltage of the ADC is configured
as 2V. So, the voltage-level correction stage (green box in Figure 5.17) is added after the
filtering stage in order to guarantee that the voltage signal is in the input range of the
ADC.
This final optimized front-end implementation will be adopted and tested in the overall IoT
system solution in Chapter 6. The final complete system will integrate the electrochemical
sensing part with the electronics part descried here to validate and prove the overall system
performance in on-line serum detection of two drugs under flow conditions.
5.2 Measure of pH and temperature for calibrations
Temperature and pH variations affect the electrochemical functions by influencing the re-
activity of many chemical species [206]. Therefore, it is of vital importance to study their
effects on point-of-care medical sensors due to their delicate use. Temperature (T) and pH
can widely vary in patients’ blood due to infectious diseases [207], acidosis or alkalosis [208].
Further, T variations may affect the pH [209]. These altered physical conditions often occur in
hospitalized patients; hence, it is necessary to provide a constant monitoring of the pH levels
in blood with respect to the T. As a result, the variable response of electrochemical sensors
need to be characterized and parametrized to provide robust and reliable measurements over
time [210]. Calibration processes for various T and pH conditions need to be performed. Dif-
ferent approaches have been investigated for pH and T monitoring, such as optical fiber [211],
oxide-based thin-film transistors [212], graphenic materials [206], soluble polymeric dual
sensors [213]. However, there are not yet complete systems that integrate the electrochemical
monitoring of anesthetic drugs with pH and T control.
We have developed a ready-to-use, easy-to-reproduce system that interfaces with a commercial
1-wire temperature sensor and commercial potentiometric pH electrodes, for integration in
the previously described custom-built potentiostatic board. A custom PCB-module sends
6The simulations were run by Abuduwaili Tuoheti, Politecnico di Torino, Italy
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Figure 5.17 – Schematic of the portable mixed signal module for pH and T sensing.
the measured data from pH and T sensors in digital form through SPI and 1-wire serial port,
respectively to the RPi computer, the core of the overall hardware system. These connections
highlight our board as a module and not a standalone product proving its flexibility and ease
of integration.
Fig. 5.16 shows the sketch of the entire monitoring system. The pH and T sensors are dipped
into the same target solution in which the electrochemical cell is immersed. Therefore, while
drug monitoring is performed by the dedicated front-end system, the pH and T of the analyzed
solution are simultaneously controlled. The Qt GUI running on RPi drives the entire system.
The schematic of the realized pH-T sensing module is shown in Fig. 5.17. We can subdivide
the architecture in two main blocks: (i) for pH and (ii) for T monitoring.
(i) pH sensing is enabled by a potentiometry technique using an Extech standard polymer
electrode (12× 160 mm). We have designed the board so that it can be connected
either to one electrode with built-in reference or to two separate electrodes, one as RE
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and one as WE. In this way, compatibility with other types of pH electrodes increases.
A switch allows the user to set the preferred configuration. We chose an inner-built
electrode connected to the PCB with BNC cable. Both the reference and the working
electrodes of the pH sensing unit are connected to the LMP91200 Analog Front End
(AFE) by Texas Instruments for low-power chemical sensing, as shown in Fig. 5.17.
This chip detects input delta voltage from the sensor and returns a differential voltage
that indicates the pH value in millivolts. In order to acquire a differential output, the
common mode voltage pin of the chip is set to a certain voltage by being connected
with the REF3220AIDBVR external voltage reference chip by Texas Instruments (Vr e f =
2.048V ). The differential analog output of the AFE is afterwards converted to digital
by the ADS1120 Analog to Digital Converter (ADC) by Texas Instruments. The ADC is
connected to the same external voltage reference chip as the AFE that provides the
suitable voltage for the conversion. Finally, the ADC SPI pins are connected through
wires to the RPi dedicated module so that all the digitalized pH values are directly
transferred to the micro-computer;
(ii) Temperature detection was achieved by using a waterproof DS18B20 digital thermome-
ter by Maxim-IC. The measured data are transferred to the micro-computer via 1-wire
bus communication. By definition, this communication needs only one data line and
the ground connection. So, the sensor is connected to the power supply of the PCB and
to a GPIO pin on the RPi.
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5.2.1 System calibration and drug measuring processes
The working principle of the developed system relies on two main processes: (i) preliminary
calibration of the pH-T system-module, and (ii) continuous and simultaneous drugs monitor-
ing, as shown in Fig. 5.18. The first process (Fig. 5.18.a) aims to create a Look-Up-Table (LUT)
that describes the sensitivity of the drug measuring system, for example propofol, at different
pH and T conditions. Indeed, it contains the slope and intercept values of the calibration line
corresponding to the specific pair (pH, T). To realize the LUT the user sets up the specific (pH,
T) conditions of the analyzed solution, the pH-T module measures these values to check them
and then, a 3-point calibration process is run by the RPi. The calibration parameters for the
respective pair (pH, T) are stored in the LUT in the RPi memory. This process continues by
manually changing the (pH, T) parameters and by acquiring new calibration lines each time.
Buffer solutions provided by Certipur with known pH values of 4.01, 7 and 10 were used for
the preliminary calibration process. Once the LUT is completed, the process ends.
The second process (Fig. 5.18.b) describes the real application of the system in drug monitor-
ing. As soon as the monitoring starts, pH and T are measured by the PCB and, according to
the measured values, the respective LUT calibration line is chosen by RPi. At this point, a RPi
Timer that overflows every 10 minutes is enabled. Further, the drug monitoring starts running
in parallel. Every 10 minutes, the Timer enables a new pH-T measurement to check these
conditions and a new calibration line is selected in case of variations. The continuous control
over pH and T is stopped by the user through the GUI.
5.2.2 Preliminary calibration procedure
As mentioned above, the millivolt values sensed by the AFE chemical-sensing chip are sent to
RPi to be converted into pH units according to the Nernst equation: E = E0−2.3· RTnF ·l og ([H+]),
where E is the measured potential from the sensing electrode, E0 is related to the potential of
the reference electrode, 2.3· RTnF is the Nernst factor and l og [H+] is the pH (H+ is concentration
of hydrogen ions) [214]. To characterize the behavior of our system a 3-point calibration was
realized for known pH buffer solutions in values of 4.01, 7 and 10 at different T values (25o -
50o - 72o - 95o). After having plotted the measured values upon each pH, we compared the
obtained trend-line with the theoretical equation. As shown in Fig. 5.19, all the calibration
lines cross the x-axis around pH 7 as predicted by theory. Only for T 25oC have we registered a
small drift. For each different known pH, we continuously acquired pH measurements with
the board for a period of 2 minutes and created each calibration point by calculating the
average of these measurements.
5.2.3 Validation of the pH-T module with propofol calibrations
The reactivity of many chemical species is highly influenced by pH and T conditions. Therefore,
it is necessary to continuously keep these parameters under control in a complete system
for medical applications. We have validated the pH-T module by studying the pH and T
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Figure 5.20 – Propofol calibration lines with: a) different pH at ambient T, b) different T at
neutral pH. c) DPV peak at different pH and d) T at 60.5 µM propofol.
dependencies in propofol RedOx reaction both in PBS and human serum solutions. Each
3-point calibration was repeated three times for each pH-T combination.
In PBS, we studied the DPV propofol oxidation process by calibrating the sensor (PGE 3H) for
broad ranges of pH and T values: (i) pH values of 2.5 - 7.4 - 10 at ambient T and (ii) T of 25oC
- 37oC - 42oC) at neutral pH where investigated. The obtained 3-point calibration lines for
[9.9 - 36.5 - 60.5] µM propofol concentrations are shown in Fig. 5.20.a and .b. We can observe
an increase in the sensitivity due to higher pH values (Fig. 5.20.a), while T variations lead to
higher measured currents (Fig. 5.20.b). This is also confirmed by Fig. 5.20.c and .d where DPV
trends are reported for fixed propofol concentration at 60.5 µM. Two phenomena are visible in
Fig. 5.20.c: (i) the increase of the height of the current peak while pH increases and (ii) the shift
of the peak position due to change in pH. Fig. 5.20.d shows the similar peak heights obtained
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Table 5.1 – Calibration LUT for propofol detection in human serum in different pH and T
conditions.
Index T pH slope intercept
1 25 6.9 5.3524×10−9 4.8168×10−6
2 25 7.4 2.8551×10−9 3.5729×10−6
3 25 7.8 3.8702×10−9 3.2325×10−6
4 38 6.9 2.1915×10−8 7.2571×10−6
5 38 7.4 8.4803×10−9 6.1782×10−6
6 38 7.8 1.2876×10−8 8.3445×10−6
7 42 6.9 4.1119×10−8 1.7582×10−5
8 42 7.4 1.0323×10−8 1.1561×10−5
9 42 7.8 1.2052×10−8 1.2869×10−5
at different T values.
Afterwards, 3-point calibrations of propofol ([16.5 - 67.7 - 112] µM) in various pH and T values
were also conducted in diluted human serum (50% dilution). The pH and T conditions were
chosen in order to simulate possible real cases of sick or healthy patients. Therefore, the
temperature range was chosen between 25oC - 38oC - 42oC also to cover the case of patients
with fever, while the pH values were ranged among 6.9, 7.4 and 7.8. This latter range was
chosen considering that livable blood pH ranges are between 6.8 and 7.8. From these tests, we
obtained the LUT in Table 5.1 where the slope and the intercept of the calibration lines are
listed for each combination of T and pH.
Similar analysis should be provided for all the target drugs monitored by the RPi-based system,
e.g. APAP and midazolam, in order to be able to run the procedure previously described in
Fig. 5.18.b. LUTs for each anesthetic compound will be stored in the RPi memory so any drug
concentration evaluation could be done according to the corresponding calibration curve.
5.3 Graphical User Interface on the RPi
A GUI in Qt-Creator environment (C++ code) was created to run on the RPi to let the user
interact with the custom-built front-ends for drugs and pH-T monitoring. Since the electronic
PCB implements three sensing channels in parallel, three electrochemical measurements can
be carried out at the same time. Therefore, the user can: (i) enable up to three channels to use
and (ii) set the desired parameters for each of these enabled sensing channels. The desired
parameters include: (a) the information about the electrochemical procedure to run, such as
applied potential for CA or start/end voltages and scan-rate for CV, and (b) the PCB hardware
configurations to set, such as the gain of the PGA. Once these parameters have been set by
the user, the measurements can be started and the acquired data from the senors are plotted
in real-time on separate graphs for each sensing channel. In addition to this, the user can
also decide to enable pH and T monitoring in parallel with the simultaneous drug sensing.
Fig. 5.21 represents all these details. In addition to that, the RPi has to send/receive wirelessly
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Figure 5.21 – Graphical User Interface (GUI) implemented on the RPi: a) main window where
the user can enable the desired sensing channel and then b) set the electrochemical procedure
parameters by pressing the SetUp Parameters and c) set the hardware parameters on the PCB by
clicking the SetUp Gain Offset button. As soon as he has set all the desired technique/sensing
channels, the measurements can be started by pressing the Start button. As many graphs
as the enabled channels appear on the screen. The user can interrupt the measurements by
clicking the Stop button while being able to perform simultaneous monitoring of pH and T.
TCP Client TCP ClientTCP Server
Figure 5.22 – TCP Server on RPi GUI that can be connected from a TCP Client, such as the
Matlab or the Android app, via TCP/IP protocol.
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the data via Wi-Fi to/from both Android apps and laptop, as shown in Fig. 5.1. To that aim, the
GUI on the RPi also includes a TCP Server that can be connected from TCP Clients, such as
from the Android app or from the Matlab code running on the laptop, via TCP/IP protocol. A
schematic representation is shown in Fig. 5.22.
5.4 System validation
In this section the validation of the RPi-based pontentiostatic circuit will be presented. Firstly,
we validated the correct functioning of the electronic system and all its implemented elec-
trochemical techniques by performing sensor calibration at C-SPE for APAP, considered as
benchmark drug due to its well-known reaction. We then focused on propofol sensing at
PGE WE with different electrochemical techniques, also in the presence of APAP interferent
anesthetic. Finally, we executed scan-rate analysis to see how the system RedOx reactions
change by making the experiments faster. Indeed, we would like to guarantee a fast detection,
especially important in the case of drugs with rapid clearance.
5.4.1 Materials and methods
APAP was purchased in powder from Sigma-Aldrich (Switzerland) while 2,6-Diisopropylphenol
(propofol) by TCI chemicals. Propofol 5.4 mM stock solution was prepared by dissolving it in
NaOH 0.1 M while APAP 30 mM stock solution was prepared by dissolving 5 mg of powder in 1
ml PBS (10 mM, pH: 7.4). Subsequent dilution has been done to obtain concentrations of: [9.9
- 19.6 - 38.5 - 56.6 - 80.5] µM and [50 - 100 - 150 - 200 - 250 - 300] µM, for propofol and APAP
respectively. All the experiments were conducted in PBS (10 mM, pH:7.4) background solution
and performed at room temperature. C-SPE with carbon WE (4 mm Ø), silver RE and carbon
CE were purchased by Dropsense (Spain). To perform electrochemical propofol detection
a wood PGE (2 mm diameter) provided by Staedtler Mars Lumograph® was used as WE. Its
specific lead composition is: 58% graphite, 36% clay and 5% wax, that corresponds to 3H
notation. This composition of the PGE lead was selected in Chapter 3 as optimum for propofol
detection in terms of sensitivity and resistance to the fouling effect over time. The wood PGE
was prepared by peeling out the two extremities. One extremity was used as electronic contact,
while the other is cut to obtain a flat surface and is immersed in the analyte solution (electro
active area, given by the sum of the flat surface and lateral dipped surface, is maintained at
∼ 2.6 mm2)). To complete the electrochemical cell Ag/AgCl RE (K0265 - diameter 4 mm) and
Pt wire from Princeton Applied Research - AMETEK was used.
A Metrohm Autolab system (PGSTAT 302N) was used as reference instrumentation to compare
and validate our measurements. The Autolab is driven by Nova 1.11 software.
A first validation was run to test the performance of the system with all the implemented
electrochemical techniques; i.e. CV, DPV and CA. To do this, we performed APAP calibrations
at commercially available C-SPE. APAP was chosen as a reference-drug due to its well-known
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Table 5.2 – Electrochemical measurement parameters for APAP detection at C-SPE.
CV Measurements
Start-V (mV) End-V (mV) V-Step (mV) Step Width (ms) Scan-Rate (V/s)
-100 1100 3.22 32 0 .1
DPV Measurements
Start-V (mV) End-V (mV) V-Step (mV)
-100 1100 3.22 PCB - 5 Autolab
Pulse-Width (ms) Pulse-Ampl. (mV) Pulse Period (ms)
50 60 68
CA Measurements
Apllied-V (mV)
450
Table 5.3 – “Feasibility study” PCB hardware parameters for APAP detection at C-SPE
Meas. Type DPOT Gain R f Gain (KΩ) Offset (mV) Channel
CV 236 2.42 966 0
DPV 216 0.86 300 1
CA 128 10 800 2
electro-activity properties. The CV DPV and CA parameters set for both Autolab and our
custom PCB are reported in Tab.5.2. Moreover, in order to compare the output currents of
our system with the commercial potentiostat, hardware parameters of the PCB have been set
as in Tab.5.3. Afterwards, we investigated the propofol detection at PGE WE with different
electrochemical techniques, also in the presence of APAP interferent anesthetic. DPV and
CV electrochemical techniques were used to characterize the system for propofol measure-
ments by plotting calibration lines (concentration versus oxidation peak current). The system
parameters for these measurements were set through the dedicated Qt-GUI on the RPi as in
Table 5.4.
The corresponding hardware parameters for the PCB were set from the GUI and are reported in
Table 5.5. According to these values, the cut-off frequency ( fc ) of the first-order active LPF (first
stage of the readout) is calculated from the capacitor (C = 1 nF) and the resistor (R f = 2.98 KΩ
Table 5.4 – Electrochemical measurement parameters for propofol and APAP detection at PGE
WE with the “feasibility study” PCB version.
CV Measurements
Start-V
(mV)
End-V
(mV)
V-Begin
(mV)
V-Step
(mV)
Step Width
(ms)
Scan-Rate
(V/s)
200 1350 210 3.22 32 0 .1
DPV Measurements
Start-V (mV) End-V (mV) V-Step (mV)
0 1100 3.22
Pulse Width (ms) Pulse Ampl. (mV) Pulse Period (ms)
50 60 68
115
Chapter 5. Electronic platform
Table 5.5 – “Feasibility study” PCB hardware configuration for propofol and APAP detection at
PGE WE.
Meas. Type DPOT Gain R f Gain (KΩ) Offset (mV) Channel
CV 186 2.98 285 2
DPV 186 9.28 333 1
Table 5.6 – Noise evaluation of the front-end circuit. SD@−3dB ,out put is the SD for output
referred voltage noise at the -3dB frequency, SD@−3dB ,i nput is the SD for input referred current
noise at the -3dB frequency, Vr ms,noi se is the rms voltage noise and Ir ms,noi se is the rms current
noise. These test parameters are obtained in the frequency range from 10 mHz to 10 kHz using
LTSpice.
Channel SD@−3dB ,out put Vr ms,noi se SD@−3dB ,i nput Ir ms,noi se GAIN (@1Hz)
CV (2) 117.45 nV/H z1/2 34 µV 15pA/H z1/2 4.34 nA 7.93 KΩ
DPV (1) 120.5 nV/H z1/2 19.51 µV 4.8 pA/H z1/2 1.06 nA 24.66 KΩ
for CV and R f = 9.28 KΩ for DPV) as: fc = 12piR f ×C . So, the cut-off frequencies are ∼ 53.4 KHz
∼ 17.15 KHz for CV and DPV, respectively. The −3 dB frequency and the cut-off frequencies
are the same for 1st-order filters. Therefore, the equivalent noise bandwidth (ENBW)7 can be
calculated by the estimated cut-off frequencies as: feqnb =α× fc , where α is a factor scale that
varies with the order of the filter and keeps in consideration the non-ideal behavior of the filter
at the cut-off frequency. In case of first-order filters α is equal to 1.57. Therefore, we obtained
a feqnb of 83.85 KHz and 26.93 KHz for CV (Channel 2) and DPV (Channel 1), respectively.
Simulations in LTSpice XVIII8 were run to characterize the circuit noise in order to prove the
good performance of the custom-built potentiostat for the actual application. The Spectra
Density (SD) functions for the output referred voltage noise at last op-amp stage of the circuit
(output of the offset correction) and input referred current noise at first op-amp stage (input of
the TIA) were simulated and from there we could evaluate the rms voltage and current noises
through this approximation:
r ms = SD@−3dB ×
√
f−3dB ×α= SD@−3dB ×
√
feqnb (5.4)
Where SD@−3dB is the value of the SD at the cut-off frequency (since in this case the -3dB
frequency f−3dB corresponds to the cut-off). Table 5.6 summarizes the value obtained for the
two considered channels.
Finally we carried out scan-rate analysis for APAP and propofol to stress the performances of
the system with faster measurements and to test the system response time in case of both CV
and DPV. To that aim, CV and DPV measurements were performed by keeping the anesthetic
concentration constant (at 36.5µM and at 300µM for propofol and APAP, respectively) and by
7The ENBW is defined as the bandwidth of a brick-wall filter, which produces the same integrated noise as the
one of the actual filter [205].
8The simulations were run by Abuduwaili Tuoheti, Politecnico di Torino, Italy
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setting different scan-rates: for CV [0.16 - 0.11 - 0.09 - 0.08 - 0.07 - 0.06] V/s while for DPV [0.08
- 0.06 - 0.05 - 0.04 - 0.03 - 0.02] V/s, keeping fixed 73.5% duty cycle. In this way, the required
time to perform a measurement is [15 - 20 - 25 - 30 - 35 - 40] s for both techniques.
Data analysis and post-processing has been done in Matlab R2016b and Igor Pro 6.22 software.
A dedicated script in Matlab applies a Savitzky Golay digital filter (order 3) to smooth the
signal data without distorting significantly [215], while data analysis consists of extrapolating
the peak area and removing the baseline of each measurement to align them with respect to
a common baseline and evaluating the height of the peaks with respect to the baseline. For
interference study, an additional step in Igor Pro 6.22 was introduced, to identify the peak
position of the two drugs; propofol and APAP by performing Gaussian decomposition. After
that peak position is identified, Matlab script is again used to evaluate the peak height to
ensure consistency in the data.
The power consumption (P =V × I ) of the electronic board was estimated to be 160 mW at 5V
supply voltage, during simultaneous measurements on the three channels with total current
consumption of 32mA.
5.4.2 Results
To evaluate the performances of the custom-built pontetiostatic system with respect to all
its implemented electrochemical techniques, we first decided to compare the APAP cali-
brations made with our system with those obtained, under the same conditions and drug
concentrations, with the commercially-available Autolab instrumentation. Measurements
are performed in neutral PBS background electrolyte by adding subsequent increasing con-
centrations of APAP: [50 - 100 - 150 - 200 - 250 - 300] µM for CV and DPV and [50 - 100 - 150 -
200] µM for CA. Referring to CV and DPV calibration curves, Fig. 5.23.a and .b, we can see that
the performances of our system are highly comparable with the one of the Autolab. On the
other hand, for CA measurements, Fig. 5.23.c, our system registers a faster stabilization of the
current underlying a faster response of the circuit. This is probably due to the fact that Autolab
integrates complex filtering options that slow its performances. Nevertheless, as shown in
Fig. 5.24, the calibration lines obtained for all calibrations are almost equivalent for both our
system and Autolab, even for CA. Moreover, the linearity of our system is confirmed by the
r 2 term that was evaluated to be 1 for CA and CV and 0.98 for DPV. Once the functionalities
of the system have been validated with respect to the Autolab instrumentation, the electro-
chemical characterization of propofol and APAP. Fig. 5.25.a and .b shows the comparison of
propofol sensing with CV and DPV techniques. We can deduce that both CV and DPV are
suitable techniques for propofol sensing since they both obtain comparable sensitivities (S,
evaluated as slope of the calibration line in Fig. 5.25.d and .e) of (30.2±5.2)×10−8 A/µM and
(11.0±1.4)×10−8 A/µM, respectively. On the contrary, if we focus on the r 2 and standard
error parameters we can notice that DPV technique obtains more stable and linear results
compared to CV. We also performed DPV calibration for APAP, as reported in Fig. 5.25.c and
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Figure 5.23 – System validation: APAP calibrations reported in comparison with the results
from the commercial Autolab instrumentation for: a) CV, b) DPV and c) CA techniques.
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Figure 5.24 – Calibration curves comparison between our system and commercially available
potentiostat: a.) CV, b.) DPV and c.) CA analysis.
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Figure 5.25 – Calibration curve studies: a) CV plots for propofol, b) DPV plots for propofol
and c) DPV calibration for APAP. Calibration lines for propofol and APAP detection based on
oxidation peak currents recorded by d) CV and e),f) DPV.
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5.25.f, to characterize its behavior at PGE so that to be able to analyze its interference with
propofol. The system is able to sense the compound in the same voltage ranges of propofol
measurements with a sensitivity of (52.6± 2.3)× 10−9 A/µM, in Fig. 5.25.f. From the DPV
characterization, an LOD of 0.53µM with a RSD% of 0.03 has been evaluated for propofol and
of 3.22µM with a RSD% of 0.02 for APAP. LOD has been evaluated from the 3σb rule, where
σb is the standard deviation of the blank measurement (n = 3), while the S is extracted as the
slope of the calibration line. When measuring the solution containing a mixture of the two
drugs, a complex voltrammogram is measured and an additional step of Gaussian decompo-
sition is required to identify the peak position of each drug. Fig. 5.26 shows the Gaussian
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Figure 5.26 – Gaussian decomposition analysis on Igor Pro 6.22 software for DPV curves of:
a) Propofol 38.5 µM, b) APAP 300 µM, and c) a mixture of the two compounds (interference
study.
decomposition step performed with Igor Pro 6.22A software. More specifically, Fig. 5.26.a
and Fig. 5.26.b show the single contribution of propofol and APAP, respectively, when the
two compounds are separately present in the analyzed solution. Fig. 5.26.c is the resulting
voltammogram obtained with both compounds mixed in the analyzed solution. Thanks to
Gaussian decomposition, it is possible to separate the two contributions from the obtained
DPV measured curve. Therefore, after having identified the APAP and the propofol current
peaks, the sensor calibration for both the compounds can be performed in Matlab, Fig. 5.27.a
and .b. From calibration lines, the sensitivity values are calculated as 28.0±1.1)×10−9 A/µM
and 18.4±0.5×10−9 A/µM for propofol and APAP, respectively.
The measurement precision is assessed by evaluating the Relative Standard Error (RSE)%:
5.94% and 5.69% for propofol and APAP, respectively. These values are also largely acceptable
for the U.S. National Center for Health Statistics (²≤ 30%) [216]. In addition, the accuracy and
reliability of the measurements were evaluated by computing the Relative Standard Deviation
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Figure 5.27 – Interference study: calibration lines for a) propofol (peak around 0.4 V) and b)
APAP (peak around 0.85 V). On the bottom, general oxidation reaction mechanisms for the
two drugs are reported.
RSD%. For propofol we obtained ≤ 10.6 RSD% and for paracetamol ≤ 10.3 RSD%, which
are within the accuracy standards established by the Food and Drug Administration (FDA)
guidance for commercial sensing-devices [217]. Therefore, we can conclude that, even if the
sensitivity is decreased, a successful monitoring of propofol is possible and validated even in
the presence of its APAP interference. The last system validation was about the speeding up
of the measurements by changing the scan-rate. Indeed, normally the clearance of difficult-
to-handle drugs, such as anesthetics, takes short-time and a rapid monitoring is requested.
Figs. 5.28 and 5.29 show the results obtained by this analysis for 36.5µM propofol and 300µM
APAP, respectively. CV and DPV measurements were tuned to complete one measurement in
[15 - 20 - 25 - 30 - 35 - 40] s. The aim of this test was to see the time response of the system,
including the occurrence of RedOx and its correct measurement. For both the drugs, it is
evident that all the scan-rates allow RedOx to happen and the oxidative peaks tend to increase
for increasing scan-rate values in CV plots (in case of APAP the reductive peak also decreases
with increasing scan-rate values).
Furthermore, from CV scan-rate analysis, it is possible to plot the current peak upon the
square-root of the scan-rate. This gives an indication of the kind of reaction happening for
the target drug. For propofol, Fig. 5.28.c reports a linear trend that means that the oxidation
is characterized by a diffusion-control process at PGE interface [218], therefore the fouling
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Figure 5.28 – Scan-rate study for 36.5µM propofol with: a) DPV and b) CV techniques. c)
Reports the relationship between scan-rate and oxidation peak current from CV.
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Figure 5.29 – Scan-rate analysis for 300µM APAP with: a) DPV and b) CV techniques. c) Reports
the relationship between scan-rate and oxidation peak current from CV.
phenomenon is avoided.
Concerning APAP, the trend in Fig. 5.29.c can also be approximated by a linear relationship
with the square root of the scan-rate meaning a diffusion-control process.
5.5 Summary and main original contributions
In this chapter we have designed and built a portable RPi-based potentiostat circuit for
the simultaneous detection of several therapeutic compounds, as well as pH and T. Indeed,
electrochemical activity of drugs is affected by these two parameters and, therefore, the drug
concentration estimation has to be done according to their value. The main electronic details
presented in this chapter are:
• The powerful single-board computer RPi has been used as the core of the electronic sys-
tem to run simultaneous monitoring of multiple drugs plus pH and T through dedicated
front-ends.
• We described the implementation process followed to obtain an optimized portable
multi-channel potentiostat, capable of detecting up to three drugs with the same front-
end. The drug monitoring front-end has been obtained by an optimization process
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in terms of improved signal-to-noise ratio, flexibility (easy to interface with different
sensors) and monitoring performances. To that aim, “star” ground (GND) configuration
was implemented to keep the noisy digital parts well separated from the more silent and
noise-sensible analog ones. Shielding guard rings were placed all around the different
layout areas of the board design. The read-out circuit implements three independent
actuation and sensing blocks for interfacing with three separated electrochemical cells
to achieve a multi-target platform. The grounded working electrode configuration
was used with a DDS architecture to apply the excitation potential waveform over the
electrochemical cell and a three-stage read-out for collecting the RedOx signal. The
three stages comprise a TIA with fixed gain, in cascade with a 4th-order Butterworth
LPF for cleaning the signal from the high-noise components, and an offset corrector to
exploit all the dynamic of the ADC.
• The custom-built potentiostat was interfaced with different kinds of electrodes, such as
C-SPE and PGE (described in the Chapters 3 and 4). Therefore, we could test the system
with two of the major anesthetic components, e.g. propofol and APAP, demonstrating
the successful detection also in solutions containing both the drugs at the same time.
Since propofol detection is the most challenging due to the undesired fouling effect
resulting from its oxidative process, we made a comparison in Table 5.7 among different
Table 5.7 – Comparison table for propofol detection using various electrochemical approaches.
Full. Sys. and Simult. Det. refer to the description of a full system with custom-built electronics
integrated with sensors capable of performing simultaneous detection of APAP and propofol
mixed in the solution, respectively. The Linear Range has to be referred to the therapeutic
range for propofol that is [1 - 60] µM.
Work WE
Full
Sys.
Fast
Scans
Fouling
Effect
Simult.
Det.
LOD
µM
Linear
Range
µM
[132] GC-PVC no
5 min
each
measure
overcome
by PVC
membrane
no 0.015±0.3 0 - 19.6
[219] GC-PVC no -
overcome
by PVC
membrane
no <1 0 - 56.6
[220]
pre-
anodized
carbon
no - - no 0.08 0.09 - 0.9
[134] GC no - - no 3.2±0.1 0 - 30
This
thesis
PGE 3H yes
scan-rate
analysis
to provide
measures
in up to 15s
overcome
by PGE
composition
yes
0.53±0.03
(RSD%)
0 - 80.5
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electrochemical approaches for propofol sensing compared to ours. From this table, we
can clearly notice that our system is the only one providing a complete system consist-
ing of custom-built electronics integrated with sensors able to perform simultaneous
detection of APAP and propofol mixed in the solution.Further, the timing to perform
a single measurement is often not discussed, and the ones we found turned out to be
much slower compared to ours. Due to the rapid PK of propofol, fast measurements are
needed to provide reliable values.
• We further presented the design and the validation of a hardware PCB module for pro-
viding the potentiostatic system with pH and T module. The pH-T module is interfaced
with the RPi through SPI communication. Therefore, while measuring the anesthet-
ics’ concentration through the dedicated front-end, the RPi can also control pH and
T measurements in parallel. It is of crucial importance to keep these two parameters
under control since they affect the electrochemical behavior of chemical compounds.
The pH-T module was preliminarily validated by running pH calibrations at different T
and verifying the theoretical Nernst equation behavior. Afterworlds, pH and T effects
on propofol RedOx reaction were investigated and LUT were obtained by collecting
intercept and slope values of calibration curves obtained for different (pH,T) human
serum solutions. The drug concentration evaluation has to be done according to the
corresponding solution’s conditions.
In the following chapter, the results collected by the final complete system, including the
custom-built RPi-based electronic board integrated with the electrochemical sensing plat-
forms included in the fluidics system, will be presented. Furthermore, the overall system was
enriched by an IoT network solution to provide an enhanced an powerful tool, ready to be
adopted by specialist medical staff. A description of the IoT architecture will be given in the
following chapter.
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The development process towards the final bio-electronic multi-panel system for anesthesia
delivery monitoring was fueled on the one side by the creation of an optimized multi-sensing
electrochemical platform as described in Chapter 3 and Chapter 4, and on the other side by
the design and the implementation of a custom-built electronic potentiostatic board driven by
a RPi for the control of the sensors in Chapter 5. Considering the anesthesia-dedicated overall
system presented in Fig. 6.1 (orange highlight), these parts correspond to Sensing Platform
RaspberryPi
c
 
I2C
Anesthetized 
Patient 
TCP/IP
4. Android GUI
2. Portable Electronic Circuit
Anesthesiologist 
TCI Pump
IntraVenous 
Infusion
Supervision
1. Sensing 
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Figure 6.1 – Sketch of the IoT system (orange part) for the on-line continuous and simultaneous
detection of anesthetics proposed to be a part of real hospital settings.
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and Portable Electronic Circuit in the figure, respectively. To extend the technology, Android
GUI and IoT cloud support were included as well.
The sensing platform, labeled as nr. 1 in the figure, shows that the electrochemical sensors are
incorporated in a fluidic device to drive the sample solutions directly on the sensing sites. The
fabrication of the fluidics will be also discussed in this chapter. Furthermore, in this chapter,
we will discuss the integration with the IoT cloud-based network developed in Android, and we
will close with the validation of the system with the first-ever demonstration of simultaneous
on-line monitoring of propofol and paracetamol concentrations over time in undiluted human
serum under flow conditions.
Section 6.2 will describe the IoT architecture developed in AndroidTM and based on the
PrYv cloud middle-ware platform. Section 6.3 will provide details about the development
and integration of the fluidics with the sensors. Finally, Section 6.4 will conclude with the
successful validation of the overall system; and Section 6.5 will further provide a solution for
the integration of the infusion pump.
6.1 State-of-the-art
To the best of our knowledge, there is no complete system with a sensing module integrated
with electronic circuit board that targets anesthesia monitoring for multiple sensing. Although
Myers et. al. proposed a feedback controlled infusion of organic-based drugs for safer anes-
thesia monitoring [219], the simultaneous detection of different drugs, the development of
a custom-built potentiostat and an IoT support were not provided. Moreover, other groups
developed various costly and bulky strategies [122, 123] for monitoring anesthetics or even via
electrochemical methods [132, 134, 139, 138], but without integration to an electronic board,
or provided electronic platforms, for different applications [190].
The novelty of the system developed in this thesis, compared to the recent literature, relies
on the fact that our system is complete and includes: (i) a low-noise, custom-built electronic
potentiostatic PCB driven by a RPi, (ii) the multi-panel electrochemical sensing platform
integrated into (iii) a fluidic system, which directs the sample on the sensing site, and (iv)
an IoT network including a Cloud system that allows the doctor to control and share all the
patient’s data through a dedicated Android app.
6.2 IoT cloud-based network & Android development
The concept of Smart Hospitals, where all the medical equipment and devices are “smart”
and able to interconnect and communicate with each other, is becoming a reality thanks
to innovative IoT solutions. In the wake of this tendency, we wanted to provide our system
with an IoT cloud-based network for anesthesia on-line monitoring. Our architecture allows
the anesthesiologist to remain simultaneously connected to all the sedated patients through
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Figure 6.2 – Sales prospective of smart-wearables by device category (reprinted from [223]).
Android apps running on a mobile device, such as a tablet or a smart-phone, and/or on a
wearable device, such as a smart-watch. Furthermore, through the Android app, the monitored
medical data from the patients can be shared on the cloud to be accessible by geographically
separated medical specialists, thereby enabling teleconsulting. Telehealth and telemedicine
systems facilitate the exchange of electronic information and data for remote monitoring,
diagnosis, telesurgery and other forms of medical services [221]. This would also be extremely
beneficial in rural areas of under-developed Countries where there is a lack of health-care
specialists [222].
The creation of the IoT solution passed through the implementation of two Android-based
architectures. The first IoT network had a smart-watch, worn by the doctor, placed at the
center of the network and able to interact via several Android applications with each of the
monitored patient. The second network introduced the cloud support (provided by the PrYv
middle-ware), which also makes the measured data available for remote monitoring and
teleconsulting. Hereafter we will describe in detail the two architectures.
6.2.1 Smart-watch as paradigm-shifting player in medical IoT
Wearable technology, such as smart-watches, are considered revolutionary in the field of IoT
since they satisfy the criteria of always-connected devices with the advantages of wearabil-
ity, multiple functionality and low cost [224, 225, 226]. As can be seen from the sales trend
by category reported in Fig 6.2, smart-watches are gaining popularity in the market. Their
use has also been investigated for patient monitoring scenarios. The majority of wearable
applications are developed for patients’ smart-watches to detect body-motion, body tempera-
ture, physical exercises and sleep quality [227]. In addition to this, monitoring systems are
also provided for specific applications, such as remote home monitoring in dementia care
[228] or for patients with specific illnesses, such as autism, pulmonary disease or Alzheimer’s
[229, 230, 231]. However, the concept of “on-line monitoring” is also crucial in the hospital
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environment, especially for critical medical scenarios, such as in Intensive Care Units (ICUs)
[232] or in operating surgery rooms [233]. Up to now, only a few wearable solutions had been
proposed for hospital use. An example is provided by the Nurse-Watch created by Bang et. al.
featured with vital sign monitoring and checklist reminders to assist nurses during their daily
responsibilities [234]. However, nurses were not allowed to move freely in the hospital areas
without keeping both the smart-watch and the smart-phone. Indeed, the connection between
these two devices was based on Bluetooth technology that can support only 10 m distances.
To overcome this limitation, we developed a dedicated Andorid wearable application for the
smart-watch, which becomes the central actor of our monitoring network for hospital environ-
ments (Fig. 6.3). The wearable device is worn by the medical doctor, responsible for the ward,
and communicates via Wi-Fi with an independent bedside monitoring system connected
to each patient. The bedside monitoring system consists of an Android application running
on a tablet that continuously receives all the data measured by the sensing platform on the
patient. In our case, the sensing platform coincides with the sensors that, integrated into the
fluidics, are driven by the electronic system to simultaneously measure the level of multiple
anesthetics in the patient.
In order to enable bidirectional communication between the smart-watch and the various
Android bedside applications connected to the network, and an intermediary server is un-
avoidable since the smart-watch Android version Wear 1.0 enables the paring of the wearable
with only one device. Only by introducing this bridge between the smart-watch app and the
patients’ apps was it possible to enable the multi-patients monitoring feature. Therefore, by
interacting with the smart-watch, the medical doctor or the caregiver (with different levels
of responsibilities) can remotely monitor the patient’s health status and can be alerted by a
notification in case of anomalous recorded parameters.
All the Android app were developed in Android Studio 2.1 using Android and Android Wearable
Software Developer Kit (SDK) [235].
Network architecture
The smartwatch-centered scenario, shown in Fig. 6.3, is based on three main building blocks:
(a) Client-Android app running on a bedside tablet, that continuously receives all the data
measured by the sensing system directly monitoring the patient. The concentrations
of the most critical parameters measured by the sensors are immediately available for
display on the bedside tablet’s screen. The idea is to provide the same potentialities of
the normally-used hospital monitors. Moreover, the acquired values are stored in files
on the memory of the device to allow a-posteriori consulting. The connection between
the sensing platform and the Android interface relies on Bluetooth (BT) technology
since short-range radio frequency transmission is required. Fig 6.4 shows an example of
monitored values displayed on the bedside Client app. This Android app was developed
starting from an app that I previously developed and validated [237], and here it was
updated to offer new functionalities based on a Wi-Fi protocol for Android intermediary-
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a. Client
Android app
b. Server-Android app
c. Smart-watch app
Figure 6.3 – IoT monitoring scenario: (a) Client-Android app gathers data from each patient’s
sensor, (b) Server-Android app redirects data to a (c) Watch-AndroidWear app to keep the
medical doctor continuously connected (reprinted from [236]).
server communication.
(b) Server-Android app runs on a tablet/smart-phone in a central workstation of the hos-
pital ward. It collects the monitored data from all the patients/clients connected to the
network enabling the bidirectional communication with the wearable device worn by
the doctor, as visible in Fig. 6.5. Thanks to this server, it is possible to overcome the
limitation of having the smart-watch connected to only one patient at time and one
patient to a single doctor/caregiver, due to Android Wear 1.0 restrictions. On the one
side, we wanted to maintain a bedside tablet near each patient to show the real-time
trend of all the measured parameters over time and for a-posteriori consulting of the
data. On the other side, we wanted to receive on-demand the data on the smart-watch
as well for alerts in case of emergencies without keeping track of the received values in
order to lessen the load on the wearable app. Therefore, through the intermediate server
the data are pushed to the smart-watch when requested by the doctor and an automatic
message is promptly sent in case of anomalies in the recorded values. All these messages
exchanged between the server and the smart-watch explicitly use the patient identifier
and the parameters-of-interest. Both the server–to-clients and server-to-smartwatch
connections adopt Wi-Fi communication. Indeed, if a BT piconet was implemented the
distance restriction would be too limiting in the final application.
(c) Smart-watch app for the doctor’s watch device developed in Android Wear 1.0. It allows
the doctor to freely move in other hospital areas and to perform different tasks in parallel
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Figure 6.4 – Client Android application: the measured values from the sensing system are
immediately displayed on the bedside tablet. An example of trend recorded for the endogenous
glucose and for exogenous propofol anesthetic are reported.
without losing the control over the critical patients under his responsibility. Through
the smart-watch the doctor, or the unit’s assistant, can query the system to receive some
critical parameters from a specific patient connected to the network; he/she can also be
alerted in case of emergency. The bidirectional communication between smart-watch
and intermediate server exploits both the Wi-Fi or the BT technologies depending on
the distance convenience. Indeed, normally the smart-watch prefers to communicate
with the server tablet via BT to save battery enabling reliable data transmission, but in
case of great distances Wi-Fi is necessary.
Communication protocol
The protocol implemented to enable the bidirectional communication between the smart-
watch and the multiple connected patients is shown in Fig. 6.6. The three peers that interact in
the system are: (a) the patient/client Android app provided with the monitoring parameters,
(b) the intermediary Android server running on a tablet that acts as a bridge to enable the
multi-clients connection, and (c) the Smart-watch app for doctors/caregivers, considered as
final users. Two main processes are handled by the communication protocol:
• Query of parameters, highlighted in blue in Fig. 6.6, when the doctor, through the smart-
watch, requests from a client a specific measured parameter. The doctor has to choose
the patient from among the connected ones and click the button corresponding to the
parameter of interest. As soon as the button is pressed, a message, containing the infor-
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a. c.b.
Figure 6.5 – a) Server Android application: it keeps track of all the patients connected to the
network and enables the bidirectional communication between them and the smart-watch.
Smart-watch Android Wear application: b) the doctor can query for specific parameters from
a connected patient, and c) is alerted in case of out-of-safe-range measured parameters.
mation about the selected patient and the requested parameter (On-demand (Patient
#, Parameter $)), is sent by the smart-watch to the central-server and from there
the message is redirected to the target patient-client app (On-demand (Parameter §)).
When the client # app receives the request, the mean of the last §samples is algorithmi-
cally evaluated and sent back to the server (Mean-§-samples), which redirects it back
to the smart-watch.
• Alerting user in case of out-of-safe-range recorded values, displayed in purple in Fig. 6.6.
As soon as, a critical measure is registered by the monitoring system, the client app sends
a message to the server with an alert about the critical parameter (Alert (Parameter
$)). The server, on its side, pushes the warning to the smart-watch with information
on the in-danger patient and the critical parameter (Alert (Patient #, Parameter
$)). The notification on the smart-watch occurs as a strong vibration and a pop-up that
shows the involved client (Patient #) and the anomalous value (Parameter $).
In order to face Internet unavailability, the alert/messages are sent several times until the
smart-watch notifies the correct receiving through a broadcast message (Alert-Received).
In this way no alert/message can be lost because as soon as the Internet connection is re-
established the data transmission is successfully accomplished.
Network validation
For the validation of the network we reproduced it by using a smart-watch for the final user
(Sony Smartwatch 3 with Android Wear 1.0) and three tablets: two tablets simulating two
patients (a Galaxy Note pro 12.2in with Android 4.4.2 KitKat and a Galaxy Tab 2 with Android
4.2.2 Jelly Bean) and connected as clients and a server tablet (Nexus 7 with Android 5.0.2
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Figure 6.6 – Communication protocol, via Wi-Fi, adopted among: a) Client/Patient #, b)
Intermediary Server and c) Smart-watch/Doctor.
Lollipop) as bridge. The pairing between smart-watch and server tablet is enabled by the
dedicated Android Wear application from Google Play Store. The other connections (client-to-
server and client-to-sensors) are handled by the developed Android applications.
Once we had established the network connections, we tested these following functionalities:
• The clients simultaneously connect to the server via Wi-Fi and to the monitoring sensing
platform via BT.
• The server connects multiple clients and keeps track of all the IP addresses of the
connected patients. Every time a new client is paired, a Spinner List on the smart-
watch is automatically updated. The doctor handles/allows the client connection and
disconnection.
• The smart-watch queries the server for receiving parameter $ from client #. In few
seconds, the user receives the desired parameter from the correct patient. We tested the
Internet transmission latencies by connecting to a personal hotspot obtaining less than
2 s for on-demand queries and less than 3 s for receiving alerts. Of course, these delays
might vary accordingly to the available Internet connection.
• The alert message is sent to the smart-watch if n values received from the monitoring
system exceed the physiological threshold. The threshold varies depending on the pa-
rameter and the number of acquired samples (n) to be averaged for the comparison with
the threshold. This n value changes depending upon the desired medical application.
• The correct reception of an alert notification on the smart-watch also in case of lack of
Internet. The alarm is sent as soon as the connection is re-established and a notification
is properly broadcast from the smart-watch.
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Figure 6.7 – Sketch of the cloud-based IoT network for the on-line monitoring of anesthesia
delivery through dedicated app. The TDM systems directly measures the anesthesia levels
in each patient and send the measurements to an Android app running on the tablet of the
anesthesiologist. From here, the data are also shared through the cloud PrYv middle-ware,
that is accessible through a Web app. This enables the possibility for telemedicine.
6.2.2 Cloud-based architecture for anesthesia monitoring
Connected and wearable medical devices are paving the way towards the realization of Smart
Hospitals where patient care is enhanced and improved by IoT. Therefore, we wanted to
include a cloud-based network in our network for anesthesia on-line monitoring. This ar-
chitecture not only guarantees the anesthesiologist can remain simultaneously connected to
all the sedated patients through an Android app, but also it enables a secure sharing of the
patient’s medical data on a cloud solution accessible by a web application. In this way, any
medical specialist, even from a great distance, can consult the shared data from everywhere
and at any time by accessing the cloud enabling the possibility for teleconsulting.
We have maintained the high flexibility and portability of the monitoring network to ensure
the possibility of interfacing with any medical device sending the measured data wirelessly. In
this cloud-supported network, sketched in Fig. 6.7, the central actor is still the anesthesiologist,
but this time he was equipped with a tablet and the smart-watch was used as a feature to
notify alerts. It receives alerts in case of out-of-safe-range parameters registered by the moni-
toring system. The incoming notification includes the name of the in-danger patient and the
information about the critical parameter. Wi-Fi technology is used for all the communications:
between the monitoring platforms, directly connected with the patient, and the dedicated
Android app running on the doctor’s mobile device, such as a tablet or a smart-phone. The
Android app enables the secure data sharing on the cloud by enabling teleconsulting. The
remote visualization and consulting was made possible by the development of a web applica-
tion, from now on referred to as WebApp1.
Our architecture allows the anesthesiologist to monitor multiple patients in parallel so that
1The WebApp was realized by Thiebaud Modoux, Software Engineer at Pryv
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Figure 6.8 – Different architectures tested to optimize the cloud-based IoT network: a) the
Target Control Monitoring (TDM) system simultaneously sends the data to the Android app
and to the PrYv middle-ware, b) the TDM system sends data to the PrYv and the Android app
takes the data from there and c) TDM sends the data to the Android app and from there the
doctor can enable also the cloud sharing of Pryv.
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the total process time is reduced while maintaining a high quality of medical performance.
With the aim of offering an optimized architecture, three different IoT network structures were
considered as visible in Fig. 6.8. The first option was to let the TDM system simultaneously
send the measured data both to the Android app and to the cloud solution, as shown in
Fig. 6.8.a. This architecture was not implemented since there was no control over the data
sent to the cloud storage by the medical specialist. Then, we evaluated the situation where
the TDM system was sending data only to the cloud and the Android app was retrieving the
data directly from PrYv, as shown in Fig. 6.8.b. This solution has also been discarded since too
much reliance was placed on the cloud solution. Finally, we decided to implement a third
solution, as shown in Fig. 6.8.c, where the TDM system sends the data to the Andorid app and
from there also to the cloud, if the doctor and the patient previously agreed on this. In this
way, the TDM is maintained lighter and the cloud sharing is enabled only according to the
patient’s permissions.
Network architecture
The scenario depicted in Fig. 6.7 based on the optimized architecture shown in Fig. 6.8.c, relies
on three main actors: (i) the anesthetized patient directly monitored by the TDM platform
which continuously sends the measured data to (ii) the anesthesiologist’s tablet where an
Android application is running and from which the data can be redirected also to the PrYv
cloud solution enabling teleconsulting from (iii) remote specialized and authorized users.
A smart-watch, worn by the anesthesiologist on-duty and paired with his/her tablet where
the Android app is running, enriches the network enabling fast alerting systems in case of
out-of-safe-threshold parameter. The notifications sent by the Android app and received by
the wearable is characterized by a strong vibration and a pop-up message displaying the name
of the critical patient and the out-of-range parameter. In this way, faster interventions are
ensured in case of emergencies. The Android app was developed in Android Studio 3.0, the
WebApp in Javascript, HTML and CSS.
Hereafter, the main parts of the network are described in detail.
(a) TDM system consists of the multi-panel electrochemical sensing platform driven by
the RPi-based custom board. The measured values are sent by the RPi, communication
master, to the Android app of the medical doctor exploiting the TCP/IP protocol. The
data are sent following a specific protocol, as shown in Fig. 6.9, consisting of 6 bytes.
The first byte (in green) contains the information about the measured drug and the
electrochemical technique adopted. The following four bytes contain the data: the
measured current value (in yellow) and the applied voltage (in blue). The last byte
identifies the stop of the data packet (in red).
(b) Android App allows the doctor to keep multiple monitored parameters under control
from several patients. The app puts the doctor at the center of the architecture by
establishing a bidirectional communication from one side with the TDM on the patient
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Figure 6.9 – Transmitted data packet between RPi-driven TDM system and Android app.
and from the other side with the cloud back-end. To guarantee an appropriate and safe
recording of the measured parameters, the data are stored both in files on the memory
of the smart-device and sent to the cloud. The main activities, reported in Fig. 6.10,
are: (a) login activity that guarantees a secure access only to authorized doctors, (b)
patient data activity where the doctor has to fill in the personal data of the patient
and, if desired, cloud sharing is enabled, (c) Pryv login activity, that appears only
if sharing has been previously selected, to sign in to the cloud environment and choose
among the sharing links, (d) device list activity to establish communication with
the TDM measuring the patient’s parameters and (e) monitoring activity where the
received data are visualized and different actions can be taken from the doctor, such
as starting and stopping the measurements or adding new patients to the network.
Furthermore, if an out-of-range value is measured during the monitoring from the TDM
on the patient, an alert is sent to the doctor’s smart-watch to ensure rapid intervention.
(c) Cloud Solution and WebApp proposes user-friendly interfaces for patients and doctors
who need to share health data while respecting of the medical regulations. This system
is based on the Pryv e-health middle-ware solution exploiting the benefit from its data
sharing features. Depending on who is accessing the sharing WebApp,two different
interfaces are shown to the user, as shown in Fig. 6.11. For a patient, Fig. 6.11.a, the main
window allows the sharing of a data-stream with the doctor, while for a doctor, Fig. 6.11.b,
the shared patients’ data-streams are listed. By selecting one of the shared subjects, the
corresponding data are plotted on multiple graphs. Thanks to this visualization tool,
the doctor can remotely monitor the patient status or access previous measurements.
The cloud is fed with the measures received and processed by the Android app that
sent them through the Pryv RESTful API (using HTTPS requests to get, update, post and
delete data).
Protocols and procedures
We have implemented some procedures to correctly set the IoT monitoring system through
the cloud. Both the patient and the doctor have to complete some basic steps, that are
summarized as work-flows in Fig. 6.12.
• Patient-side Work-flow: the patient gives prior consent to share his/her sensitive data
on cloud during the monitoring. The patient has to access the WebApp (or create an
136
6.2. IoT cloud-based network & Android development
a. Login b. Patient Data
c. PrYv Login
Choose Sharing 
d. Monitoring
e. Device List
A
dd
 P
at
ie
nt
Figure 6.10 – Main activities of the AnControl Android app running on the anesthesiologist
tablet or smart-phone. a) Login to guarantee secure access, b) Patient Data to fill with the
patients information, c) PrYv Login if the doctor has enabled data sharing on the cloud, plus a
Choose Sharing pop-up to select the correct patient’s sharing, d) Monitoring where the data
are visualized on plot after having created the Wi-Fi connection with the specific monitoring
device. To do that, the doctor has to select it in the e) Device List. From the Monitoring it is
possible to Add Patient whenever necessary.
a. Patient Interface b. Doctor Interface
Figure 6.11 – WebApp user-friendly interfaces for: a) patient and b) doctor interaction with the
PrYv e-health middle-wear.
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Figure 6.12 – Work-flow charts for patient-side and doctor side. In particular, doctor-side can
be subdivided in local and remote monitoring.
account if first access), relying on Pryv shared access feature, to authorize the doctor to
access a subset of data of his/her account. A consent form is presented to the patient
and by clicking on a button, the patient can explicitly enable the doctor to access the
data. This action results in the creation of a shared access between the patient and the
doctor and in an automatic email that is sent to the doctor with a notification about the
patient decision. From now on, the patient sees the new share in a list and can revoke it
at any time.
• Doctor-side Work-flow is subdivided in two sub-flows depending on the role of the
doctor:
– Local Monitoring Work-flow for the in-charged anesthesiologist. After that new
patient authorizes the sharing of a subset of data an email is received by the
medical specialist containing a link to access the sharing. Through this link, the
doctor is redirected to the WebApp where, after the login, the incoming request
from the patient can be accepted. At this point, the doctor can use the Android app
to keep control of all the patients under his/her responsibility and, if the patient’s
consent was set, to send the data on the cloud platform. The steps to use and
navigate in the Android app were summarized in Fig. 6.12.
– Remote Monitoring Work-flow for the medical doctor in teleconsulting. In addition
to the Android app, any allowed medical specialists can remotely access patient’s
shared data through the WebApp. To do so, the doctor has to log on to the WebApp
where a list of accepted patients sharing is available for remote consulting. The
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shared links are listed according to the creation date and they access a visualiza-
tion tool when clicked. The visualization tool is a simple web application where
patients’ data are plotted using Plotly javascript library.
Network validation
To simulate the scenario in Fig. 6.7 we used a Galaxy Note pro 12.2in with Android 5.1.1
Lollipop paired with a Sony Smartwatch 3 for the doctor monitoring, while two RPi-based
TDMs were included to simulate two anesthetized patients. Finally, a laptop was used to
access the WebApp on-cloud. We have validated the main features of the IoT architecture:
• The simultaneous communication of the Android app with the RPi and the cloud solu-
tion via Wi-Fi technology.
• The multiple patients connection to the doctor’s Android app. Therefore, the anesthesi-
ologist can easily follow different surgeries in parallel.
• The patient access in the WebApp and the possibility of sharing a subset of data with the
doctor. An automatic email with the link to the shared data is sent to the doctor. Then,
we also test the revoking of patient sharing.
• After receiving the email from the patient, the doctor uses the sharing link to access the
WebApp and visualize the cloud data.
• The continuous receiving and the immediate visualization of the measured data received
from the RPi-based TDM on the Android app.
• We have evaluated the latency time for an event creation call on Pryv API as under 100 ms,
which is comparable to a standard HTTP request without any overhead. However, this
parameter is influenced by the quality of the Internet connection, the server location and
the size of the payload. In our case we tested the network with an Hotspot; the server was
located in Switzerland and the events were data with double-precision floating-point.
• We proved the correct reception of the alert notification on the doctor’s smart-watch
when more than n measured values from one patient’s monitored drug exceed the
physiological threshold. The notification happens as a strong vibration and a pop-up
displaying the name of the critical patient, and the out-of-range drug.
6.3 Realization of the sensing platform with fluidics integration
We finally realized a fluidic system to be integrated with the electrochemical sensors identified
in the Chapters 3 and 4. In this way, through the fluidics, the sample solution is directly driven
to the sites for detection. Considering that the infused anesthetic agents vary depending
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Figure 6.13 – Sketch of the sensing platform with the modular fluidic chambers for SPE, PGE
plus T and pH monitoring.
on the kind of medical intervention and on the patient undergoing anesthesia, we wanted
to create a modular fluidic device with different chambers, each for the specific drug to be
analyzed plus one for monitoring the temperature and pH of the blood stream. In this way, the
set up can be customized depending on the specific medical practices to be followed. Fig. 6.13
sketches the idea of the modular fluidic device.
Concerning the C-SPE used for midazolam monitoring (Chamber 1 in the figure) a commer-
cially available flow cell for standard format SPEs from Metrohm can be adopted (FLWCL), as
seen in Fig. 6.14. The electrochemical cell is placed in the middle of the strip with inlet and
outlet coming from the top. The closing system is based on powerful magnets included in the
structure.
On the other hand, the passive electrochemical cell for propofol and APAP consists of a PGE WE
(2.5 mm Ø) an Ag/AgCl RE (4 mm Ø) and Pt-wire CE (0.5 mm Ø). There is no commercial flu-
idics for this electrochemical cell; hence, we have designed and fabricated it in PDMS material.
6.3.1 Fabrication of fluidic chambers in PDMS (Chambers nr.2 and nr.3)
The development process of the fluidic devices started from fluidic simulations performed in
Comsol Multiphysics®2 software to guarantee optimum mixing properties inside the chamber.
Therefore, three different geometries have been investigated before the fabrication: (i) round,
(ii) hexagonal and (iii) hexagonal with internal walls. Laminar Flow Single Phase mode simula-
2The Comsol simulations were run by Zijian Huang, internship master student at LSI, EPFL, Switzerland.
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Figure 6.14 – Flow cell for standard format SPEs from Metrohm (Chamber 1 in Fig. 6.13).
Table 6.1 – Fluid parameters set for Comsol simulations.
serum solution
density (g/mL) 1.0242 [239]
viscosity (mPa·s) 1.27 [240]
tions in Comsol Multiphysics environment were run. In these simulations, laminar flow was
ensured by adopting an appropriate Reynold value and by evaluating the inlet flow velocity µ
by the flow rate Q = 10.4µL/s as µ=Q/A = 0.053 m/s, where A is the cross section area of the
inlet (radius = 0.25 mm). Pressure at the inlet/outlet was set to zero and back flow at the outlet
was suppressed. The domain equation in the model is incompressible Navier-Stokes equation,
which is used for the main chamber to describe the fluid property [238]. The parameters to
simulate serum solution flow as fluid were set as in the Table 6.1.
Fig. 6.15 reports the outputs obtained by the three simulations run for round, hexagonal and
hexagonal with internal walls fluidic chambers. As we can deduce from the simulation results
in Fig. 6.15, the internal soft-walls, which act as obstacles for the fluid flow, facilitate the
internal mixing by causing turbulences. Therefore, the fluidic chamber was created in PDMS
following this optimized geometry.
The fabrication of the chamber was carried out in the PDMS line (zone 12 in the cleanroom
facilities) in the Center of Micronanotechnology (CMi) at EPFL following the process flow
describe in Fig. 6.16.a. For the mold fabrication a 5th generation Desktop laser cutter from
Full Spectrum emitting a very powerful beam of light (40W CO2) was used to print on PMMA
layer (thickness of 3mm) the mold geometry previously designed in Inkscape software and
exported in scalable vector graphics (svg) format. Top picture in Fig. 6.16.a shows the laser
cutter and Inkscape logo used in this first process step. After the PMMA mold is ready, it is then
immobilized at the base of a Petri dish (8 cm Ø) thanks to double-side tape. The following
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Figure 6.15 – Comsol simulation results for different geometries of the fluidic chamber: (a)
circular, (b) hexagonal and (c) hexagonal with internal walls.
steps of the work-flow were carried out in CMi facilities. Fig. 6.16 shows the different steps
and devices used for the PDMS creation. First, the mold’s surface was conditioned to prevent
PDMS sticking through a silanization passivation. This helps to release the PDMS from the
mold at the end of the fabrication process. PDMS solution was obtained by dispensing PDMS
(max 45 g) in a plastic cup, together with a catalyst (curing agent, max 4.5 g) in a proportion
of 10 : 1 (Fig. 6.16.b). Then the plastic cup has to be placed in the mixing machine and, after
having adjusted the revolution balance according to the total weight of the cup, the process
to homogenize the mixture starts (1 min of mixing at 2000 rpm plus 2 min of defoaming at
2200 rpm, Fig. 6.16.c). Afterwards, the PDMS mixture is poured over the passivated mold
placed in the Petri dish and removed all the bubbles removed by degassing in the desiccator
(Fig. 6.16.d). Finally, PDMS was cured in the oven for at least 1 hour at si m80oC (Fig. 6.16.e).
As soon as the PDMS is ready, it is detached from the mold (Petri dish) and it will constitute
the main chamber. The top cover of the fluidic chamber has been created following the same
process for the manufacture of the PDMS but using only a Petri dish as a mold to obtain a flat
surface. To keep the two parts together, e.g. upper cover on the top of the hexagonal chamber,
two PMMA discs, one with a central hole, were made with the laser cutter. We drilled four
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Figure 6.16 – Fluidic device fabrication: a) process flow to be followed that starts with the
construction of the PMMA mold by laser cutter. b) PDMS solution obtained by mixing PDMS
and curing agent (1:10), and c) mixing and defoaming the obtained composition. After having
poured the PDMS in the mold, d) all the air bubbles have to be removed, and, finally, d) it has
to be cured at 80oC overnight.
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Figure 6.17 – Sandwich structure of the fluidic device: PMMA discs holding together the PDMS
chamber.
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Figure 6.18 – Fluidic chamber tested with red dye flow.
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Table 6.2 – Flux velocities evaluation of the fluidics at different pump velocities (expressed in
revolutions per minute (rpm)).
Pump Velocity (rpm) Time to fill (s) Velocity (µL/s)
48 5 10.4
47 5.8 8.9
46 6.4 8.1
45 6.7 7.7
44 7.3 7.1
43 7.5 6.9
42 9 5.7
symmetrical holes on the two disks to allow the passage of screws so as to obtain a sandwich
structure with the fluidic device in between. The screws were tightened with bolts to prevent
leaking. Fig. 6.17 shows the final fluidic device filled with green dye. The chamber flux in the
chamber and leaking have been tested with dye, as shown in Fig. 6.18, before being used for
anesthetic detection.
To complete the monitoring system, a dedicated module for temperature and pH control of
the blood stream was also included in the final configuration. In fact, Chamber 3 Fig. 6.13
shows the integration with the two sensors chosen for this monitoring, which are the DS18B20
waterproof digital thermometer by Maxim-IC, and the Extech standard polymer electrode
(12×160 mm) for pH, as shown in Chapter 5.
6.3.2 Characterization of the fluidic device
We found the correspondence between the internal velocities of the Minipuls 3 peristaltic
pump provided by Gilson Inc. armed with a PVC tube (diameter = 0.38 mm, length = 460 mm
and volume = 52 µl) and the effective fluid flux through the custom fluidics. Hereafter, we
report the results in Tab. 6.2. Among these velocities (expressed in revolutions per minute
(rpm)), 46 rpm or 48 rpm are the most suitable for reproducing the fast variability rate of the
drug concentrations that characterize difficult-to-dose drugs, such as anesthetics. Therefore,
for the final validation of the overall system in Chapter 6 Section 6.4 the measures in flow
conditions were performed at these velocities.
Further, the mixing parameters also have to be optimized. A preliminary qualitative evaluation
was performed by using various dye solutions, as already shown by Fig. 6.18. After this
empirical characterization, we evaluated the time required to ensure homogeneous drug
concentration in the fluidic chamber. To that aim CA measurements in PBS solution for both
APAP and propofol drugs were carried out.
For APAP CA detection, we applied a fixed potential of 0.9 V to the electrochemical chamber
and we set the pump velocity at 46 rpm. For propofol CA procedure the applied potential
was set at 1 V and the pump velocity at 48 rpm. Every 3 minutes, we replaced the input drug
sample with another one having a higher drug concentration. Fig. 6.19 shows the two CA
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Figure 6.19 – CA measurements for: a) APAP and b) propofol drugs.
time-trends for APAP and propofol. From these graphs it is possible to deduce that the steady
state was reached after around 50s by the increase of the drug concentration.
Based on this, 50s can be considered as the minimum waiting time to ensure that the drug
concentration in the electrochemical chamber is the same as to the one in the input beaker.
6.4 Overall system validation
The present section focuses on the validation of the novel IoT monitoring system that has been
proposed in the previous sections of this chapter. We have applied the realized IoT solution to
a medical systems to offer an enhanced tool able to provide rapid and precise information
on patients’ sedation status at any time and from any place (within or outside the hospital).
We finally assembled the whole system, shown in Fig. 6.1, to test its performances for drugs
monitoring. It comprises: (i) the multi-panel electrochemical sensing platform integrated
into (iii) a fluidic system, which directs the sample on the sensing site (Sensing Platform), (i)
a low-noise, custom-built electronic potentiostatic PCB driven by a RPi (Portable Electronic
Circuit), and (iv) an IoT network including a Cloud system (IoT Cloud Support) that allows the
doctor to control and share all the patient’s data through a dedicated Android app (Android
GUI).
The electronic platform, consisting of the PCB and the RPi, was included in a containing box
(27 × 21 × 13 cm) to guarantee its portability.
We validated the performance of our system by detecting the two complementary anesthetic
compounds, e.g. propofol and APAP, under flow conditions in human serum. By these crucial
experiments we demonstrate, for the first time, that our system has the potential to be used
for multiple anesthetics monitoring in the future.
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Material and methods
2,6-Diisopropylphenol (Propofol) was purchased from TCI chemical and dissolved in 0.1
M NaOH to prepare the stock solution of 5.4 mM. Subsequent dilutions of propofol stock
solution were prepared in PBS (10 mM, pH:7.4) or in serum to obtain concentrations in the
range [9.9 - 80.5] µM. The compounds APAP, NaOH and heat inactivated human male serum
were purchased from Sigma Aldrich (Switzerland). APAP stock solution 30 mM was prepared
by dissolving 5 mg of APAP powder in 1 ml PBS (10 mM, pH:7.4). Subsequent dilutions of
APAP stock solution were made in PBS or serum in the range [50 - 300] µM. The propofol and
APAP simultaneous detection was achieved by using a three-electrode electrochemical cell
consisting of a PGE as WE, to overcome fouling effects due to propofol oxidation, a K0265
Ag/AgCl electrode from Ametek Scientific Instruments as RE and a Pt wire as CE. We chose the
wood PGE 3H from Staedtler Mars Lumograph with composition: 58% graphite, 36% clay and
5% wax (binder).
A Minipuls 3 peristaltic pump provided by Gilson Inc. and armed with a PVC tube (diameter =
0.38 mm, length = 460 mm and volume = 52 µl) was used to simulate the flux in the fluidic
chamber. Good mixing properties in the fluidic chamber are guaranteed in 50s from the
exchange of the analyzed solution at the inlet. The validation of the fluidics was presented in
Section 6.3.
CA and DPV electrochemical procedures were carried out to validate the system for propofol
and APAP detection. The corresponding parameters were set through the RPi integrated GUI
and are summarized in Tab. 6.3. Whenever a new data is read from the sensing platform, it is
sent by the RPi to the Android app running on the anesthesiologist’s tablet or smart-phone,
exploiting Wi-Fi technology.
Table 6.3 – Electrochemical parameters for DPV, and CA measurements of APAP and Propofol.
DPV Measurements APAP
Start-V (mV) End-V (mV) V-Step (mV)
-100 1100 5
Pulse-Width (ms) Pulse-Ampl. (mV) Pulse Period (ms)
50 90 68
DPV Measurements Propofol
Start-V (mV) End-V (mV) V-Step (mV)
0 1100 5
Pulse-Width (ms) Pulse-Ampl. (mV) Pulse Period (ms)
75 90 102
CA Measurements: APAP and Propofol
APAP Applied Voltage (mV) Propfol Applied Voltage (mV)
900 1000
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Figure 6.20 – DPV calibration lines with standard error bars (n = 3) obtained under flow
conditions in undiluted human serum for: a) proprofol and b) paracetamol.
6.4.1 Validation of the system in undiluted human serum
The conclusive and decisive validation of the system is based on the results obtained for
the simultaneous detection of propofol and APAP in undiluted human serum under flow
conditions.
To characterize the system we initially carried out DPV calibrations in flow conditions (pump
velocity set at 48 rpm) for both propofol and APAP in human serum, as complex human fluid.
We reported in Fig. 6.20 the calibration lines obtained. Sensitivity values were evaluated to be
3.967×10−09±1.9×10−10 and 3.056×10−08±8.39×10−10 for propofol and APAP, respectively.
After having characterized the system, two main crucial experiments were carried out to assess
the system performances:
• Mixing test: serum solution containing three different APAP concentrations (50 - 150 -
300 µM) was fluxed from lower to higher concentration (pump velocity set at 48 rpm) in
the chamber and measured by the system every 1 min 30s. Afterwards, while the APAP
concentration was maintained at 300 µM, various propofol concentrations (20, 50 and
80 µM) were added to the solution and measurements were taken every 1 min and 30s
for each concentration. Fig. 6.21 displays the obtained DPV curves from this experiment.
It is clear from the figure that any peak is evident in the blank control measurement,
obtained when fluxing undiluted human serum without any drug. Thereafter, only one
peak at ∼ 0.7 V (orange area) is visible when only APAP is present in the fluxed solution.
The peak increases with the increase of the drug concentration. As soon as propofol
is added in the solution (while APAP is kept constant) two other peaks at ∼ 0.45 V and
∼ 0.6 V (green areas) arise. The two peaks become higher when propofol concentration
in the solution increases, while the APAP peak is not affected significantly. Therefore,
we can conclude that these drugs do not interact with each other.
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Figure 6.21 – Mixing test: DPV measurements in undiluted human serum fluxing (pump set at
48 rpm) a solution containing, first, three increasing concentrations of APAP (50 - 150 - 300
µM) and then three solutions with fixed APAP concentration (300 µM) and three increasing
concentrations of propofol (20 - 50 - 80 µM). Blank measurement with no drug in fluxing
serum solution is reported as control.
• In-time monitoring test: the chamber was filled with serum without any drug. Then,
a serum solution containing 300 µM of APAP was fluxed (pump velocity 48 rpm) to
the system. We performed one DPV measurement (30s measurement time) every 10s
of fluxing of the APAP solution. After 12 min we have changed the fluxing solution
with serum containing only 60 µM propofol. The same frequency of measurement was
applied; a DPV every 10s during 12 min. The exchange of the fluxing solutions was
done in the 10s of mixing in order to not interrupt the procedure. Fig. 6.22 reports the
measured peak currents over time, which can be converted into drug concentration
values according to the linear calibration equation expressed in Fig. 6.20. Therefore,
to convert the current value in a concentration it is only necessary to substitute the
x parameter in the corresponding equation and the corresponding concentration is
provided by the y estimation. For the purposes of our analysis, we preferred to keep the
data in current values to be able to visualize the two trends of APAP and propofol on the
same plot.
The results of human serum detection, mixing test and in-time monitoring test show that with
our system, we are capable of in-time monitoring of the change in concentration of two drugs,
e.g. APAP and propofol, in undiluted human serum due to sample flux over a period of time.
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Figure 6.22 – In-time monitoring test: the concentration trends of APAP (300 µM) and propofol
(60 µM) is monitored over time in undiluted human serum under fluxing conditions (pump
set at 48 rpm).
6.5 Infusion pump integration: towards closed loop delivery
The introduction of an automatic control system, capable of delivering anesthesia according
to the level of sedation of the patient, is extremely desirable and would lead to enormous
benefits in terms of correct drug dosage and efficacy, by reducing over- or under- dosing mal-
practices [241]. The use of such an automatic controlled delivery system is fundamental to the
realization of closed-loop anesthesia practices where the feedback controlled administration
of drugs is tuned by the actual level of anesthesia measured by the sensing platform. By far the
most largely used closed-loop controlling algorithm is the Proportional-Integral-Derivative
(PID) algorithm. Basically, it automatically applies accurate and responsive corrections to a
control function, which in the anesthesia delivery system is the PK/PD mathematical model
of the injected drug implemented in the TCI pump. It does this by reading the measured value
provided by the electrochemical sensor and by minimizing the error-difference between the
actual measure and the desired level of anesthetic concentration [242].
Therefore, to facilitate the integration of the PID algorithm and the sensing platform as feed-
back in automatic and reliable drug delivery closed-loop systems, FIS systems are needed to
ensure operation with very small sample volumes of samples, and to provide effective testing
tools to evaluate sensor capabilities in real time [243]. Thanks to FIS it is possible to reproduce
in an easier way the in-vitro dissolution tests, that are normally extremely laborious due to
the large number of samples required, in an automated, precise and reproducible way. Up to
now, various approaches have been presented in the literature to provide automatic testing
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Figure 6.23 – Set-up of the realized FIS
tools [244, 245, 246]. However, these set-ups were not able to reproduce the in-time PK profile
of the drug [247]. To this aim, we created an innovative solution for designing an automatic
FIS driven by the RPi to assess the performance of our system in continuous monitoring over
time.
6.5.1 Raspberry Pi-driven Flow-Injection System (FIS)
The FIS setup has been preliminarily validated by carrying out a qualitative test with a dye; we
then successfully proved its ability in reproducing an in-time concentration trend for APAP
drug.
6.5.2 FIS set-up
The set-up of the FIS is depicted in Fig. 6.23. The RPi has a central role in the FIS. On the one
side, it activates an injection pump, Braintree Scientific Inc.™NE-1000 Programmable Single
Syringe Pump [248] completed by 1 ml or 0.5 ml plastic syringes with Polytetraflon®tubing
from AWG (inner ® 0.41 mm) connected to the needle. The syringe is charged with the drug
to reproduce the desired concentration trend in a given base-volume of buffer solution. The
injection dose is regulated according to a PK mathematical model of the drug implemented in
Matlab. Therefore, from the other side, the RPi receives from the Matlab script the instruction
with the evaluated amount of the target concentration to achieve. This communication relies
on Wi-Fi technology (TCP/IP protocol).
To accomplish the set-up, we used a Gilson™Minipuls 3 peristaltic pump to dilute the base-
volume with fresh buffer solution, a VWR magnetic stirrer to facilitate the mixing in the base-
volume, and the PGSTAT101 Autolab and C-SPE from Metrohm to run the electrochemical
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Figure 6.24 – Schematic representation of the communication protocols adopted between
Matlab and RPi (TCP/IP) and between RPi and syringe pump (serial communication).
experiments for APAP detection (CV procedure applying voltages from -0.1 V to 1.1 V with 0.1
V/s scan-rate). We armed the perystaltic pump with Tygon™LMT-55 peristaltic pump tubing
(® 0.38 mm) for APAP, while PVC tubing (® 1 mm) were used for dye tests.
As is evident from the figure, the system can be sub-divided into two parts according to their
functionalities: (i) the “increasing concentration” part that relies on the syringe, and (ii) the
“diluting concentration” driven by the peristaltic pump. On one side, the syringe pump is
programmed to push the plunger of the syringe filled with the administered drug by means
of a moving plate. On the other side, the peristaltic pump withdraws the solution from the
base-volume beaker and fills it with fresh buffer solution. We have calibrated the in/out flows
of the base-volume beaker to keep the volume constant. The two system parts are made
running in a synchronized manner to reproduce the drug concentration trend in the base-
volume. Therefore, while the peristaltic pump continuously dilutes the base-volume with
buffer solution, the syringe pump injects the right amount of the drug to achieve the target
concentration. We calibrated the peristaltic pump flux and we fixed it at a constant rate before
starting each test. The RPi drives and communicates with the syringe pump through a physical
serial connection RS-232. We realized a custom adapter to connect the RPi USB port with the
syringe pump RJ-11 socket. Through the RPi we can configure the syringe pump. The main
setup parameters to be configured are: (i) pumping rate, (ii) target volume, and (iii) syringe
diameter. Knowing these parameters, the pump can automatically evaluate the injection time
and regulate the plunger speed. As soon as the RPi receives a new calculated injection dose
from the Matlab script, it sends the evaluated value to the syringe pump that confirms the
correct reception of the command by sending back an acknowledgment message. Fig. 6.24
sketches the communication protocols adopted in the transmission of the next evaluated
injection from the Matlab code to the RPi and then to the syringe pump.
We set the the pump to perform direct injection every time a new injection command is
received. The injection is carried out by uniformly pushing the syringe plunger to constantly
increase the amount of drug in the base-volume to reproduce a linear drug concentration
trend.
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Figure 6.25 – An example of injection dose calculation for reproducing a sample target con-
centration trend. The baseline dilution is determined for a flow rate of 1 ml/min in a 1 ml
base-volume. Differences among the plots have been exaggerated for readability.
6.5.3 Injection dose calculation
The Matlab process for estimating the next injection value to obtain a desired concentration
trend in time has to keep in consideration the constant dilution effect due to the peristaltic
flow fixed at a constant speed. The relation between dilution action and peristaltic flow is
expressed in Eq. 6.1. This equation determines how an initial concentration [Ci ] in a certain
volume V decreases in time (t f i = t f − ti ), if a dilution flow rate Q is maintained [249].
[C f ]=
[Ci ]
e
Q·(t f −ti )
V
(6.1)
where [C f ] is the final concentration.
We can simplify Eq. 6.1 by expressing
[C f ]
[Ci ]
as an unique coefficient δ(t f i ). Moreover, under
a continuous dilution, we can consider t f i as an intermediate time tm between two consec-
utive measurements (tn+1− tn). Therefore, to reproduce a desired time-trend of the drug
concentration ([Ct ]), we can evaluate the subsequent dose to be injected by using Eq. 6.2.
[Cdose ]=
[Ct ]− ([Cn] ·δ(tm)), [Ct ]≥ [Cn] ·δ(tm)0, [Ct ]< [Cn] ·δ(tm) (6.2)
where [Cn] is the concentration at t = tn , tm = tn+1− tn , and [Cdose ] is the required concentra-
tion to be injected.
Fig. 6.25 represents the concept behind this injection evaluation method implemented in
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Figure 6.26 – Dye test: Vcol is the dye volume in the base-volume beaker. In the upper part
these values are the dye injections.
Matlab. The e blue dotted line (target concentration) refers to the time-trend to reproduce
according to Eq. 6.2, while the green line (obtained concentration) keeps track of the actual
concentration in the base-volume. Considering the difference ∆C between the diluted previ-
sion of the actual concentration Cn1 and the target concentration Ct1, the new dose [Cdose ]
is evaluated and injected at the time tn . The calculation of [Cdose ], as in Eq. 6.2, relies on the
dynamic dilution continuously performed by the peristaltic pump. The algorithm predicts
the drug concentration at the time tn+1 if no further drug is injected, red dashed line in the
figure (dilution prevision). The black squares in the figure ((injected amounts)) show all the
concentration values to be administered. Before sending these amounts to the syringe pump, a
previous conversion in volume unit is needed. This conversion depends on the concentration
of the drug stock solution. The converted values are sent to the RPi that notifies the pump.
The pump continuously infuses each volume in a time tm to ensure a smooth time-trend.
6.5.4 FIS validation
We validated the FIS by performing two different tests: (i) a qualitative test of the dilution ability
with a green dye, and (ii) a quantitative test of reproducing a drug concentration time-trend
for APAP. The time-trend to reproduce was characterized by a fast rising drug concentration
followed by an exponential decrease of the concentration until the steady-state.
Qualitative test with dye
We injected green food dye in water, considered as the buffer solution (1 ml base-volume).
The peristaltic flow rate was set at 1 ml/min. The injection dosage was programmed to obtain
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Figure 6.27 – APAP test: in the graph the sensed concentration for each measurement in time
(green line), the evaluation in % of the variation between measured and expected concentra-
tions (blue line) and the injected doses (red crosses). In the inset the CV oxidation peaks for
the dilution are reported.
a linear increase in time of the dye concentration in the base-volume and then an exponential
decrease caused only by dilution effect. The test was performed under stirring conditions to
facilitate the mixing properties (level 9 of the magnetic stirrer). The visual results of the test are
shown in Fig. 6.26. There is clearly a linear augmentation of the color tone intensity while the
syringe is active, while an exponential reduction of the intensity is visible due to the dilution
effect.
Quantitative test with APAP
We challenged the FIS in reproducing a time-trend similar to a real drug administration by
using APAP as a benchmark compound. We obtained the increasing trend by injecting APAP
solution six times (one dose every 75 seconds) and then we monitored the dilution progress in
the following 15 minutes. The results of this analysis are shown in Fig. 6.27. The base-volume
was 6 mL and the peristaltic flow was set at 0.86 ml/min. PBS solution was used as buffer
solution. The base-volume solution was stirred (200 rpm) between each measurement to
ensure good mixing after drug injection. To quantify APAP concentration in the base-volume
solution CV measurements were performed.
Thanks to this qualitative test, it was possible to find out the main trade-offs of the realized FIS:
(i) the dimension of the base-volume with respect to the syringe injection speed (evaluated
from syringe dimensions), (ii) the constant speed of the peristaltic flow, (iii) the stirring
condition needed to obtain a well-mixed solution.
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6.6 Summary and original contributions
In this chapter, we have finally completed our system of a fully functional and autonomous
device for multi-sensing detection and delivery of anesthetic compounds over time. An ad-hoc
fluidic device has been realized to automatically direct the human sample to the sensing spots.
The developed system was also integrated with an Android-based IoT architecture to facilitate
the doctor in monitoring multiple clients under his/her responsibility. Smart devices, such as
tablets, smart-phones and smart-watches have been used in the network. Furthermore, we
discussed a novel approach for implementing automatic delivery by the use of the RPi so that
we have integrated also integrated the infusion pump within the system.
We concluded the chapter by demonstrating the successful simultaneous detection of the
concentration trends of two anesthetic drugs in human serum over time.
Main research contributions from this chapter can be summarized as follows.
• IoT network
We have investigated and realized a novel approach to deal with intensive care moni-
toring scenarios by using an IoT solution. The developed IoT network keeps the anes-
thesiologist connected with all the patients under his/her responsibility at all times.
Through this Android-based network, the monitored data are rapidly visualized on the
mobile device of the anesthesiologist, such as a tablet or a smart-phone, and an alert
notification is received on the doctor’s smart-watch in case of an out-of-safe-range
parameter registered from a connected patient. The short latencies for data/messages
transmission ensure rapid medical interventions in case of emergency. In addition, the
data can be shared and stored on the cloud enabling teleconsulting. This ensures a safer
and continuous monitoring of the anesthesia delivery over time. These IoT features
were achieved through two architectures: one based on a smart-watch app, the other
supported by a cloud solution provided by PrYv e-health middle-ware. The first one
relies on a smart-watch, through which the responsible doctors/caregivers can contin-
uously keep the key parameters of several critical patients under control at the same
time. The wearable device enables requests for measured parameters from a specific
connected patient, and sends alerts in case of anomalies.
The latter includes a cloud-based network centered on a dedicated Android app running
on the anesthesiologist’s tablet/smartphone. The app bidirectionally communicates on
the one side with the RPi-based TDM system measuring the anesthetic concentrations
in the patient, and, on the other side, with the cloud back-end solution provided by PrYv
and accessible by a WebApp. In case of any anomaly in measured data, the doctor is
alerted with a notification pushed by the Android app to the smart-watch.
One further advantage of our IoT networks is that they can be considered as on-the-top
monitoring solutions that can be interfaced with a variety of other medical applications
requiring continuous patient monitoring. All that is needed is a medical device that is
able to wirelessly send the measured data for the integration with this architecture.
If we compare the features of our network with the ones offered by previously presented
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Table 6.4 – Comparison among different IoT solutions in health-care for hospital (HS) or home
(HM) monitoring.
Work Medical Application Architecture Cloud Full system HS/HM
[250] Elderly patients
Cloud provider,
ECG sensor,
mobile device app
3 3 HM
[251] Medical imaging
Cloud,
imaging device
3 7 HS
[252] ECG health
Cloud system,
ECG sensor,
mobile device app,
desktop software
3 3 HM
This thesis:
wearable
system
Anesthesia
TDM system,
mobile device app,
smart-watch
7 3 HS
This thesis:
cloud
system
Anesthesia
Pryv middle-ware,
TDM system,
mobile device app,
smart-watch,
WebApp
3 3 HS
IoT solutions in the literature, as summarized in Table 6.4, it is evident that the majority
of them provide home monitoring for elderly people, but none are realized to provide
an ad-hoc cloud-based solution for hospital practices. We have instead provided, with
the second architecture, the first dedicated IoT cloud-based solution for anesthesia in
medical practices.
• Fluidics
We designed a modular fluidic device which aims to interconnect different fluidic
chambers, each for a target drug. We fabricated in PDMS the fluidic chamber for a PGE-
based electrochemical chamber. We implemented an optimized geometry based on a
hexagonal shape and internal walls that was guaranteeing the best mixing properties
in proximity of the sensing site. Similarly, we created the fluidic chamber for pH and
temperature sensors that was presented in Chapter 5, Section 5.2. Finally, the modular
fluidic is completed by a commercially available fluidic chamber for the C-SPE.
• Automatic anesthetics injection system with pump
We have interfaced an infusion pump to be controlled by the RPi, using a novel approach
for FIS. We tested the system by carrying out both qualitative and quantitative tests. As
a consequence of the quantitative test we demonstrated that the system can reproduce
the time-trend of any administered anesthetic compound, such as APAP. Furthermore,
we could identify the main trade-offs of the system: (i) the dimension of the base-volume
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with respect to the syringe injection speed (evaluated from syringe dimensions), (ii)
the constant speed of the peristaltic flow, and (iii) the importance off a stirring action
in obtaining a well-mixed solution for sensing. The system is potentially able to: (i)
reproduce any concentration trend, just by adjusting its intrinsic characteristics (e.g.
tubing dimensions, base- volume, and injection syringe volume) according to the target,
and (ii) be used in any fluidic unit containing the sensors to be tested. An improved
set-up of the system would include a programmable peristaltic pump so that it would
be possible to interrupt the dilution effect whenever static conditions are required for
measurement.
• Validation of the overall system
We finally validated the IoT overall system by performing some crucial experiments aim-
ing at simultaneous anesthetics detection over time. We showed that it works efficiently
for the simultaneous detection of propofol and APAP in human serum, considered as
complex human bio-fluid. We have run two main experiments: one testing the mixing
performances of the fluidic system and the other verifying the simultaneous detection
of multiple anesthetic compounds over a period of time. We have thus demonstrated,
for the first time, the successful detection of the concentration of the two drugs over 24
min.
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7 Conclusions and future work
The objective of this thesis was the design, realization and characterization of a complete mon-
itoring system to be used in intravenous anesthesia delivery, e.g. in surgeries or Intensive Care
Units (ICUs). The anesthesia cocktail is made of a hypnotic, such as propofol; an analgesic,
such as paracetamol; and a muscle relaxant, such as midazolam. A correct and personalized
balance of this triad is crucial for inducing and maintaining a certain level of sedation over a
determined period of time. Up to now, TCI pumps have been used to infuse the anesthetics
in patient’s veins under the control of the anesthesiologist. The software implemented in
the TCI pump incorporates the PK models of the infused drugs to dose their administration
accordingly. The anesthesiologist also keeps control of the BIS, evaluated by an EEG signal
that is related with the patient’s level of sedation. However, main limitations of the actual
practices rely on these facts: (i) on the one hand the PK models in the TCI cannot reproduce
the inter-patient variabilities in metabolism, and (ii) on the other the BIS is evaluated in an
indirect manner, hence it can be affected by artifacts.
To overcome these limitations, a reliable technique for measuring drugs in plasma concentra-
tion during the anesthesia administration has been to be developed in this thesis.
Electrochemical sensors have been used for the on-line and simultaneous monitoring of
multiple anesthetic compounds together with pH and temperature. Custom-built electronics
that can actuate the sensing device, collect the data and transmit them wirelessly the data
have been implemented. The main contributions and achievements obtained by this thesis
are summarized below.
• Fouling resistant electrode for Propofol long-term direct monitoring Electrode foul-
ing is a well-known undesired effect resulting from phenolic oxidation reaction. The
oxidation of propofol, which is a phenolic compound, produces free radicals that lead to
the formation of an electro-polymerized layer covering the sensor’s surface. This causes
a decrease of the electrode’s sensitivity over subsequent measurements. A ready-to-use
pencil graphite electrode (PGE) with a specific lead composition of 58% graphite, 36%
clay and 5% wax has been identified as the best solid-state electrode for direct propofol
monitoring in terms of (i) propofol sensitivity and (ii) fouling resistance properties over
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time. Furthermore, electrochemical cleaning procedures were also implemented to
guarantee an optimum sensing performance of the electrode for long-term propofol
detection. This important and novel finding has been patented [253]. We achieved a
monitoring of the propofol concentration of over 4 hours, as well as the drug detection
in time in undiluted human serum under flux conditions.
• Carbon-based electrodes for direct monitoring of paracetamol and midazolam We
have reported the electrochemical detection of midazolam in undiluted human serum
by using MWCNTs-modified SPE for the first time. With MWCNT-nanostructured elec-
trodes, not only midazolam, but also paracetamol (APAP) detection was achieved in the
therapeutic range, under fluxed conditions and in complex solutions like human serum.
• Interference study We have also conducted an interference study among propofol,
midazolam and APAP compounds to optimize and better characterize the sensing units.
According to the results obtained by this analysis, we concluded that APAP and propofol
can be detected simultaneously by the same PGE WE while midazolam does not have
any interference action with the other target drugs. A Gaussian decomposition process
has been used to discriminate the current contributions of APAP and paracetamol to
the measured signal. Acid pH solutions may be preferred to improve the detection of
these anesthetics.
• Raspberry-pi based custom-built electronic potentiostat In this thesis we investigated
the use of the powerful RPi board as the central unit of the electronic system to drive
the simultaneous monitoring of multiple drugs plus pH and T through dedicated front-
ends. The potentiostatic circuit board constructed with COTS implements three parallel
actuation and sensing blocks for interfacing with three separate electrochemical cells
for enabling simultaneous monitoring. A 4th-order Butterworth low-pass filter has
been included in each channel of the read-out circuit for cleaning the signal from the
high-noise components. Wireless data transmission relies on WiFi technology. The
electronic system showed great performances when compared to the commercially
available Autolab potentiostat by Metrohm PGSTAT302N. The main advantages of our
system are related with low costs, multi-detection of several drugs and pH and T at
the same time, small dimensions (integrated in a containing box of 27 × 21 × 13 cm
dimensions), and higher portability.
• IoT Android-based network IoT “smart” solutions in hospital environments are nowa-
days adopted to provide powerful tools for medical staff activities to guarantee im-
proved and safer patient care. In the present work, we further investigated a medical
IoT network to provide our system with a cloud-based solution for anesthesia on-line
monitoring. We developed Android apps to allow the anesthesiologist to remain si-
multaneously connected to all the sedated patients in order to keep control over the
monitored parameters. Alert notifications are sent to the medical doctor whenever an
out-of-physiological-range parameter is measured on one of the monitored patients, to
ensure fast intervention. The Android apps were developed to run on mobile devices,
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such as a tablet or a smart-phone, or on wearable device, such as a smart-watch. Fur-
thermore, the monitored medical data from the patients can be shared on the cloud to
be accessible at any time and from any place, hence enabling teleconsulting.
• System integration and validation tests The present research was focused on the com-
plete design and fabrication of the sensing and the electronic platforms and their inte-
gration in a complete IoT system for the on-line monitoring of anesthesia compounds.
We also realized and characterized a fluidic device in which we have encapsulated the
sensors. The fluidics drives the sample solution directly on the sensing sites. In the final
chapter we showed the integration of the different components, the enrichment of the
system by the IoT solution, and the in-vitro validation of the working prototype. We
proved the excellent performance of the final overall prototype by running two crucial
tests validating the multi-drug detection in undiluted human serum. With our system
we were able to monitor the in-time variations of the concentration of two drugs, e.g.
APAP and propofol, under flow conditions.
The results achieved in this thesis confirmed the promising performance of the prototype.
However, further research could be dedicated to improve the system. Possible future works of
this work are listed hereafter.
• Blood-separation fluidics An advanced microfluidic system could offer the possibility
to: (i) perform on-chip separation of plasma from the whole blood [254] and (ii) vary the
sample pH to more acid contents to optimize the detection. The sketch of this fluidics
structure, which includes blood-separation and mixing modules, is shown in Fig. 7.1.
• Miniaturization of the sensing electrodes Miniaturized electrodes would be highly at-
tractable, reducing the volume of the sample and facilitating its integration in catheter-
like tools. This would lead to an easier use of the device and to the possibility of measur-
ing the concentration of the drug directly in the patient’s veins without adding further
delay due to the blood sampling system.
• Optimized electronics Further optimization of the electronic platform would be benefi-
cial on the one hand in reducing the power consumption and on the other by improving
the S/N ratio. In particular, the front-end for midazolam detection should be revised.
Due to the high midazolam concentrations (mM) that are normally administered, a high
current comes from the electrochemical cell leading to a saturation of the electronic
front-end. Alternative architectures could be investigated to overcome this saturation
issue. In the light of an optimized electronics, switched capacitors architectures could
offer a suitable solution since they require less power and less area respect to tradi-
tional op amp configurations and, moreover, they offer a wider range of voltage gains
[255, 256].
With this thesis, we successfully created a first multi-panel prototype for the simultaneous
monitoring of several anesthetic compounds over time, contributing a great step forward
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Figure 7.1 – Sketch of the advanced micro-fluidic device able to provide on-chip serum separa-
tion from blood and mixing properties (inspired by [254]).
for the state-of-the-art. The research presented in this thesis is the foundation for further
developments in clinical applications.
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Figure A.1 – Micro-controller firmware work-flow.
163
Appendix A. Micro-controller firmware
Electrode Index
Technique tag
Stop byte
Write/Read
Start byte
CA
C V
Set Voltage
Start Voltage
Stop Voltage
Sweep Time
Volt StepDPV
Pulse Apmlit.
Pulse Width
Pulse Period
Start Voltage
Stop Voltage
D
at
a
D0D1D2D3D4D5D6D7
Initial Voltage
Initial Voltage
Figure A.2 – Data packet adopted in the communication protocol from RPi to PCB: start byte,
data and stop byte.
A.1 main.c
The main.c file contains the entrance of the whole firmware and the while(1) loop that
runs continuously. The flow-chart in Fig. A.1 shows the firmware architecture of the micro-
controller. Inside the loop, there are the individual states for each of the three electrochemical
channels to control if any measurement has been started by the user (Start Flag for each
channel). If a measurement is started/running then the corresponding technique is performed
according to the user’s request.
A.2 Twi_protocol.h
The Twi_protocol.h file defines the protocol for I2C communication as reported in Fig. A.2.
Namely, we can further identify:
• the stop tag as 1-byte set to 0×BB.
• In start byte the Technique tag as 4 bits [D7-D4] indicating the measurement type ac-
cording to Table A.1.
• If D3 in start byte is 1: the master (RPi) writes to the slave (micro-controller), viceversa if
it is 0.
• In start byte the Electrode index is indicated in [D2-D0] according to Table A.2.
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Table A.1 – Measurement type extracted from the Technique tag bits.
D7 D6 D5 D4 Hex Type
1 0 1 0 A CA
1 1 1 1 F CV
1 1 0 1 D DPV
1 1 0 0 C Stop Measurement
Table A.2 – Sensing channel extracted from the Electrode index bits.
D2 D1 D0 Electrode index
0 0 0 0
0 0 1 1
0 1 0 2
A.3 Setup_twi.c
The Setup_twi.c file is responsible for configuring the Two Wire Interface (TWI) ports for I2C.
This communication is adopted to set up the digital potentiometers and to interface with the
RPi. Some fundamental functions are:
• Setup_twi_master() configures the TWI port of the micro-controller as master in the
communication with the digital potentiometers for their configuration.
• Setup_digitalPot() is called as soon as the TWI master configuration is accom-
plished. This function sends the configuration data to the potentiometers from the
micro-controller.
• Reset_twi_master()disables the master-mode for the TWI port of the micro-controller
so that it can be configured again as TWI slave or master in the next communication.
• Setup_twi_slave() configures the TWI port of the micro-controller as a slave in the
communication with the RPi.
• Slave_process() is assigned whenever the TWI port of the micro-controller is set as
slave. It handles the process data interrupt. It is the most crucial function since it is
responsible for processing the data and commands during the I2C communication with
the RPi.
During the data processing, the master reads/sends data from/to the slave. The procedure for
read and write operations are different.
• Master read operation: the RPi (master) wants to read data from the micro-controller
(slave). Before reading the data, the RPi sends a 1-byte data that contains: (i) the index
of the sensor electrodes from which to read the data, (ii) the read indication flag and
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(iii) the type of measurement. As soon as the data is received from the TWI slave, the
slave parses the 1-byte data to extract the index and the measurement type so that it
can put the required data to the send buffer. After that the RPi has sent the 1-byte data,
it executes read operation and waits TWI slave to send the data back. The data packet
from the micro-controller to the RPi consists in a start byte, 2-byte of data containing
the applied voltage for the measure, 2-byte data with the value of the measured current
signal from the RedOx, and a stop byte. This data packet is the same indistinctly from
the electrochemical technique is running.
• Master write operation: the RPi (master) will send to the micro-controller (slave) the
configuration parameters for running a certain type of measurement chosen by the
user. The master sends a 1-byte data, named as start byte, containing: (i) the configu-
ration parameters for running a certain type of measurement, (ii) the specific sensing
channel, which is identified by an index, and (iii) the write operation flag. When the
micro-controller receives the start tag from the RPi, it extracts the measurement type,
the read/write operation type and the electrode index. Knowing the measurement type,
the slave assigns to the receive data counter the maximum expected data bytes
(4-byte received for CA, 8-byte received for CV and 14-byte for DPV) to receive and sets
the start receiving flag as true. When the consequent data arrives, the slave continues to
save them in the receive buffer array until the expected data bytes are received. Once
completed the receiving of the data packet, the slave assigns the received data to the
corresponding sensing channel and updates the start measurement flag of the corre-
sponding channel. For CA measurement, any timer is required since the excitation
waveform is a fixed potential. On the contrary, for CV and DPV measurements, that
requires more complex excitation waveform to be applied on the electrochemical cell,
there are three timers TCC4,TCC5 and TCD5, one for each sensing channel. The data
packet received from the RPi ends with a stop byte.
Finally, when the user decides to finish a measurements, the RPi sends a stop measure-
ment command containing: (i) the electrode index and (ii) the stop measurement tag.
As soon as this command is received, the output of the corresponding DAC is reset, and,
in case of CV or DPV measurements running, also the timers are disabled.
A.4 Setup_timer.c
The Setup_timer.c file is responsible for updating the counts and timing for given types of
electro-chemical techniques, such as CV and DPV. Since there are three electrodes (indexes:
0-2), three timers are dedicated to each of them. TCC4 for electrode 0, TCC5 for electrode 1,
TCD5 for electrode 2. Each timer can operate independently, hence enabling the possibility
of running different measurements in parallel. For running CA measurements, any timer is
needed since a fixed potential is applied over the electrochemical cell. For performing CV
measurements, the excitation waveform consists of linear sweep potential ramp between
Vst ar t and Vend . To realize the ramp, a voltage value is applied for a given amount of time
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(δt ), then it is increased by a given voltage step (δV =Vstep ) and then, the new voltage value
is apply for another δt) of time, and so on until the end of the ramp. The scan rate is given
by δV /δt . The total number of increment (No f Steps) starting from the start voltage (Vst ar t ) is
calculated by:
No f Steps = (Vend −Vst ar t )/Vstep (A.1)
While the applied potential (Vappli ed ) at each step (Nstepi ndex ) is calculated as:
Vappl i ed =Vst ar t +Vstep ×Nstepi ndex (A.2)
Each time the timer overflows, the step counter Nstepi ndex is increased by 1 until it reaches
the No f Steps . When it reaches the maximum value of steps, the step counter Nstepi ndex starts
to decrease by 1 at each timer overflow until it reaches the 0. When step counter Nstepi ndex is
0, it is again increased and so on until the measurement is stopped by the user.
Finally, for running DPV measurement, two different periods (first period and second period)
has to be evaluated considering the pulse width and the pulse period. Initially, the timer
period is set to the first period. In the first period, a voltage that is the sum of start voltage
(Vst ar t ), pulse amplitude (Vpul se Ampli tude ) and voltage steps (Vstep ) is applied, as shown in
Eq. A.3. When the timer overflows, the timer period is set to the second period. In the second
period, a different voltage value is applied, which is one pulse amplitude (Vpul se Ampli tude )
smaller than the previous one, as calculated in Eq. A.4. When the timer overflows after the
second period, then it is set again to the first period and the process is repeated. Similarly as CV
measurement, the number of steps (No f Steps) for DPV can be calculated as in Eq. A.1. The step
counter (Nstepi ndex ) can increase until it reaches the maximum number of steps and, after
that, it can decrease until it reaches the 0, then the process is repeated until the measurement
is stopped by the user.
VF i r stPer i od =Vst ar t +Vpul se Ampli tude +Vstep ×Nstepi ndex (A.3)
VSecondPer i od =Vst ar t +Vstep ×Nstepi ndex (A.4)
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